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Foreword 
 
 The supply of and demand for illicit drugs at first seem to be quite separate: drugs 
are manufactured, trafficked and sold on the illicit market by one group of people; the drugs 
are bought and consumed by others. However, illicit drug supply and demand are in fact 
inextricably linked components of a single phenomenon. The demand for drugs stimulates 
the supply; the availability of drugs, in turn, creates demand, as more people become 
dependent upon drugs. 
 In chapter I of its report for 2004, the International Narcotics Control Board analyses 
this interaction between supply and demand and emphasizes the need for a balanced and 
integrated approach. It is all too easy for government action against the drug problem to 
focus on supply, which is just one element of the problem. While that may produce results, 
even dramatic results, in the short term, including large seizures of illicit drugs, it does not 
and cannot have a long-term effect because new sources soon emerge to meet continuing 
demand. Unfortunately, there are no quick ways to reduce demand; sustained preventive 
intervention is required to do that. It is therefore essential to develop comprehensive 
strategies, combining action to reduce both supply and demand. Then and only then will 
there be significant progress in dealing with drug abuse problems. 
 Chapter II of the report presents a review of the Board’s consultations with 
Afghanistan pursuant to article 14 of the Single Convention on Narcotic Drugs of 1961. In 
the first democratic elections, held in October 2004, Hamid Karzai was elected President of 
Afghanistan. Unfortunately, the widespread drug problem has become a severe threat to this 
new democracy, as well as the stability and economic recovery of the country as a whole. 
Illicit opium poppy cultivation continues to increase in Afghanistan, supplying three quarters 
of the world’s heroin; in addition, Afghanistan has become a major source of cannabis resin 
for illicit markets in West Asia and beyond and a destination for smuggled psychotropic 
substances and precursors. 
 In response, Afghanistan has adopted a national drug control strategy aimed at 
eliminating the cultivation of illicit crops and the illicit production of and trafficking in 
narcotic drugs, psychotropic substances and precursors within a 10-year period. The United 
Nations Office on Drugs and Crime, together with the international community as a whole, 
is supporting Afghanistan in its efforts to achieve that goal and to comply with the 
international drug control treaties. Ultimately, however, it is the responsibility of the 
Government of Afghanistan to fulfil its commitments under the international drug control 
treaties and to ensure that its people are protected from the drug scourge. 
 In October 2004, the Board convened an expert group in Vienna to consider the 
problem of illicit sales of controlled substances through Internet pharmacies. Such sales 
contravene the Convention on Psychotropic Substances of 1971 in several respects. Firstly, 
Internet pharmacies are not licensed to deal in internationally controlled substances as 
required by article 8 of the 1971 Convention. Secondly, the preparations that they sell are 
advertised to the general public, which is contrary to article 10. And thirdly, contrary to 
article 12, the requirements for import or export authorizations are not observed. Despite 
those contraventions, it is difficult to apprehend the traffickers involved and such illicit sales 
have increased continuously over the past few years. That is because if laws are 
strengthened and enforced in the country where an Internet pharmacy is located, the 
pharmacy can easily be “relocated” to another country. Moreover, there are no international 
standards for Internet pharmacies and no record-keeping requirements. Investigators cannot 
obtain information on subscribers from Internet service providers, nor can they, in many 
cases, prevent the drug traffickers from purging information on their customers. 
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 The Economic and Social Council, in its resolution 2004/42 of 21 July 2004, entitled 
“Sale of internationally controlled licit drugs to individuals via the Internet”, called on States 
to actively pursue those that are in violation of the importing or exporting provisions of the 
international drug control treaties. To achieve that, it is essential that authorities work in 
close cooperation with Internet service providers and the pharmaceutical and chemical 
industries. It is also important to exploit the opportunities offered by the Internet by 
disseminating information aimed at discouraging people from abusing drugs. 
 The rate of HIV/AIDS infection among injecting drug abusers has been increasing 
rapidly in some parts of the world, particularly in Eastern Europe and Asia. In many cases, 
the alarming spread of HIV/AIDS and other infectious diseases is associated with 
shockingly low levels of awareness of the basic facts about those diseases and their modes 
of transmission. Governments must address such ignorance and find ways to limit the spread 
of HIV. In doing so, they must ensure that current drug control policies do not perpetuate the 
vicious circle of injecting drug abuse and HIV/AIDS. Measures to prevent the spread of 
infectious diseases must not be seen as facilitating or even promoting drug abuse, which is, 
after all, the root of the problem. In other words, the primary and overriding focus of all 
interventions must be to prevent drug abuse because it is a dangerous and damaging practice 
in its own right and it has the potential to create even more havoc by contributing to the 
spread of HIV/AIDS and other serious infectious diseases. 
 
 
 
                         Hamid Ghodse 
                           President of the International Narcotics Control Board 
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 I. Integration of supply and demand reduction strategies: moving beyond a 
balanced approach 
 
 
 
1. The ultimate goal of both supply and demand 
reduction strategies is the same: to minimize or 
eliminate the use and abuse of illicit drugs. If that goal 
is attained, the development of substance use disorders 
and the health and social problems associated with 
them will also be reduced. Since the supply of and 
demand for illicit drugs are inextricably connected, 
programmes aimed at reducing the drug problem 
should be integrated, complementary and mutually 
reinforcing rather than isolated or competing activities. 
2. Illicit drug use is a complex behaviour dependent 
upon the individual, his or her environment and the 
drugs themselves. Illicit drug markets at all levels are 
affected by the interaction between the demand for 
drugs and their availability. The interaction is 
influenced by social, cultural, economic and political 
forces. 
3. Early efforts to confront drug abuse issues, 
including international drug control instruments, 
focused on reducing the supply of illicit drugs. The 
first formal international recognition that drug supply 
is linked with demand was the inclusion of an estimate 
system for licit narcotic drugs in the 1931 Convention 
for Limiting the Manufacture and Regulating the 
Distribution of Narcotic Drugs, in order to prevent the 
diversion of such drugs into illicit channels. 
4. The international drug control treaties1 are the 
foundation of international efforts against the abuse of 
illicit drugs. They codify supply reduction measures 
and recognize the impact of the demand for illicit 
drugs on its relationship to supply. Parties to those 
treaties are required to, inter alia, give special attention 
to, and take practical measures to reduce, the demand 
for illicit drugs. 
5. In previous reports,2, 3, 4 the International 
Narcotics Control Board has emphasized the need for a 
balanced approach to the world drug problem, noting 
that addressing the demand for illicit drugs must be 
combined with continued efforts to restrict their 
cultivation and manufacture, to limit the availability of 
source materials and precursors and to reduce the 
availability of drugs at the street level. The need for 
such a balanced approach has also been stressed in the 
1987 Comprehensive Multidisciplinary Outline of 
Future Activities in Drug Abuse Control5 and in 
various resolutions of the General Assembly, the 
Economic and Social Council and the Commission on 
Narcotic Drugs. 
6. The General Assembly at its twentieth special 
session adopted the Declaration on the Guiding 
Principles of Drug Demand Reduction (Assembly 
resolution S-20/3, annex), in which it called for a 
balanced approach between demand reduction and 
supply reduction, each reinforcing the other, in an 
integrated approach to solving the drug problem. The 
Joint Ministerial Statement and further measures to 
implement the action plans emanating from the 
twentieth special session of the General Assembly, 
adopted during the ministerial segment of the 
forty-sixth session of the Commission on Narcotic 
Drugs,6 reaffirmed the integrated and balanced 
approach. 
7. Neither demand reduction programmes nor 
supply reduction programmes alone have been fully 
successful in addressing the drug problem. In the 
present chapter, the Board examines the relationship 
and interaction between the supply of and demand for 
illicit drugs and the synergistic impact of 
complementary efforts. It emphasizes the need for 
policy makers, competent and national authorities and 
others involved in implementing drug control strategies 
to utilize balanced, combined and integrated 
approaches at all levels for maximum effectiveness. 
 
 
 A. Market perspectives 
 
 
  Illicit drug markets 
 
8. There is a clear association between drug 
availability (supply) and drug consumption (demand) 
in illicit drug markets. In its simplest form, this means 
that drug supply satisfies and creates demand and that 
drug demand supports the existing drug supply or 
creates a new one. That association is illustrated by the 
availability of alcohol and nicotine and the problems 
related to their use, despite attempts to change attitudes 
and use through education and prevention efforts. The 
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same rationale may be applied to controlled 
substances. Although that association is not direct, 
within certain limitations, as an addictive drug 
becomes more available, a larger number of vulnerable 
individuals will be exposed to it, the likelihood of drug 
experimentation will increase and the problems 
associated with drug abuse will become more 
prominent. 
9. This one-dimensional view, however, hides the 
complexities inherent in the interaction between the 
supply of and demand for illicit drugs. In reality, this 
continuum is affected by factors such as alternative 
substances and sources, new markets and users, relapse 
and social, ideological and economic challenges. While 
individual supply and demand reduction efforts have 
had a positive impact, most have been limited in 
duration, location or substance. Demand, particularly 
among chronic users and those attempting to profit 
from the demand, has led traffickers to seek alternative 
sources or substances. Drug traffickers may attempt to 
establish new drug markets and to expand existing 
ones by recruiting new users and marketing new 
substances. How supply can create demand is 
illustrated by the crack cocaine epidemic in the United 
States of America in the 1980s, during which a new 
and cheaper form of a traditional drug became widely 
available. 
10. Recent evidence suggests that illicit drug demand 
can vary inversely with price.7 Supply reduction efforts 
have increased the prices of illicit drugs to levels far 
above those which would have otherwise prevailed. 
Studies also indicate that this inverse relationship also 
applies to measures of morbidity from drug use (for 
example, emergency department episodes). The extent 
to which higher prices affect the extent of demand for 
and abuse of illicit drugs is dependent on the specific 
substance, the age and social status of the individuals, 
the type of market and prevailing social, cultural and 
economic conditions. There is strong evidence that, at 
least for cannabis, price and easy availability, along 
with peer pressure, influence naïve adolescents in their 
decision to begin experimenting with drugs. For older 
and chronic drug abusers, price might have less of an 
influence on the decision to continue drug abuse.8 
Furthermore, experience has shown that vigorous law 
enforcement efforts do not always result in price 
increases.9 
11. Drug policy makers often analyse the availability 
of illicit drugs and illicit drug markets as both major 
determinants and major consequences of drug abuse, 
particularly in terms of where and how they interact 
with the demand for drugs and with responses to the 
drug problem. Illicit drug markets may be considered 
as new or emerging or as well established or mature. 
Such markets vary by, inter alia, the type of substances 
involved, the number and type of abusers. Mature 
markets are composed of a small proportion of heavy 
drug abusers who consume large volumes of illicit 
drugs (for example, heroin addicts) or a large number 
of abusers who each consumes a smaller volume of 
illicit drugs (for example, abusers of methylene-
dioxymethamphetamine (MDMA, commonly known as 
Ecstasy)). Those markets may exist side by side in 
local communities, individual countries or different 
regions. 
12. The determination and understanding of the type 
of illicit drug markets in a given area enable policy 
makers to establish focused strategies regarding the 
supply of and demand for illicit drugs in those markets. 
There are substantive differences in the dynamics of 
supply and demand in well-established (mature) and 
new illicit drug markets. Interdiction efforts are most 
effective when aimed at disrupting mature illicit drug 
markets, whether at the local, national or international 
level. Arresting and imprisoning a large number of 
drug users or street-level dealers may not be as 
valuable in a mature illicit drug market; arresting a 
smaller number of larger distributors or more violent 
and disruptive offenders may be more effective in 
situations where heavy drug abusers account for the 
bulk of illicit drug demand and consumption.  
13. When a relatively small proportion of drug 
abusers consume most of the volume of the illicit drugs 
in a mature market, supply and demand are primarily 
influenced by what happens to that group. Demand for 
illicit drugs in that population is not significantly 
affected by prevention based on education or 
information-based programmes. Drug abuse treatment 
intervention may be more effective in reducing demand 
in that population. Treatment often begins with referral 
of the individual for an addiction-related problem, such 
as a criminal act, a workplace safety issue or an 
infectious disease. The availability of and access to 
quality treatment facilities and associated programmes  
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may reduce the number of illicit drug users, the 
quantity of illicit drugs used and, consequently, illicit 
drug trafficking and supply.  
14. Reducing the availability of illicit drugs in a 
mature market may also lead chronic drug abusers to 
seek treatment and may reduce demand. For example, a 
reduction of the heroin supply in the Australian Capital 
Territory between 1999 and 2002 was accompanied by 
a large decline in ambulance call-outs and an increase 
in methadone treatment admissions. During the same 
period, there was also a decrease in heroin purity and 
property crime.10 Such a situation is possible if law 
enforcement activities are sustained and complemented 
by demand reduction efforts; however, if those 
activities are not sustained and complemented by 
demand reduction efforts, the situation may go back to 
the way it was. 
15. In emerging illicit drug markets, both supply and 
demand are particularly sensitive to early efforts to 
reduce availability. Law enforcement has the potential 
to focus its efforts, to respond quickly and to be drug-
specific. Early intervention in these areas may have a 
significant deterrent effect and prevent demand from 
developing. It is important to react in a timely manner, 
as authorities may be hesitant to reallocate resources to 
an emerging drug problem until it is well recognized. 
The arrest of illicit laboratory operators and the 
dismantling of laboratories producing new synthetic 
substances (controlled substance analogues), coupled 
with drug control efforts and public health warnings, 
have prevented the development or spread of 
significant illicit drug markets and problems. 
16. Prevention and education efforts, if started early 
in a new illicit drug market, may reduce demand, even 
though they often lag behind in raising awareness of 
the dangers of a newly emerging drug. Individuals with 
significant risk factors, including those associated with 
family, peer group, social, environmental and 
psychological difficulties, are more likely to become 
new drug users in emerging illicit drug markets. Early 
intervention aimed at minimizing the influence of such 
risk factors and reducing drug abuse by developing life 
skills can be effective in reducing illicit drug demand. 
Reducing the number of vulnerable individuals and the 
level of vulnerability will make it less likely that 
emerging drug markets will become established, thus 
reducing the need for and ultimately the supply of 
illicit drugs.  
17. Established attitudes against drug abuse will 
influence whether or not new illicit drugs will take 
hold on the market and even whether or not illicit 
drugs in general will be available. If successful 
programmes to reduce drug abuse are not maintained, 
complacency and tolerance for illicit drug use may 
develop, creating a fertile environment for drug 
dealers. The drug epidemic that began in the 1960s has 
been attributed, in part, to a lack of protective 
knowledge about the dangers of drug abuse.11 Ongoing 
education and prevention programmes that form part of 
regular health education programmes protect the 
population against seductive claims about certain drugs 
of abuse. 
18. Social and economic factors also affect the 
relationship between the supply of and demand for 
illicit drugs in establishing new markets. Some areas in 
which illicit drugs are produced are prime targets for 
such expansion. The drugs are readily available, and 
there are often poor economic and social conditions 
and political unrest. Drug trafficking may be one of the 
few sources of income. The supply of illicit drugs in 
areas in which the drug crops are cultivated or the 
illicit drugs are processed or transported, together with 
the above-mentioned factors, has also created demand 
for the drugs in those areas. For reasons that have not 
yet been determined, that demand has been increasing 
more rapidly in some areas and slower in others. The 
number of drug abusers has been increasing in some 
countries that were once considered source or transit 
countries. In some areas in Asia, particularly in 
countries where the problems associated with 
amphetamine-type stimulants mainly involved the 
manufacture of and transit traffic in such stimulants, 
the abuse of such stimulants has spread to other 
countries and has occurred among broader population 
groups.12 Reducing supply in those areas would have a 
positive impact on the demand for illicit drugs. 
19. The increasing availability of high-speed 
technology has also complicated actions by authorities 
in addressing the dynamics of supply and demand. The 
Internet is a significant source of information about all 
types of drugs, health problems and treatments. Drug 
education and prevention programmes reach more 
people more quickly by using Internet technology. At 
the same time, however, unregulated Internet web sites 
advertise and sell controlled pharmaceuticals, contrary 
to laws in the importing countries and elsewhere. They 
provide forums for the free exchange of information on 
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illicit drugs (such as how to make them and administer 
them), including new illicit drugs and their effects, and 
on other related illicit drug activity, leading to 
increased experimentation with and demand for such 
drugs. This problem particularly affects young people, 
who frequently rely on the Internet for information and 
are prone to experimentation. 
20. Making effective use of scientific and 
technological advances is critical to international drug 
control efforts. Communication and other technology 
now enable law enforcement authorities to collect and 
exchange information in real time in a secure 
environment, to conduct surveillance more effectively, 
to search for and identify contraband more rapidly and 
to conduct controlled delivery operations. 
 
  Licitly manufactured controlled drugs 
 
21. The supply of and demand for drugs 
manufactured for medical purposes can also affect the 
illicit drug problem. International drug control treaties 
and national controls attempt to limit the cultivation, 
production, manufacture and use of drugs to an 
adequate amount required for medical and scientific 
purposes and to ensure that these drugs are available to 
meet legitimate needs. Weak or inappropriate controls 
and some commercial promotional activities contribute 
to increased drug availability, and people will have 
greater access to more drugs than are required to meet 
their legitimate needs. That, in turn, may increase the 
potential for new drug abusers and illicit demand. For 
example, the abuse of psychotropic substances in some 
countries is associated with a lack of enforcement of 
prescription requirements resulting in such drugs being 
available over-the-counter.  
22. This increased demand may be satisfied through 
the diversion of existing products or through 
trafficking in pharmacologically similar illicit 
substances. When illicit drugs are in short supply, 
chronic drug abusers may turn to drugs manufactured 
for medical purposes as alternatives or reinforcing 
drugs, contributing to increased and often sustained 
demand for them. The oversupply and inappropriate 
prescription of drugs manufactured for medical 
purposes also contribute to increased demand. The 
international drug control treaties have been successful 
in reducing the availability of those drugs on the illicit 
market. However, criminal organizations have partly 
counteracted that by supplying sophisticated look-alike 
medicines that are particularly in demand by addicted 
persons and, at the same time, financially profitable for 
such organizations.  
23. Reducing demand through responsible and 
adequate prescribing by the medical profession, as well 
as concerted action to eliminate the supply of such 
illicitly manufactured medicines, should influence the 
demand for and, ultimately, the supply of illicit drugs. 
At the same time, however, adequate availability and 
appropriate prescribing of drugs for the treatment of 
medical disorders may also reduce the demand for and 
rate of abuse of controlled substances. This, in turn, 
may also affect the supply of illicit drugs. 
24. For example, when methadone and 
buprenorphine, used in the treatment of opiate 
dependence, are diverted and sold to purchase heroin, 
that also contributes to increased demand for and 
supply of illicit drugs. Furthermore, many drug abusers 
use benzodiazepines or amphetamines to enhance the 
effects of opioids, to alleviate withdrawal or abstinence 
syndromes, to temper the effects of cocaine or to 
modulate withdrawal states. 
25. The repercussions of unbalanced government 
controls and law enforcement may adversely affect the 
availability of drugs for medical purposes and may 
unduly limit access to medicines required for medical 
and scientific purposes. The international drug control 
treaties require Governments to establish data 
collection systems to assess the legitimate demand for 
and supply of those substances. Coordination of drug 
supply and demand activities among health, regulatory 
and law enforcement agencies, the medical community 
and the pharmaceutical industry can ensure that 
controlled substances are available to meet legitimate 
needs while preventing their oversupply. 
 
 
 B. Goals of supply and demand reduction 
strategies 
 
 
26. Supply reduction efforts support demand 
reduction efforts because, for some drugs, in times of 
short supply, illicit drug prices may increase, illicit 
drug purity may decrease, and it is more likely that 
chronic drug abusers will seek treatment and new drug 
abusers have less opportunity to obtain drugs. 
Similarly, demand reduction activities can make supply 
reduction activities more effective: decreased demand 
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leads to fewer addicts and new drug abusers; and when 
there are fewer drug abusers, criminal networks may be 
weakened and there is less economic incentive for 
traffickers to manufacture illicit drugs. Demand 
reduction activities also minimize the likelihood that 
drug abusers will switch to other drugs of abuse when 
their drug of choice is not available; instead, they may 
be motivated to seek treatment for their addiction. 
27. Drug abusers are often coerced into criminal 
activities such as drug trafficking, prostitution, fraud 
and theft in exchange for a steady supply of drugs. 
They are frequently made responsible for distributing 
illicit drugs to younger drug users or persons who 
experiment with drugs. Drug prevention efforts, 
coupled with accessible treatment programmes offering 
psychosocial support and pharmacological therapy, 
supported by local law enforcement efforts that target 
the drug trafficking activities of addicts, may have a 
synergistic effect: reducing both the supply of and the 
demand for illicit drugs. Programmes that offer 
alternatives to prison and combine both law 
enforcement and individual recovery components have 
proved to be effective both in treating health conditions 
associated with drug abuse and in reducing crime; they 
may also prevent young drug abusers from coming into 
contact with the criminal culture in prison. 
Consequently, demand reduction activities such as 
treatment alternatives that provide choices for drug 
abusers outside drug distribution networks may affect 
drug trafficking organizations and reduce their ability 
to supply illicit drugs. 
28. Supply reduction programmes attempt to reduce 
the quantity of illicit drugs available for abuse. To 
maximize their efficiency and effectiveness, most of 
those efforts focus on the drug sources, including illicit 
crop cultivation sites, illicit drug laboratories, drug 
trafficking organizations at the regional, national or 
local level and street-level dealers. Supply reduction 
measures vary depending on the source of the drug. 
Crop eradication, chemical control and the dismantling 
of illicit drug laboratories are effective in addressing 
problems of illicit drug production. Interdiction efforts 
are important at all levels of the distribution system, 
including areas in which smuggling is significant, as 
well as in local communities. Measures such as penal 
sanctions and alternative development programmes are 
an integral part of both supply and demand reduction 
programmes and illustrate the need for law 
enforcement, health and social authorities to work 
together. 
29. Both supply reduction programmes and demand 
reduction programmes generally have measurable 
outcomes. Most Governments monitor drug, chemical 
and clandestine laboratory seizures, arrests, 
prosecutions and convictions, the diversion of 
substances to the illicit market and the price, purity and 
availability of various illicit drugs. Reporting and 
sharing such information in a timely manner, in 
compliance with international treaty obligations, help 
to ensure that the most effective programmes are 
implemented. For demand reduction programmes, there 
are measurable outcomes such as participation; the 
number of persons reached in the target population; the 
number of persons trained; the rates of recidivism; the 
involvement of the family, the community and non-
governmental organizations; improvement in 
educational performance; and the development of best 
practices. Successful outcomes are enhanced by long-
term commitment and funding; the involvement of 
target populations (families, schools and communities) 
in the design and implementation of programmes; 
improved life skills; and consideration of gender, 
culture, age, risk and socio-economic factors. 
30. The objectives of demand reduction programmes 
are to prevent and reduce the use of illicit drugs, to 
treat the addicted and to reduce the adverse 
consequences of illicit drug use. Demand reduction 
programmes provide for and encourage the active 
participation of the general public and target those at 
particular risk, regardless of the location or economic 
conditions. Community-, school- and family-based 
prevention programmes promote proper attitudes about 
the availability and use of illicit drugs and the 
perception of their risks. They may also increase 
awareness of vulnerability, risk and factors that are 
closely associated with a disposition to use illicit 
drugs, with a society’s tolerance for drug dealers, with 
the likelihood of adolescent drug experimentation and 
with the public’s attitude towards illicit drug 
availability. 
31. In areas where illicit drugs are constantly present 
and there is little or no awareness of the consequences 
of substance abuse, society may have developed a 
tolerance for illicit drug use, regarding it as an 
inevitable part of everyday life. Demand reduction 
programmes involving all segments and levels of 
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society can raise the awareness of a society and 
sensitize it to the adverse consequences of illicit drug 
use. They can also reduce tolerance for such activity 
and prevent children and adolescents from being 
exposed to illicit drugs. Unified programmes working 
against drug abuse and drug trafficking organizations 
can result in society adopting the proper attitudes 
towards drug abuse and ultimately reduce illicit drug 
availability. Furthermore, citizens involved in such 
programmes are more likely to support police in 
counteracting drug trafficking, to support the use of 
resources for supply and demand reduction efforts and 
to reinforce social networks that increase resilience 
factors that reduce the likelihood that individuals abuse 
drugs. Drug abuse prevention programmes that use 
media professionals to spread messages about the 
dangers of drug abuse help to establish a cultural 
mindset that enables youth to be against drug abuse 
and to resist the entreaties of drug dealers. Drug abuse 
prevention activities can succeed in changing attitudes 
and influencing drug-using behaviour, and that, in turn, 
may lead to reduced drug abuse and, subsequently, 
reduced supply of illicit drugs. 
32. The benefits of the prevention and treatment of 
drug abuse and the rehabilitation of drug abusers are 
well documented.13, 14 The effectiveness of demand 
reduction programmes and their interaction with 
supply reduction programmes can be enhanced through 
the use of evidence-based strategies embodied in 
national and international guidelines. Governments are 
increasingly recognizing the importance of efforts to 
make demand reduction an integral part of their drug 
control strategies. The Board is encouraged that the 
Executive Director of the United Nations Office on 
Drugs and Crime, in his second biennial report on the 
outcome of the twentieth special session of the General 
Assembly,15 noted that 89 per cent of reporting States 
indicated that they had a national strategy for demand 
reduction during the period 2000-2002; moreover, 
82 per cent of the States with a national strategy 
reported that the strategy incorporated the Guiding 
Principles of Drug Demand Reduction. 
33. Best practices, which have been published by 
many organizations, differ from region to region and 
from community to community. Some treatment 
paradigms, including methadone maintenance and 
other drug substitution therapies, are not accepted by 
the authorities in some countries. However, research 
clearly indicates that, for persons with severe forms of 
drug dependence, ongoing pharmacotherapy similar to 
that for other chronic illnesses has had positive effects, 
such as improved personal health and social 
functioning and reduced public health and safety 
threats.16 Those programmes have an effect on the 
supply of illicit substances, since addicts successfully 
participating in treatment programmes have less need 
for illicit drugs and have reduced contact with criminal 
organizations. Targeted demand reduction programmes, 
such as personalized therapeutic programmes, early 
contact with adolescent experimenters and psychiatric 
comorbidity treatment, may all increase the number of 
drug abusers who seek treatment and remove 
themselves from the influence of criminal 
organizations; that, in turn, has clear implications for 
the illicit drug supply. 
 
 
 C. Global relationship between supply 
and demand 
 
 
34. Supply and demand forces interact within and 
between communities, countries and regions. Local 
demand reduction and interdiction efforts have an 
impact both on the local situation and on illicit drug 
manufacturing and trafficking at the international level. 
The global continuum of supply and demand is 
manifested in several ways. Drug traffickers attempt to 
find new production areas or trafficking routes in 
response to successful supply reduction efforts in a 
particular area, country or region. As long as there is 
demand for an illicit drug, sources will be found to 
satisfy that demand and vice versa. Sustained 
successful supply reduction programmes depend on 
demand reduction programmes in those countries 
which are major consumers of illicit drugs. Successful 
national programmes, although not sufficient to 
address worldwide problems, form the basis of 
cooperative and complementary strategies. 
35. The integration of diplomacy, drug control 
policies, international cooperation and law 
enforcement intervention in the 1970s resulted in a 
significant disruption of the heroin markets in certain 
regions. Turkey was a traditional supplier of opium for 
legitimate pharmaceutical products. Opium poppy 
cultivated in Turkey was also the source material for 
the heroin sold on illicit markets. The Government of 
Turkey imposed a ban on all opium production in 1972 
that, in conjunction with law enforcement efforts, 
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succeeded in significantly reducing heroin supplies in 
Europe and the United States. With the support of the 
international community and substantial and sustained 
funding of alternative development programmes, 
Turkey did not resume production of opium but 
switched to the production of concentrate of poppy 
straw to meet legitimate medical demand. Those efforts 
were successful in eliminating the diversion and 
availability of opium in Turkey for heroin manufacture. 
However, the reduction in the supply of and demand 
for heroin was short-lived, as demand reduction efforts 
were not sufficient to ensure long-lasting proper 
attitudes towards illicit drugs in those countries where 
heroin was most widely abused. Consequently, other 
sources of supply emerged to meet the existing 
demand. Programmes targeting the supply of illicit 
drugs must be regional or global in nature and must be 
complemented by demand reduction initiatives in all 
areas where demand exists. 
36. Shortly after its introduction as a sleep aid, 
methaqualone became a popular street drug in many 
countries. National drug control and law enforcement 
efforts quickly reduced its availability on the illicit 
market in several countries. However, continued 
availability of the drug in some areas and established 
demand led to trafficking and the development of 
counterfeit products. Bilateral drug control measures in 
those countries where methaqualone was being 
manufactured and those where the drug was being 
abused were followed by significant seizures and 
ultimately by strict international trade controls and a 
rescheduling action. Continued education programmes 
and other forms of intervention, supported by law 
enforcement activities, eliminated both the supply of 
and the demand for methaqualone in many countries. 
Currently, the abuse of methaqualone continues to be 
significant in only one regional market (Eastern and 
Southern Africa). The case of methaqualone 
demonstrates that coordinated and integrated efforts by 
Governments, guided by the Board, can result in a 
dramatic global reduction in the supply of a particular 
illicit drug and, consequently, significantly reduce the 
demand for that drug. 
37. Bolivia instituted a comprehensive supply 
reduction strategy that reduced coca production by 
70 per cent between 1995 and 2001. Sustained 
eradication, alternative development, strict drug laws, 
precursor control and interdiction programmes, 
together with attempts to address social and economic 
needs, were supported by strong government 
commitment, focused budget and resource allocation 
and the financial and political backing of a number of 
Governments. Those combined actions resulted in a 
significant disruption in the traffic (including the 
transit traffic) in cocaine and precursor chemicals and 
in the dismantling of key criminal organizations and 
the seizure of their assets. As cocaine manufacture 
decreased, cocaine purity dropped (to 47 per cent in 
2001) and demand for Bolivian cocaine base 
decreased. However, that development was not 
accompanied by similar changes elsewhere in the 
region, and coca bush cultivation increased in other 
areas. 
38. Political, economic and social issues also 
prevented the successful developments in Bolivia from 
being sustained. While strong political commitment is 
critical to sustained successful drug control 
programmes, unsuccessful programmes resulting from 
a lack of commitment or implementation efforts may 
reduce the likelihood of positive social and economic 
development and even lead to more political instability. 
Although expansion of alternative development 
opportunities with the involvement of local authorities 
(which will improve social and economic conditions) 
are important to future success, an increased level of 
coca bush cultivation, if not reversed, may lead to 
more political instability and make it extremely 
difficult to develop social and economic programmes. 
Similarly, increased levels of illicit opium poppy 
cultivation and opiate trafficking in Afghanistan are 
likely to lead to further political instability and 
difficulties in the reconstruction efforts in that country. 
39. Monitoring the drug situation in those areas 
where programmes are being implemented, as well as 
where illicit drugs are being consumed, and sharing 
that information with others are important to ensuring 
flexible responses to the changing dynamics of supply 
and demand. In the United States, indicators of demand 
for cocaine show that the number of cocaine abusers 
has stabilized in recent years. The annual prevalence 
figure is approximately 60 per cent lower than in 1985, 
the peak of the crack cocaine epidemic. Traffickers 
continue to try to establish new markets: demand 
appears to be growing in South America and new 
market outlets are being established in Asia and 
Europe, thus indicating a shifting cocaine market. 
International organizations and Governments monitor 
the illicit cultivation of opium poppy and coca bush. 
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Reporting and sharing information on such 
developments facilitates the evaluation of the 
effectiveness of various programmes for development 
and drug crop eradication and the identification of 
areas that require increased efforts and resources. 
There are indications that programmes in Peru and, 
most recently, in Brazil and Colombia to deal with 
problems involving illicit drugs and diverted chemicals 
have refocused their efforts, making use of the lessons 
learned from the integrated approach applied in other 
countries. Integrated and balanced programmes such as 
the Plan of Action on Drug Control in Africa: 2002-
2006, which is being implemented by the African 
Union, have incorporated economic, social and health-
related activities into a regional drug control strategy. 
Coordinated government commitment to drug control 
policies within and between regions prevents drug 
trafficking organizations from moving to areas with 
less control in order to conduct their illegal activities, 
creating new demand or meeting existing demand. 
 
 
 D. National and local perspectives 
 
 
40. An understanding of the nature and extent of each 
drug problem, its origin, effects and ramifications will 
help national and local authorities to take advantage of 
the knowledge of the dynamics of supply and demand 
and to establish meaningful goals, outcome measures 
and priorities. Surveys, questionnaires and 
epidemiological studies are useful in characterizing the 
relationship between the supply of and the demand for 
illicit drugs. They can be coupled with measures of 
availability, consumption, morbidity and mortality. 
Although a long-term goal is to develop scientifically 
tested data collection systems, such systems are 
expensive and often not timely. There is a need for 
short-term practical analyses, based on real-time 
information from law enforcement and health 
authorities. 
41. Programmes aimed at changing or maintaining 
general attitudes towards drug abuse are not usually 
subject to substance or population variables. 
Nevertheless, the public’s perception of drugs and drug 
policy varies from country to country and from region 
to region. Attempting to change attitudes requires 
concerted action. Key components include strong 
commitment at the national level, a coordinated effort 
involving all relevant institutions and involvement of 
the community in building consensus against the 
acceptance of drug abuse. The most effective 
programmes are early education interventions that are 
part of a broad-based curriculum, emphasize the risks 
involved in all forms of drug abuse, have political and 
societal support and are accompanied by strong supply 
reduction efforts 
42. The dissemination of information, in particular 
information regarding the harmful effects of drugs, has 
traditionally been a common component of drug abuse 
prevention. Evaluations have shown that such efforts 
can increase the target group’s knowledge of the 
adverse consequences of drug abuse and can contribute 
to the development of more appropriate attitudes 
towards drugs. Recent studies have shown a positive 
correlation between (a) exposure to messages about the 
dangers of drug abuse and the development of an 
appropriate attitude towards drugs and (b) the 
decisions that adolescents make regarding the abuse of 
a wide range of substances. 
43. Attitudes are used to predict future trends in drug 
use, particularly for new users. In member States of the 
European Union, disapproval and the perception of 
great risks attached to experimenting with cocaine, 
heroin and MDMA (Ecstasy) have increased among 
adolescents; that is especially true for Ecstasy. Media 
coverage, together with an increasing awareness that it 
is possible that damage to the brain may result from 
prolonged use of Ecstasy in high doses, appears to 
have contributed to a downward trend in the abuse of 
that drug. 
44. The lessons learned and the experience of several 
decades of drug abuse prevention suggest that three 
general elements should be included in prevention 
programmes: (a) addressing the values, perceptions, 
expectations and beliefs that the community associates 
with drugs and drug abuse; (b) developing the personal 
and social skills of people, especially children and 
young people, to increase their capacity to make 
informed and healthy choices; and (c) creating an 
environment where people have the possibility to 
develop and lead healthy lifestyles. 
45. Properly focused leadership and the firm 
commitment of Governments at the highest political 
level to disrupt the illicit drug trade and to reduce the 
demand for illicit drugs constitute the foundation for 
addressing the relationship between illicit drug supply 
and demand. Such leadership is critical to the 
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coordination of drug control efforts at all levels—by 
regional, national and local authorities, as well as by 
non-governmental organizations. Unified government 
commitment to strong drug control policies facilitates 
the appropriate allocation of financial and human 
resources and ensures that all relevant institutions work 
together. 
 
 
 E. Criminal justice, health and social 
agencies working together 
 
 
46. Since illicit drug supply and demand are 
inseparable parts of a single problem, the success of 
efforts to reduce the one is related to a commitment to 
simultaneously reduce the other. Programmes 
involving partnerships between law enforcement and 
health and social authorities can generate synergy and 
can be cost-effective. In order to achieve that 
objective, a number of obstacles must be overcome. 
For example, in many cases, demand reduction and 
supply reduction agencies have conflicting agendas 
and approaches. 
47. A successful multidisciplinary approach requires 
mutual respect between the personnel and agencies 
involved. If one group does not trust or respect another, 
that may hinder communication, the coordination of 
activities or their acceptance by the community. 
Although each discipline and agency maintains 
professional independence, continuing interdisciplinary 
training and education promote the development of an 
effective workforce with common goals, resulting in 
more effective planning and implementation of the 
programmes. Sustained, dedicated and balanced 
funding is necessary and justified because of the 
significant reduction in costs to criminal justice, law 
enforcement, health and social programmes.17 
48. The deterrent effect of law enforcement efforts 
influences the demand for illicit drugs. The risk of 
penal sanctions may act as a deterrent to members of 
the general population who have never abused drugs. 
Though the risk of such sanctions does not, in all 
cases, deter addicts who require drugs regardless of the 
consequences, the impact of law enforcement efforts 
on supply may force addicts to take advantage of 
treatment and psychosocial intervention. Collaboration 
between the criminal justice system and the treatment 
or health-care system in the form of drug courts and 
similar programmes is found in a number of countries. 
Such programmes utilize the coercive powers of the 
courts to mandate treatment and to promote abstinence 
and appropriate social behaviour. The goals are to 
reduce drug abuse and associated criminal behaviour 
by maintaining drug offenders in treatment services to 
address their addiction and other needs; recovering 
addicts who are trying to reintegrate into society are 
particularly prone to relapsing and to reinitiating risky 
social behaviour. Cross-training among the various 
professional disciplines involved is critical to the 
success of such joint programmes. Police authorities 
can then contribute to mitigating some of the 
environmental risk factors for drug abuse, such as 
deviant peer groups, criminal groups or abusing 
families, while simultaneously disrupting illicit drug 
markets. Reviews of drug courts and similar 
programmes in several countries indicate that drug use 
and criminal behaviour are substantially reduced while 
offenders are participating in drug courts and that 
recidivism appears to be reduced. Drug courts generate 
cost savings, at least in the short term, from reduced 
incarceration time, reduced criminality and lower 
criminal justice costs, and drug courts are able to reach 
individuals who have abused substances for many 
years.18 
49. In many countries, there are proportionately more 
drug abusers in the prison population than in the 
general population. That indicates that there is a need 
to provide treatment for drug abusers who are in prison 
and to keep illicit drugs out of prison; studies have 
shown that such treatment can be highly effective. 
Alternatives to incarceration have been used for first-
time drug possession offenders, probation being 
dependent on the requirement that the offender remain 
drug-free; in some cases, this is verified by periodic 
drug-testing. Mandatory treatment for recidivist users 
has also been used in place of, or in addition to, 
incarceration. Budgetary implications abound here 
since, for such alternatives to work, adequate treatment 
facilities are necessary. It does no good to mandate 
treatment or other services for offenders if such 
services are not available. Nevertheless, criminal 
justice systems are important in reaching drug addicts 
who are not covered by traditional drug treatment or 
other services. In addition, there is a need to provide 
treatment and other services for drug abusers who are 
not criminals instead of reserving such services only 
for those who have been brought in through the 
criminal justice system. 
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 F. Recommendations 
 
 
50. Supply reduction programmes or demand 
reduction programmes individually have had limited 
success. The supply of and demand for illicit drugs are 
inextricably linked to form a continuum and should be 
treated as such. Balanced strategies continue to treat 
supply and demand as separate issues. Integrated 
strategies at all levels, which combine components of 
supply and demand reduction in multidisciplinary 
programmes, have a synergistic effect.  
51. In order to assist Governments in meeting the 
goals set for 2008 in the Political Declaration adopted 
by the General Assembly at its twentieth special 
session (Assembly resolution S-20/2, annex), the 
Board makes the following recommendations: 
 (a) Supply reduction activities should be 
integrated into and coordinated with demand reduction 
activities. Efforts among government ministries and 
agencies responsible for law enforcement, health, 
education, social issues and economic development 
activities should be integrated into a complementary 
strategy. Efforts at various levels of government should 
also be coordinated to ensure both a unified approach 
and singular commitment; 
 (b) A central national authority, with a balanced 
representation of supply and demand reduction 
agencies, to coordinate efforts and to prioritize the 
distribution of financial and other resources among 
those responsible for providing health, law 
enforcement, criminal justice, education and social 
services should be considered; 
 (c) Training programmes for criminal justice 
and public health, education and social service officials 
on the interaction of both dimensions of the problem 
and strategies should be developed and implemented; 
combined training activities will contribute to mutual 
understanding between these groups; 
 (d) Research and analysis of existing 
programmes to obtain scientific evidence should be 
conducted and the results used to develop evidence-
based integrated supply and demand programmes and 
to update them as appropriate; 
 (e) Governments should be encouraged to 
compile practical and effective experiences of supply  
 
and demand strategies and to exchange them with 
local, national, regional and international authorities; 
 (f) Interdiction efforts are most effective if they 
focus on disrupting illicit drug markets and sources of 
supply. Efforts to restrict the cultivation of illicit crops 
and the manufacture of illicit substances at the source 
are critical and require international cooperation and 
sustained support in the form of economic, political, 
financial and technical aid. Eradication of illicit crop 
cultivation and interdiction in source areas should be 
accompanied by parallel social and alternative 
development programmes. Alternative sources of work 
and education programmes targeting at-risk 
populations are essential; 
 (g) Supply reduction through street-level law 
enforcement activities are most effective when 
integrated with other programmes aimed at reducing 
demand. Targeted education programmes can 
complement law enforcement activities. Consideration 
should be given to providing alternatives to 
incarceration for some non-violent drug users and to 
increasing services to drug abusers in prisons. The 
convergence of criminal justice pressure and public 
health services that can encourage drug abusers and 
hard-to-reach addicts to obtain the necessary treatment 
has been effective in some areas; 
 (h) Sustained education programmes are 
important in eliminating tolerance for and creating and 
maintaining appropriate attitudes against illicit drug 
availability and use. Such programmes address the 
perceptions of drug abuse; develop personal and social 
skills to help individuals make informed and healthy 
choices; create an environment where people can 
develop and lead healthy lifestyles; and are integrated 
into the public health curriculum in school-, 
community- and family-based prevention programmes; 
 (i) In order to protect drug abusers from the 
influence of criminal networks, consideration should 
be given to providing combined demand and supply 
reduction programmes that increase access to 
treatment, provide alternatives to incarceration and 
offer greater opportunities for rehabilitation and social 
integration. People- and service-oriented policing 
integrated into community-level demand reduction 
initiatives has been effective. 
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 II. Operation of the international drug control system 
 
 
 
 A.  Status of adherence to the international 
drug control treaties 
 
 
52. The Single Convention on Narcotic Drugs of 
196119 and the Convention on Psychotropic Substances 
of 197120 form the basis of the international drug 
control system. The accession of all States to those 
treaties and the universal implementation of all the 
treaty provisions are prerequisites for effective drug 
control worldwide, including the achievement of the 
objectives of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988.21 
 
  Single Convention on Narcotic Drugs of 1961 
 
53. As at 1 November 2004, the number of States 
parties to the Single Convention on Narcotic Drugs of 
1961 stood at 180, of which 176 were parties to that 
Convention as amended by the 1972 Protocol.22 The 
Board welcomes the accession, in 2004, of the Congo to 
the 1961 Convention as amended by the 1972 Protocol. 
A total of 12 States have not yet become parties to the 
1961 Convention: 2 States in Africa (Angola and 
Equatorial Guinea), 4 in Asia (Bhutan, Cambodia, the 
Democratic People’s Republic of Korea and Timor-
Leste), 1 in Europe (Andorra) and 5 in Oceania 
(Kiribati, Nauru, Samoa, Tuvalu and Vanuatu). (Andorra 
and Bhutan have already become parties to the 1988 
Convention.) The Board urges all those States to 
implement the provisions of the 1961 Convention and 
become parties to that convention without further delay. 
54. Four States (Afghanistan, Chad, the Lao People’s 
Democratic Republic and Nicaragua) are parties to the 
1961 Convention but have not yet become parties to the 
1972 Protocol amending the 1961 Convention.23 The 
Board reiterates its request to those States to take action 
to accede to or ratify the 1972 Protocol as soon as 
possible (see also paragraphs 163 and 164 below). 
 
  Convention on Psychotropic Substances of 1971 
 
55. As at 1 November 2004, the number of States 
parties to the 1971 Convention stood at 175. The Board  
 
welcomes the accession of the Congo to the 1971 
Convention. 
56. Of the 17 States that have yet to become parties to 
the 1971 Convention, there are 3 in Africa (Angola, 
Equatorial Guinea and Liberia), 2 in the Americas (Haiti 
and Honduras), 5 in Asia (Bhutan, Cambodia, the 
Democratic People’s Republic of Korea, Nepal and 
Timor-Leste), 1 in Europe (Andorra) and 6 in Oceania 
(Kiribati, Nauru, Samoa, the Solomon Islands, Tuvalu 
and Vanuatu). (Andorra, Bhutan, Haiti, Honduras and 
Nepal have already become parties to the 1988 
Convention.) The Board urges all these States to 
implement the provisions of the 1971 Convention and to 
become parties to 1971 Convention without delay. 
 
  United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 
 
57. The Board welcomes the accession of the 
following States to the 1988 Convention during the 
period under review: Congo, Lao People’s Democratic 
Republic and Micronesia (Federated States of). As at 
1 November 2004, a total of 170 States, plus the 
European Community (extent of competence: 
article 12), were parties to the 1988 Convention. A total 
of 22 States have not yet become parties to the 1988 
Convention: 7 States in Africa (Angola, the Democratic 
Republic of the Congo, Equatorial Guinea, Gabon, 
Liberia, Namibia and Somalia), 3 in Asia (Cambodia, 
the Democratic People’s Republic of Korea and Timor-
Leste), 3 in Europe (the Holy See, Liechtenstein and 
Switzerland) and 9 in Oceania (Kiribati, the Marshall 
Islands, Nauru, Palau, Papua New Guinea, Samoa, the 
Solomon Islands, Tuvalu and Vanuatu). The Board urges 
all those States to implement the provisions of article 12 
and to become parties to the 1988 Convention as soon as 
possible. 
58. The Board is pleased to note that, with the 
exception of Switzerland, all States that are major 
manufacturers, exporters and importers of scheduled 
chemicals are now parties to the 1988 Convention.  
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 B. Cooperation with Governments 
 
 
  Reports on narcotic drugs 
 
  Submission of annual and quarterly statistics 
 
59. The majority of States regularly submit the 
mandatory annual and quarterly statistical reports. As at 
1 November 2004, a total of 175 States and territories 
had submitted to the Board annual statistics on narcotic 
drugs for 2003, in conformity with the provisions of 
article 20 of the 1961 Convention. That accounts for 
83 per cent of the 210 States and territories required to 
furnish such statistics. A total of 188 States and 
territories provided quarterly statistics of imports and 
exports of narcotic drugs for 2003; that figure represents 
90 per cent of the 210 States and territories requested to 
furnish those data. 
60. In 2004, the Board noted an improvement in the 
furnishing of statistical data by Honduras, Mongolia and 
Yemen. In addition, after not furnishing annual 
statistical reports for several years, the British Virgin 
Islands, the Comoros, Djibouti, Dominica and French 
Polynesia resumed submission of those reports. The 
Board urges all Governments to furnish in a timely 
manner all statistical reports required under the 1961 
Convention. The Board will continue to monitor closely 
the situation in countries whose Governments do not 
regularly submit the required reports and will consider 
further measures to ensure their compliance with their 
obligations under the 1961 Convention. 
61. Parties to the 1961 Convention are obliged to 
submit annual statistical reports on narcotic drugs to the 
Board not later than on 30 June following the year to 
which they relate. The Board continues to be concerned 
that several States, including some that are major 
manufacturers, importers, exporters or users of narcotic 
drugs, such as Brazil, Canada, India, the Netherlands 
and Thailand, did not comply in 2004 with that 
requirement and furnished their reports with a 
significant delay. The late submission of reports makes 
it difficult for the Board to monitor manufacture of, 
trade in and consumption of narcotic drugs and hampers 
the analysis by the Board. The Board urges all States 
that experience difficulties in complying in a timely 
manner with their reporting obligations to take all 
measures necessary to ensure the observance of the 
deadline set in the 1961 Convention for the submission 
of annual reports. 
 
  Estimates of requirements for narcotic drugs 
 
62. The universal application of the system of 
estimates is indispensable for the functioning of the 
control system for narcotic drugs. Lack of adequate 
national estimates is often an indication of deficiencies 
in the national control mechanism and/or health system 
of a country. Without proper monitoring and knowledge 
of the actual requirements for narcotic drugs, there is a 
risk, if estimates are too high, that drugs traded in a 
country may be in excess of medical needs and may be 
diverted into illicit channels or used inappropriately. 
Similarly, if estimates are too low, there is a risk that 
there will not be sufficient narcotic drugs available for 
medical treatment. A well-functioning health system is 
necessary to assess the actual requirements of narcotic 
drugs in every country. 
63. As at 1 November 2004, annual estimates of 
narcotic drug requirements for 2005 had been furnished 
by 176 States and territories, or 84 per cent of the States 
and territories required to furnish such estimates. The 
Board is concerned that several States and territories 
failed to provide their estimates in time for examination 
and confirmation by the Board. The Board had to 
establish estimates for them in accordance with 
article 12, paragraph 3, of the 1961 Convention. 
64. The estimates established by the Board are based 
on the estimates and statistics reported in the past by the 
respective Governments. The estimates have in some 
cases been considerably lowered, as a precaution in 
view of the risk of diversion. As a result, the States and 
territories concerned may experience difficulties in 
importing in a timely manner the quantities of narcotic 
drugs required to meet their medical needs. The Board 
urges the States and territories concerned to take all the 
necessary measures to establish their own estimates of 
narcotic drug requirements and furnish those estimates 
to the Board as soon as possible. The Board is ready to 
assist those States and territories by providing 
clarifications on the provisions of the 1961 Convention 
relating to the system of estimates. 
65. The Board reviews the estimates received, 
including supplementary estimates, with a view to 
limiting the use and distribution of narcotic drugs to the 
amount required for medical and scientific purposes and 
to ensuring adequate availability of those drugs for such 
purposes. The Board contacted several Governments 
prior to confirming estimates for 2005, as those 
estimates, according to the information available, 
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appeared to be inadequate. The Board is pleased to note 
that, in 2004, as in previous years, most Governments 
provided clarifications promptly or corrected their 
estimates. 
66. The Board notes that the number of supplementary 
estimates furnished by Governments in accordance with 
article 19, paragraph 3, of the 1961 Convention 
increased in 2004 compared with recent years. A total of 
414 supplementary estimates had been received by 
1 November 2004, compared with fewer than 250 in 
2001. The Board urges Governments to calculate their 
annual medical needs as accurately as possible and to 
make every effort to submit supplementary estimates 
only in cases involving unforeseen circumstances. 
 
  Frequent problems in reporting estimates and 
statistics of narcotic drugs 
 
67. The Board examines the statistical data and 
estimates furnished by Governments and contacts the 
competent authorities, as necessary, in order to clarify 
inconsistencies identified in their reports that may 
indicate shortcomings in national control systems and/or 
the diversion of drugs into illicit channels. The most 
frequent problems in reporting include the omission of 
data on stocks of narcotic drugs in the relevant estimates 
or statistical reports submitted by Governments to the 
Board and confusion in reporting estimates and 
statistical information concerning preparations exempted 
from some reporting requirements (preparations in 
Schedule III of the 1961 Convention). The Board 
encourages all Governments to ensure precise reporting 
on narcotic drugs. 
68. In addition, in 2004, as in 2003,24 several 
Governments did not comply with their obligation under 
article 20, paragraph 1 (e), of the 1961 Convention to 
furnish to the Board statistical reports on seizures of 
narcotic drugs and disposal thereof. The Board reiterates 
its request to the Governments concerned to adopt all 
measures necessary to ensure that statistics on seizures 
of narcotic drugs and disposal thereof, covering 
information from all relevant national authorities, are 
submitted to the Board, including information on the 
quantities of seized drugs released for licit purposes. 
While other international organizations use the seizure 
data reported by Governments mainly for trend analysis, 
the purpose of reporting such data to the Board is to 
ensure that seized drugs have been handled properly and 
that those drugs have not been diverted back into illicit 
channels. In addition, the reporting on seized drugs 
released for licit purposes, including medical and 
scientific purposes, is important for the analysis of the 
licit supply of those drugs in individual countries and 
worldwide. 
 
  Reports on psychotropic substances 
 
  Submission of annual and quarterly statistics 
 
69. As at 1 November 2004, a total of 155 States and 
territories had submitted to the Board annual statistical 
reports on psychotropic substances for 2003 in 
conformity with the provisions of article 16 of the 1971 
Convention. The rate of submission for 2003 was one of 
the highest in the past 10 years. 
70. The cooperation of some States, however, 
continues to be unsatisfactory. In recent years, more 
than one third of the States in Africa and Oceania failed 
to submit annual statistical reports. 
71. The failure of some main manufacturing and 
exporting States to submit annual statistical reports on 
psychotropic substances continues to create difficulties 
for international control, in particular if those States 
failed to submit on time for the previous two years their 
annual statistical reports on psychotropic substances. 
Statistical information on the manufacture, import and 
export of psychotropic substances in those countries is 
necessary to prepare a reliable analysis of global trends 
in manufacture and international trade of psychotropic 
substances. Missing or inaccurate data on exports and 
imports hinder identification of discrepancies in trade 
statistics, thereby impeding international drug control 
efforts. The Board urges the authorities of the countries 
concerned to examine the situation and to cooperate 
with the Board in providing annual statistics on 
psychotropic substances within the deadline, as required 
under the 1971 Convention. 
 
  Assessments of requirements for psychotropic 
substances 
 
72. Assessments of annual domestic medical and 
scientific requirements (simplified estimates) have been 
submitted to the Board by Governments pursuant to 
Economic and Social Council resolution 1981/7 with 
respect to substances in Schedule II of the 1971 
Convention and Council resolution 1991/44 with respect 
to substances in Schedules III and IV of that convention. 
Pursuant to Council resolution 1996/30, the Board 
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established in 1997 assessments for 57 Governments 
that had failed to furnish such information. Since then, 
almost all of those Governments have established their 
own assessments. The assessments are communicated to 
competent authorities of all States and territories that are 
required to use them as guidance when approving 
exports of psychotropic substances. 
73. Despite the fact that assessments of requirements 
for psychotropic substances submitted by States and 
territories do not require confirmation by the Board and 
need not be submitted on an annual basis, the provision 
of accurate assessments is necessary to ensure the 
functioning of the control system. The Board has 
recommended to the Governments to review and update 
their assessments of annual medical and scientific 
requirements for psychotropic substances at least every 
three years. While the majority of Governments submit 
modifications from time to time, a few Governments 
have decided to submit revised assessments every 
year, as is the case with regard to estimates for narcotic 
drugs. 
74. The Board is concerned that a number of 
Governments have not updated their assessments for 
several years. Their assessments may no longer reflect 
their actual domestic medical and scientific 
requirements for psychotropic substances. Assessments 
that are lower than the actual legitimate requirements 
may delay imports of psychotropic substances urgently 
needed for medical or scientific purposes in the country 
concerned because of the need to verify the legitimacy 
of import orders. Assessments that are significantly 
higher than the actual legitimate needs may create an 
opportunity for diversion of psychotropic substances 
into the illicit traffic. The Board encourages all 
Governments to ensure that their assessments are 
regularly updated and that it is informed of any 
modifications. 
 
  Reports on precursors 
 
  Submission of annual information on substances 
frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances 
 
75. As at 1 November 2004, 135 States and territories, 
together with the European Commission (on behalf of 
the States members of the European Union), had 
provided the Board with the required annual information  
 
on chemicals used in the illicit manufacture of narcotic 
drugs and psychotropic substances (on form D). The 
Board notes that Canada, after the adoption of 
comprehensive precursor control legislation, has 
resumed its reporting to the Board. 
76. The Board urges those parties to the 1988 
Convention which have not yet submitted such 
information or have failed to submit it for a number of 
years to provide the required data as soon as possible. 
Those parties, which include Afghanistan, Albania, 
Morocco, Mozambique, New Zealand, the Republic of 
Moldova, Serbia and Montenegro, Turkmenistan and 
Zimbabwe, should comply with their treaty obligations 
as soon as possible. 
77. While over 40 Governments have reported 
seizures of precursors for 2003, few of them have 
supplemented that data with the required additional 
information on non-scheduled chemicals, methods of 
diversion and stopped shipments. The Board calls upon 
all Governments effecting seizures or intercepting 
shipments of precursors to thoroughly investigate those 
cases and to report the results to it. That information is 
needed to identify new trends in illicit drug manufacture 
and trafficking in precursors. 
 
  Submission of annual information on the licit 
trade in and uses of substances in Tables I and II 
of the 1988 Convention 
 
78. Data on the licit trade in, uses of and requirements 
for scheduled substances is essential to the effective 
verification of the legitimacy of transactions. Adequate 
mechanisms and procedures for monitoring the licit 
trade enable Governments to know the trade patterns 
and to identify unusual transactions, which is essential 
to preventing attempted diversions. Therefore, the 
Board  encourages all Governments that have not yet 
done so to collect and report the relevant data in 
accordance with Economic and Social Council 
resolution 1995/20.25 
79. Almost 10 years ago, all Governments recognized 
the need for such voluntary information. The Board 
notes with satisfaction that most States and territories 
submitting form D are also including such information 
in their reports. For example, in the Americas and 
Europe, approximately 95 per cent of Governments 
submitting form D are also providing data on licit trade. 
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80. All of the major manufacturing and exporting 
countries have continued to furnish comprehensive 
information on exports of scheduled substances. The 
Board welcomes the fact that China, a major exporter of 
precursors, has for the first time provided it with data on 
licit trade in substances in Table I of the 1988 
Convention. Canada, which is one of the major 
importers of acetic anhydride, potassium permanganate 
and pseudoephedrine, has also furnished compre-
hensive data on licit trade in, uses of and requirements 
for those and other substances. The Board invites 
Pakistan, which imports significant quantities of 
ephedrine and pseudoephedrine, to also furnish the 
requested data. 
81. All major exporting countries participating in 
Operation Topaz and Operation Purple, the international 
tracking programmes for acetic anhydride and potassium 
permanganate, have continued to provide information on 
individual exports of those substances through pre-
export notifications. The number of Governments 
reporting exports and imports of potassium 
permanganate was the highest recorded in the past five 
years. More and more Governments also report on their 
licit requirements for the two substances. 
82. A large number of Governments have reported 
data for 2003 on the licit movement of and requirements 
for ephedrine and pseudoephedrine, precursors of 
methamphetamine. Some of the main countries 
exporting, importing and trans-shipping a relatively 
newly scheduled precursor, norephedrine, have also 
provided data on licit trade in that substance.  
83. With regard to other key precursors of 
amphetamine-type stimulants, it has been noted that no 
country reported any imports or exports of 
3,4-methylenedioxyphenyl-2-propanone for 2003. More 
countries provided data on imports and exports of 
1-phenyl-2-propanone and safrole for 2003 than for 
previous years. The increase in reporting may be 
partly   attributed to the growing awareness of 
Governments of the importance of monitoring the trade 
in relevant precursors through mechanisms already in 
place, such as Project Prism. The Board trusts that with 
the further development of cooperation under Project 
Prism, which is aimed at monitoring both the 
international trade in and domestic distribution of those 
substances, more comprehensive data will become 
available. 
 
 
 C. Prevention of diversion into the illicit 
traffic 
 
 
  Narcotic drugs 
 
  Diversion from international trade 
 
84. The system of control measures set out in the 1961 
Convention provides for effective protection of 
international trade in narcotic drugs against attempts at 
their diversion into the illicit traffic. In 2004, as in 
recent years, no cases involving the diversion of narcotic 
drugs from licit international trade into illicit channels 
were detected, despite the very large quantities of drugs 
and the large number of transactions involved. 
85. Effective prevention of the diversion of narcotic 
drugs from international trade requires the 
implementation by Governments, in cooperation with 
the Board, of all control measures for those drugs, as 
provided for in the 1961 Convention. While most 
Governments have been fully implementing the system 
of estimates and the import and export authorization 
system, some Governments authorized in 2003 and 2004 
exports of narcotic drugs from their countries in excess 
of the corresponding total of the estimates of the 
respective importing countries. The Board reminds the 
Governments concerned that such exports are contrary 
to the provisions of article 31 of the 1961 Convention 
and could result in the diversion of narcotic drugs if 
falsified import authorizations were used by drug 
traffickers. The Board has contacted the Governments in 
question and urged them to ensure compliance with the 
provisions of article 31 of the 1961 Convention when 
authorizing exports of narcotic drugs in the future. 
 
  Diversion from domestic distribution channels 
 
86. In 2003, the Board sent a questionnaire to selected 
developing countries to obtain information on the 
diversion and abuse of pharmaceutical preparations 
containing narcotic drugs. The replies received 
confirmed that there has been some diversion and abuse 
of such preparations, in particular codeine syrups and 
tablets, dextropropoxyphene tablets and ampoules, and 
pethidine ampoules. The most frequent methods of 
diversion include illegal purchases from wholesalers and 
retailers, as well as theft from various domestic 
distributors, including hospitals. Several countries 
reported that smuggling from abroad was one source of 
the illicit supply of the preparations. 
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87. The Board requests all Governments concerned to 
strictly implement the control measures stipulated in the 
1961 Convention to stop the diversion and abuse of 
pharmaceutical preparations. The Board notes with 
appreciation that some Governments have taken such 
measures. For example, in Malaysia, close monitoring of 
the distribution of cough mixtures containing codeine 
and pholcodine was introduced and the size of cough 
mixture packages containing pholcodine was reduced. In 
Thailand, the dispensing of codeine cough syrups 
without prescription in drugstores and clinics was 
stopped. In Zimbabwe, a prescription requirement was 
introduced for cough mixtures containing codeine. 
88. In some countries, the diversion and abuse of 
narcotic drugs involve preparations for which certain 
control measures (such as prescription requirement) are 
not mandatory under the 1961 Convention. While the 
availability of those preparations for medical purposes 
should not be reduced, the Governments concerned 
should carefully examine the impact of those 
exemptions on the diversion and abuse of such 
preparations in their countries and, if necessary, apply 
more appropriate levels of control, in accordance with 
the provisions of article 39 of the 1961 Convention. 
89. The Board urges the Governments of countries 
into which pharmaceutical products containing narcotic 
drugs are smuggled from abroad to raise the awareness 
of their customs authorities regarding that problem and 
to actively seek the cooperation of the countries out of 
which the products are smuggled, in order to stop those 
illegal activities. The Board is at the disposal of the 
interested Governments to facilitate the investigation of 
cases involving the smuggling of such preparations. 
90. Governments of some countries in which problems 
with the diversion and abuse of pharmaceutical prepara-
tions containing narcotic drugs were identified in the 
past, such as Egypt, India and Pakistan, have not sub-
mitted the questionnaire or stated that information is not 
available. The Board requests the Governments con-
cerned to establish a mechanism for collecting informa-
tion on the problem, so that, if necessary, measures 
against such diversion and abuse can be taken promptly. 
The Board urges international entities, such as the World 
Health Organization (WHO) and the United Nations 
Office on Drugs and Crime, to assist Governments, 
wherever appropriate, in preventing the diversion and 
abuse of pharmaceutical preparations containing 
controlled substances and in monitoring trends in that 
area. 
91. The diversion of pharmaceutical products 
containing narcotic drugs from domestic licit 
distribution channels and the abuse of such products 
continue to be problems not only in developing 
countries, but also in some developed countries. In the 
United States, a nationwide survey carried out by the 
University of Michigan in 2003 indicated that the extent 
of non-medical use of prescription drugs among young 
people was second only to the extent of cannabis abuse. 
According to the survey, among persons in their final 
year of secondary school (ages 17-18) the abuse of 
hydrocodone was more than double the abuse of 
cocaine, Ecstasy or methamphetamine. Among the 
persons in that age group, 10 per cent reported 
non-medical use of hydrocodone and about 5 per cent 
reported non-medical use of oxycodone. 
92. The Board welcomes the fact that prevention of 
the diversion and abuse of pharmaceutical preparations 
has become one of the priorities in the National Drug 
Control Strategy of the United States. The Government 
is developing prescription monitoring programmes to 
facilitate the collection, analysis and reporting of 
information on the prescribing, dispensing and use of 
pharmaceuticals, in order to identify and prevent cases 
of diversion or inappropriate prescribing. 
93. Cases involving the diversion and abuse of 
opioids, in particular methadone and buprenorphine, 
when prescribed for substitution treatment have been 
identified in many countries. The Board requests the 
Governments of countries where opioids are used for 
substitution treatment to take measures to prevent their 
diversion. Such measures may include supervised 
consumption, short dispensing intervals and central 
registration of all opioids prescribed for treatment 
purposes. The Board notes that there have been reports 
in Austria of the diversion of slow-release oral morphine 
tablets used for substitution treatment. The Board, aware 
that the Austrian authorities are investigating the 
situation, would appreciate being informed promptly 
of the results of that investigation and, if necessary, 
of action taken by the authorities to prevent such 
diversion. 
94. The Russian Federation reported cases involving 
the use of poppy seeds for the illicit manufacture of  
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extracts containing alkaloids, to be subsequently abused. 
The investigation of those cases revealed that poppy 
seeds used for the illicit manufacture of such extracts 
were contaminated with poppy straw, which was the 
main reason for the relatively high alkaloid content in 
the extracts. The poppy seeds in question were 
imported into the Russian Federation from various 
countries to be used for culinary purposes. The Board 
encourages all Governments to be vigilant with respect 
to attempts by traffickers to use poppy seeds mixed 
with poppy straw for illicit drug manufacture and to 
prevent the export and import of such consignments, in 
accordance with their obligations under the 1961 
Convention concerning international trade in poppy 
straw. 
 
  Psychotropic substances 
 
  Diversion from international trade 
 
95. Licit international trade in psychotropic substances 
in Schedule I of the 1971 Convention has been limited 
to occasional transactions involving in almost all cases 
quantities of no more than a few grams. There have been 
isolated attempts to divert substances in Schedule I over 
the years, but they have all been thwarted as a result of 
the strict international control mechanism for those 
substances. 
96. For most substances in Schedule II of the 1971 
Convention, licit international trade has been restricted 
to a limited number of transactions. The only major 
exception is international trade in methylphenidate, 
which, since the beginning of the 1990s, has 
increasingly been used in the treatment of attention 
deficit disorder (ADD). In recent years, international 
trade in dexamfetamine, also used in the treatment of 
ADD, has increased, though to a much smaller extent. In 
the past, the diversion of substances in Schedule II from 
licit international trade into the illicit traffic was 
frequent; however, no significant cases involving such 
diversion have been identified since 1990. That is 
attributable to the implementation by Governments of 
the control measures for substances in Schedule II 
provided for in the 1971 Convention and to the almost 
universal application of additional control measures 
(assessments and quarterly statistical reports) 
recommended by the Board and endorsed by the 
Economic and Social Council. 
97. Those strict control measures have eliminated the 
use of international trade for the diversion of substances 
in Schedule II into illicit channels. In some cases, 
however, strong demand in illicit markets for a specific 
pharmaceutical preparation containing a substance in 
Schedule II has led to the illicit manufacture of 
counterfeit preparations. One example of that is the 
ongoing illicit manufacture of counterfeit Captagon, a 
pharmaceutical preparation that, in its licit form, 
contains fenetylline. Numerous diversions of licitly 
manufactured Captagon and/or the base substance 
fenetylline occurred during the late 1980s. Since the 
beginning of the 1990s increased control measures have 
succeeded in stopping such diversions. Diversion 
attempts have been thwarted in all cases except one: in 
1998, 70 kg of fenetylline were diverted from 
Switzerland to Azerbaijan. As fenetylline can no longer 
be obtained from licit sources, traffickers have resorted 
to the use of illicitly manufactured fenetylline, in 
addition to substituting other stimulants for fenetylline. 
In recent years, most of the tablets seized have 
contained amphetamines, in addition to stimulants not 
under international control. 
98. The illicit markets for the counterfeit Captagon 
tablets are countries in the area of the Persian Gulf. The 
illicit consignments are to a large extent smuggled 
through Turkey. The Turkish law enforcement 
authorities are aware of the problem and are making 
every effort to identify diversion attempts. Millions of 
counterfeit Captagon tablets are seized in Turkey every 
year, which is an indication of a well-established 
international trafficking network. According to Turkish 
seizure data, Bulgaria is the country most often 
identified as the source of the seized tablets. 
99. Licit international trade in psychotropic substances 
in Schedules III and IV of the 1971 Convention is 
common; there are thousands of individual transactions 
involving such substances each year. The analysis by the 
Board of data on international trade in substances 
included in those schedules has indicated a significant 
decrease in the number of cases involving diversion of 
those substances from international trade in the past five 
years. Cases identified by national authorities during the 
past year involved quantities of no more than 1 kg, 
whereas during the 1990s such cases often involved 
quantities of several hundred kilograms. That positive 
development is the result of the implementation by 
Governments of treaty provisions, combined with 
voluntary additional controls over international trade 
recommended by the Board and endorsed by the 
Economic and Social Council, such as the system of 
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assessments of annual requirements for psychotropic 
substances, the import and export authorization system 
and additional reporting. 
100. Despite those positive developments, there 
continue to be attempts to divert substances in 
Schedules III and IV of the 1971 Convention. In all 
cases, the diversion attempts have involved substances 
identified many years ago as target substances for 
specific illicit drug markets. During the past year, two 
such attempts involved pemoline (a stimulant) and 
temazepam (a benzodiazepine), both of which are 
included in Schedule IV of the 1971 Convention. Both 
substances have been the target of numerous diversion 
attempts over the past decade and are known for their 
street value in specific illicit drug markets. In both 
cases, drug traffickers appeared to have placed an order 
to establish business relations with manufacturers or 
wholesalers with the intention of then using that first 
order to establish trust with their business partners 
before placing larger follow-up orders. 
101. The case of attempted diversion of pemoline 
mentioned in paragraph 100 involved Nigerian drug 
dealers who tried to illegally import 90 kg of pemoline 
from China. As in previous attempts to divert large 
quantities of pemoline into West African countries, the 
pemoline was purportedly needed for veterinary 
purposes: to facilitate the transport of cattle over long 
distances. The investigation carried out by the Board in 
cooperation with the Chinese and Nigerian authorities 
revealed that the drug traffickers had first established 
contact with the manufacturing company in China by 
Internet. That case demonstrates that certain 
psychotropic substances, even after a considerable 
period of time during which their availability on the 
illicit market has been restricted, continue to be 
attractive to drug traffickers; thus, attempts to divert 
such a substance may occur long after the large-scale 
abuse of the substance has stopped. 
102. The same applies to a diversion attempt involving 
temazepam, a benzodiazepine that has, for many years, 
been one of the most popular psychotropic substances 
on the illicit drug market in the United Kingdom of 
Great Britain and Northern Ireland, particularly in 
Scotland. Over the years numerous attempts to divert the 
substance to the illicit market have been discovered and 
prevented. Whenever a prospective source has been 
discovered and closed down by the competent 
authorities of one country, drug traffickers have shifted 
their operations to another country. In the most recent 
case of an attempted diversion of temazepam, a 
company in Kosovo (Serbia and Montenegro) ordered 
6 kg of temazepam from India. The Indian authorities, 
noting that no assessment had been established for the 
substance by the authorities in Kosovo, contacted 
through the Board those authorities, who confirmed that 
they had never authorized the transaction. 
103. In both of the above-mentioned cases, the 
vigilance of the competent authorities of the exporting 
country prevented the diversion attempt. The Board 
notes with appreciation the increasing cooperation of 
national authorities with the Board, as well as between 
the national authorities of different countries, which has 
contributed to a significant improvement in international 
drug control. As shown in the above two examples, 
almost all diversions have been prevented as a result of 
the vigilance of competent authorities and law 
enforcement authorities and, in some cases, the 
voluntary cooperation of manufacturers of psychotropic 
substances. The Board notes with appreciation that 
exporting countries use the assessments of requirements 
of psychotropic substances published by the Board to 
verify the legitimacy of trade transactions. Such 
verification is especially important in the case of orders 
placed by companies in the few countries that have not 
yet introduced mandatory import authorizations for all 
psychotropic substances. Trade transactions identified as 
suspicious because the import orders exceed the 
established assessments are either verified with the 
Board or brought to the attention of the importing 
country. That process facilitates the identification of 
diversion attempts. 
104. Encouraged by this positive development in 
international cooperation, the Board again calls on all 
Governments to continue to be vigilant with respect to 
orders for psychotropic substances in Schedules III 
and IV of the 1971 Convention and, if necessary, to con-
firm with the Governments of importing countries the 
legitimacy of those orders prior to approving the export 
of those substances. The Board continues to be at the 
disposal of Governments to facilitate such confirmation. 
 
  Diversion from domestic distribution channels 
 
105. In contrast to international trade, the diversion of 
psychotropic substances from domestic distribution 
channels continues; such diversions involve, in some 
cases, relatively large quantities of psychotropic 
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substances. Reports in various countries on the abuse 
and seizure of psychotropic substances indicate that the 
diversion of pharmaceutical products containing such 
substances from licit domestic distribution channels is 
becoming the most important source for illicit drug 
suppliers. The methods used by drug traffickers to divert 
those products include: theft from factories and 
wholesalers; pretended export; falsified prescription; 
and the supplying of substances by pharmacies without 
the required prescriptions. 
106. The majority of the diversion cases have involved 
relatively small quantities of psychotropic substances 
destined either for abuse by an individual drug addict or 
for small-scale dealing. Seizure data, however, show 
that the large-scale diversion of such substances from 
domestic distribution channels also frequently occurs. 
For example, more than 100,000 doses of buprenorphine 
ampoules were seized in Pakistan only in the first half of 
2004; 77,250 ampoules were seized in one major haul. 
All of the seizures were effected during smuggling 
attempts by commercial air shipment from India. 
107. In March 2004, the Board was informed by the 
Swiss authorities about an attempted diversion of 
2,040 packages of Toquilone compositum® tablets, 
containing methaqualone, a substance in Schedule II of 
the 1971 Convention. The diversion was attempted by a 
citizen of Serbia and Montenegro who presented to each 
of a number of Swiss pharmacies a prescription for 
120 packages of Toquilone that had been issued by a 
physician in Serbia and Montenegro. Because of the 
vigilance of the Swiss pharmacies, the sales were not 
effected and the competent authorities of Switzerland 
were immediately alerted. 
108. The Board continues to request the cooperation of 
Governments with regard to the diversion and 
smuggling of flunitrazepam (under the brand name 
Rohypnol) from Eastern European countries to Nordic 
countries. In the 1990s, the substance was diverted from 
licit manufacturers in the Czech Republic. Investigations 
undertaken to ascertain whether licitly imported 
flunitrazepam tablets had been diverted from domestic 
distribution channels concluded that no cases of 
diversion had been confirmed in the Russian Federation. 
It should be noted, however, that the competent 
authorities of Belarus have reported the uncovering of a 
channel used for the diversion of flunitrazepam from 
Belarus to Lithuania. The last significant seizure of the 
substance in Sweden, made in January 2004, involved 
119,500 tablets of Rohypnol. A sample of those tablets 
tested by a manufacturing company in Switzerland 
revealed that the tablets consisted of a counterfeit 
version of green Rohypnol 1 mg tablets. The Board 
appreciates the cooperation of the Governments of the 
Russian Federation, Sweden and Switzerland in the 
above-mentioned investigations. 
 
  Precursors 
 
109. Traffickers have been increasingly using new 
routes and new methods of diversion of substances for 
the illicit manufacture of drugs. Responses to those 
developments require modern and flexible approaches to 
achieve maximum effect. The experience of the past 
year has shown that the rapid exchange of information 
concerning both licit trade and trafficking in precursors 
is currently the most effective way to prevent such 
diversion. In particular, through pre-export notifications, 
Governments have been able to rapidly verify the 
legitimacy of individual shipments. In exercising its 
functions under article 12 of the 1988 Convention, the 
Board, through its secretariat, continues to act as the 
international focal point for the exchange of information 
under Operation Purple, Operation Topaz and Project 
Prism. Operational procedures and mechanisms, 
developed through informal and practical forums, have 
been particularly useful. The Board and Governments 
have therefore continued to place high priority on 
establishing and maintaining such mechanisms. Full 
details of the activities undertaken under the operations 
and of the overall impact of those activities are 
contained in the 2004 report of the Board on the 
implementation of article 12 of the 1988 Convention.26 
110. A total of 20,227 transactions have been notified to 
the Board and examined under the operations during the 
past two years. With the assistance of the Board, 
national competent authorities have initiated additional 
inquiries in 639 of those cases, which resulted in 
161 seizures and 242 stopped shipments and in the 
identification of 7 attempted diversions and 10 actual 
diversions. The Board has also initiated a further 
605 inquiries, which led to 21 seizures and 56 stopped 
shipments and the identification of 7 attempted 
diversions and 6 actual diversions. 
111. With regard to future activities, under the 
operations special efforts should be made to collect, 
analyse and share real-time operational information and 
intelligence on the licit trade and traffic in precursors. 
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Real-time exchange of information on investigations 
into seizures, stopped shipments and diversion attempts 
is essential in order to identify both the method of 
diversion and the persons involved. Controlled 
deliveries should be used to the maximum extent 
possible, depending on the circumstances of each 
individual case. It is the Board’s intention to examine 
the possibilities for harmonizing the work of the three 
operations, based on the lessons learned from each of 
them. 
112. The Board wishes to remind Governments that the 
objectives of the operations are in line with the goals 
agreed at the twentieth special session of the General 
Assembly concerning amphetamine-type stimulants and 
the control of precursors. Governments are therefore 
urged to make available appropriate resources to support 
operational activities, with a view to meeting those 
goals. For its part, the Board will continue to support 
those activities, through its secretariat and in accordance 
with its mandate under the 1988 Convention. 
 
  Project Prism  
 
113. During 2004, activities of Project Prism, the 
international initiative against diversion of precursors of 
amphetamine-type stimulants, focused on specific time-
bound operations, including the monitoring of 
international trade in safrole, preventing diversions of 
pharmaceutical preparations containing pseudo-
ephedrine and locating laboratories involved in the illicit 
manufacture of 1-phenyl-2-propanone. The Board urges 
each Government to designate without delay a single 
contact point, or central national authority, to serve as 
the focal point for all operational activities under Project 
Prism, which will assist in ensuring coordination of 
national efforts and the smooth flow of information. 
114. Because of the more effective monitoring of 
international trade, traffickers are increasingly turning to 
smuggling chemicals and pharmaceutical preparations 
containing, in particular, ephedrine and psuedo-
ephedrine. Project Prism has therefore focused on 
backtracking investigations into seizures of precursors 
of amphetamine-type stimulants at ports of entry or 
illicit drug laboratory sites. The Board notes that there 
were numerous successes in that area in 2004, such as 
the cooperation between the Governments of China and 
Poland with regard to a major case involving the 
smuggling of 1-phenyl-2-propanone into Poland. 
115. A specific time-bound operation focusing on 
backtracking investigations will be launched in Europe 
with the objective of identifying companies and 
individuals responsible for the manufacture and 
diversion of 1-phenyl-2-propanone in the region. The 
Board welcomes the launching of a limited-time 
initiative for tracking preparations containing ephedrine 
and pseudoephedrine; the initiative will focus on the 
supply of pre-export notifications for shipments of 
pharmaceutical preparations in international trade and 
will proceed on a country-by-country basis. 
116. The Board reviewed the information supplied by 
Governments on the licit movement of safrole and found 
it to be very limited. The Board has therefore endorsed 
the task force proposal to launch a three-month 
international programme for tracking safrole in order to 
identify the exporters and, on the basis of that 
information, the manufacturers and producers involved. 
The Board urges all Governments concerned to support 
the above-mentioned initiatives under the Project. 
 
  Operation Purple 
 
117. Operation Purple, the intensive international 
tracking programme for potassium permanganate, has 
continued to be useful to Governments in preventing 
diversions of the substance for use in the illicit 
manufacture of cocaine. During the phase of the 
operation from 1 January 2004 to 1 November 2004, a 
total of 780 shipments, involving over 20,000 tons of 
potassium permanganate, were monitored. Furthermore, 
17 shipments in international trade, involving 620 tons 
of potassium permanganate, were stopped, as there was 
reason to suspect that the shipments were to be diverted. 
118. One of the main objectives of the Board is to 
monitor the shipment of potassium permanganate to 
countries not participating in Operation Purple. The 
Board has noted, in particular, an increase in the number 
of shipments reported to non-participating countries in 
the African region. Following the Board’s enquiries, 
suspicious orders have been identified. For example, the 
Board appreciates the efforts of the competent 
authorities of Morocco and Egypt, which are, 
respectively, the first and the second largest importers of 
potassium permanganate in Africa. Morocco is currently 
also the fifth largest importer of potassium 
permanganate in the world. 
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119. The Board notes with concern that there is limited 
reporting on trafficking in potassium permanganate in 
countries in Central America and South America. Those 
are the countries most affected by the smuggling of 
potassium permanganate and the subsequent 
manufacture of cocaine. The Board therefore urges all 
those countries to establish the necessary mechanisms 
for providing information on seizures of potassium 
permanganate. 
 
  Operation Topaz 
 
120. The 46 participating States and territories and the 
relevant international organizations have continued to 
use Operation Topaz as an effective tool to monitor 
international trade in acetic anhydride and to quickly 
launch backtracking investigations into seizures of that 
precursor. In addition, the operation has provided a good 
opportunity to develop synergies between law 
enforcement and regulatory authorities. 
121. The Board welcomes the fact that two more States, 
Serbia and Montenegro and Turkmenistan, joined the 
operation in 2004 and that two non-participating 
countries, Japan and the Republic of Korea, are now 
supplying pre-export notifications for all shipments of 
acetic anhydride. 
122. The patterns of trade in acetic anhydride have 
remained largely stable over the past few years. During 
the first 10 months of 2004, nearly 750 shipments of 
acetic anhydride, amounting to over 210,000 tons of the 
substance, were reported in international trade by 
17   States and territories. The Board assisted 
Governments in identifying six attempted diversions of 
acetic anhydride and also facilitated the launching of 
backtracking investigations in three significant cases. 
The Board would like to emphasize the usefulness of 
operational meetings such as the one hosted by the 
Government of Austria in Vienna in June 2004.27 Those 
meetings bring together investigators from various 
countries concerned by a case, or a series of cases, with 
the aim of exchanging information on investigations and 
deciding on further action necessary for the dismantling 
of trafficking activities. The Board encourages other 
Governments involved in Operation Topaz to organize 
such meetings, where necessary, and stands ready to 
assist in that regard. 
123. Shipments of acetic anhydride to West Asia remain 
a special focus of Operation Topaz. There is no licit 
requirement for the substance in Afghanistan, and trade 
in acetic anhydride in the region is extremely limited. 
For example, in 2004, only two shipments of acetic 
anhydride to Afghanistan or its neighbouring countries 
were reported: both of those shipments were to 
Pakistan. The only seizure of acetic anhydride reported 
in the region was one in Afghanistan amounting to 375 
litres. It therefore appears that the acetic anhydride 
being used in illicit heroin manufacture in that country 
is smuggled through its neighbouring countries and not 
diverted in the region. The Board urges all 
Governments to make full use of the mechanisms 
established under Operation Topaz for addressing the 
issue of heroin manufacture in West Asia. 
 
 
 D. Control measures 
 
 
  Export of poppy seeds from countries 
prohibiting cultivation  
 
124. In its resolution 1999/32, the Economic and Social 
Council called upon Member States to take measures to 
fight the international trade in poppy seeds from 
countries where no licit cultivation of opium poppy was 
permitted. The Board notes with appreciation that 
several States have taken such measures. Strict control 
measures were implemented in India for the import of 
poppy seeds. Similarly, the authorities of Myanmar and 
Pakistan have adopted measures against trade in poppy 
seeds from illicit sources. 
125. The Board wishes to remind all Governments that, 
since the cultivation of opium poppy is prohibited in 
Afghanistan, the import of poppy seeds from that 
country would be contrary to the efforts of the 
Government of Afghanistan to eradicate illicit opium 
poppy cultivation. The Board urges all Governments to 
prevent all imports of poppy seeds from illicit opium 
poppy cultivation. The Board would appreciate being 
informed of action taken by Governments to implement 
Council resolution 1999/32, including any legislative 
and administrative measures taken and any seizures of 
poppy seeds made by their law enforcement authorities 
because the seeds in question originated in countries 
where opium poppy cultivation is not permitted. 
 
  Implementation of scheduling decisions for 
psychotropic substances 
 
126. Some Governments have reported difficulties in 
implementing the scheduling decisions for psychotropic 
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substances within the time frame stipulated by the 1971 
Convention, namely 180 days after the date of the 
communication of such a decision by the Secretary-
General to all States. The Board reminds the 
Governments concerned of their obligations under 
article 2 of the 1971 Convention and requests them to 
consider putting in place necessary legislative and 
administrative arrangements to enable them to ensure 
prompt scheduling with a view to complying with their 
treaty obligations. The Board wishes to call the attention 
of Governments to the national scheduling systems in 
force in some countries that allow for automatic 
scheduling of substances under the national control 
system of those countries whenever a substance is put 
under international control. 
 
  Controls over international trade in 
psychotropic substances 
 
127. The Board notes with appreciation that Cambodia, 
the Comoros, Côte d’Ivoire, Ghana, Japan, Kyrgyzstan, 
Portugal, Slovakia, Sweden and Uganda extended in 
2004 the system of import and export authorizations to 
include all substances in Schedules III and IV of the 
1971 Convention. The Republic of Korea extended the 
import authorization requirements for the following 
substances: amfepramone, gamma-hydroxybutyric acid 
(GHB), mazindol, pemoline, phentermine and zolpidem. 
Cameroon has notified that the substances pentazocine, 
alprazolam, chlordiazepoxide and zolpidem require 
import authorizations. At present, export and import 
authorizations are required by national legislation for all 
substances in Schedule III in 186 countries and 
territories and for all substances in Schedule IV in 
192 countries and territories. The Board continues to 
collect samples of import authorization forms issued by 
national authorities. Those samples allow the Board to 
verify the legitimacy of import orders at the request of 
exporting countries. The Board calls on all Governments 
that have not yet provided it with such samples to do so 
without further delay. 
128. The Board requests the Governments of all 
countries that do not yet control the import and export of 
all psychotropic substances by the system of import and 
export authorizations to introduce such controls. 
Experience shows that countries that are the centres of 
international commerce but do not have such controls 
are at particular risk of being targeted by drug 
traffickers. The Governments of some of those 
countries, including the Government of Ireland, with 
which the Board has had a dialogue on this issue for a 
long time, have stated their intention to extend the 
import and export authorization system to all 
psychotropic substances. The Board trusts that they will 
implement those controls as soon as possible. The Board 
urges all the other States concerned, regardless of 
whether or not they are parties to the 1971 Convention, 
to also introduce such controls. 
129. Several exporting countries received in 2003 
import authorizations for quantities of psychotropic 
substances in excess of assessments established by the 
authorities of the importing countries. The Board notes 
that the number of countries issuing such authorizations 
for quantities above the assessments has declined in 
recent years. The Board appreciates the support received 
from some major exporting countries, including France, 
Germany, India and Switzerland, that have been 
consistently reminding the importing countries of any 
failure to comply with the assessment system. The 
Board reiterates its request to all Governments to 
establish a mechanism to ensure that their assessments 
are in line with their actual legitimate needs and that no 
imports exceeding the assessments are authorized. 
130. In accordance with Economic and Social Council 
resolutions 1985/15 and 1987/30, Governments should, 
in their annual statistical reports, provide the Board with 
details on trade in substances in Schedules III and IV of 
the 1971 Convention. Those details should include the 
names of the countries of origin for imports and the 
countries of destination for exports. Complete details on 
trade movements were submitted by 132 Governments. 
With few exceptions, all the major manufacturing and 
exporting countries furnished such information for 2003. 
However, about 20 parties to the 1971 Convention failed 
to provide that information, which may indicate certain 
deficiencies in their national reporting systems. The 
Board encourages the Governments of the countries 
concerned to improve their data collection systems in 
order to ensure the submission of details on trade in 
substances in Schedules III and IV in their future reports 
to the Board. 
131. Many exporting countries request the assistance of 
the Board in verifying the legitimacy of import 
authorizations for psychotropic substances purportedly 
issued by the authorities of the importing countries. The 
Board notes with concern that in certain cases responses 
to the Board’s inquiries for confirmation of the 
legitimacy of import orders have taken months. The 
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Board is concerned that failure to cooperate with it may 
hinder the investigation of diversion attempts and/or 
cause delays in the legitimate trade in psychotropic 
substances. The Board would like to draw the attention 
of the Governments of Bosnia and Herzegovina, Gabon, 
the Islamic Republic of Iran, Kenya, Myanmar, the 
Republic of Korea, Somalia and Sri Lanka to the 
importance of responding in a timely manner to the 
Board’s requests, in order to avoid delaying imports, 
which have an adverse effect on the availability of 
psychotropic substances for legitimate purposes. 
 
  Lack of precise information in data collected by 
law enforcement agencies on seizures of 
psychotropic substances 
 
132. The Board has noted difficulties in providing 
specific information regarding the collection and 
classification of data on seizures of psychotropic 
substances. The review of the annual reports 
questionnaire of the Secretary-General in the mid-1990s 
resulted in, among other things, the classification of 
such substances into the following three groups: 
amphetamine type (amphetamine, methamphetamine); 
hallucinogens (lysergic acid diethylamide (LSD)); and 
sedatives and tranquillizers (barbiturates, benzo-
diazepines, methaqualone). Providing such detail allows 
for more in-depth analysis of trends in trafficking in 
psychotropic substances. In response, a number of 
competent national authorities have provided more 
specific data; sometimes the data have been classified 
down to the substance level. At the same time, however, 
many national authorities, in particular law enforcement 
agencies, continue to use terms such as “tablets” or 
“synthetic drugs” or they use a term such as “Ecstasy” 
for drugs containing substances other than MDMA that 
have been seized at rave parties, as MDMA is the 
substance most commonly seized at those events. That 
practice is attributable to a lack of laboratory equipment 
and also to insufficient training of national law 
enforcement agencies. The Board wishes to draw to the 
attention of international organizations such as the 
International Criminal Police Organization (Interpol) 
and the Customs Co-operation Council (also called the 
World Customs Organization) to the important role that 
they could play in that matter, particularly in raising the 
awareness of national law enforcement authorities by 
distributing substance-specific information and 
providing training to such authorities. 
 
 
 E. Ensuring the availability of drugs for 
medical purposes 
 
 
  Demand for and supply of opiates  
 
133. The Board, pursuant to the 1961 Convention and 
relevant Economic and Social Council resolutions, 
examines on a regular basis issues affecting the supply 
of and demand for opiates used for medical and 
scientific purposes and endeavours, in cooperation with 
Governments, to maintain a lasting balance between the 
two. A detailed analysis of the current situation with 
regard to the supply of and demand for opiates for 
medical and scientific purposes worldwide is contained 
in the 2004 technical report of the Board on narcotic 
drugs.28 
 
  Monitoring of the global situation of supply of 
opiate raw materials 
 
134. The Board notes with appreciation that most 
Governments of producing countries have adhered to its 
recommendations and taken action to reduce the 
production of opiate raw materials, those rich in 
morphine and those rich in thebaine, to reflect the global 
demand for those raw materials. For both types of raw 
materials, production had, until recently, been increasing 
at levels well in excess of global demand. For opiate raw 
materials rich in morphine, the increase in 2003 was at a 
lower rate; in that year total production amounted to 
487 tons in morphine equivalent. For opiate raw 
materials rich in thebaine, total production declined to 
80 tons in thebaine equivalent in 2003. Advance data 
submitted by the major producing countries indicate that 
global production of opiate raw materials rich in 
morphine is expected to decline to 440 tons in morphine 
equivalent in 2004, while production of raw materials 
rich in thebaine is expected to rise to an estimated 
95 tons in thebaine equivalent. At present, it is antici-
pated that global production of both types of opiate raw 
materials will be slightly higher than the level of global 
demand, which is about 400 tons in morphine equivalent 
for raw materials rich in morphine and 90 tons in 
thebaine equivalent for raw materials rich in thebaine. 
135. Increases in the total area cultivated with opium 
poppy in producing countries and in the agricultural 
yields obtained, coupled with technological progress, 
have resulted in overproduction and increasing stocks of 
opiate raw materials observed in recent years. Stocks of 
both types of opiate raw materials reached a record high 
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at the end of 2003. Consequently, those stocks continue 
to be more than sufficient to cover the global demand 
for opiate raw materials for one year. Although global 
demand will slightly increase in 2004 for both types of 
raw materials, it is not expected to exceed the estimated 
production in that year. Stocks of opiate raw materials 
are therefore expected to increase further in 2004. 
136. The Board notes with appreciation that, for 2005, 
most Governments have followed its advice and 
maintained the area to be cultivated with opium poppy 
well below the level of 2002 or 2003, which should help 
to keep the level of production of opiate raw materials in 
line with global demand. The Board trusts that all 
Governments of producing countries will adhere to the 
estimates system for the cultivation of opium poppy and 
will keep cultivation within the upper limits of the 
estimates confirmed by the Board or send 
supplementary estimates to the Board, if necessary.  
137. The Board urges all producing countries to act in 
accordance with the objectives and established policies 
of international drug control and to maintain their future 
production of opiate raw materials at a level reflecting 
the actual requirements for such raw materials 
worldwide, thus avoiding an inappropriately high level 
of stocks, which might be a source of diversion if they 
are not tightly controlled. In view of the continued 
inadequate global consumption of opiates for the 
treatment of pain, the Board reiterates that it would 
welcome a further increase in global demand for opiates 
(see also paras. 143 and 144 below). The Board 
encourages Governments to take steps to increase the 
medical use of opiates in their countries in order to meet 
their real needs for the treatment of pain. 
 
  Control over the cultivation of opium poppy 
destined for the extraction of alkaloids 
 
138. The Board has highlighted on several occasions 
the need for enhanced control over the cultivation of 
opium poppy and the subsequent production of poppy 
straw, in line with the relevant Economic and Social 
Council and General Assembly resolutions (see, for 
example, the report of the Board for 2003).29 The Board 
notes the recent technological progress achieved in the 
cultivation of opium poppy, which has resulted in 
significant increases in the concentration of alkaloids in 
opium poppy plants in several producing countries. The 
potential for diversion of opium poppy plants licitly 
cultivated in the relevant countries, as well as the abuse 
potential of alkaloids obtained illegally from such 
plants, has therefore also increased substantially. The 
Board urges all Governments of producing countries to 
review the adequacy of the existing controls over the 
licit cultivation of opium poppy in their territories and, 
if those controls are found to be inadequate, to take 
remedial measures without delay. 
 
  Prevention of the proliferation of production of 
opiate raw materials 
 
139. In line with the relevant Economic and Social 
Council resolutions, the Board calls on all Governments 
to contribute to the maintenance of a balance between 
the licit supply of and demand for opiate raw materials 
and to cooperate with it in preventing the proliferation 
of sources of production of opiate raw materials. Most 
recently, in its resolution 2004/43, the Council urged 
Governments of all countries where, in the past, opium 
poppy had not been cultivated for the licit production of 
opiate raw materials, in the spirit of shared 
responsibility, to refrain from engaging in the 
commercial cultivation of opium poppy, in order to 
avoid the proliferation of supply sites. 
140. The Board wishes to remind Governments that 
narcotic drugs and their raw materials are not ordinary 
commodities and that therefore market economy 
considerations should not be the decisive factors when 
deciding on whether or not to permit drug crop 
cultivation. The Board appeals to all Governments to 
comply with Economic and Social Council 
resolution 2004/43. 
 
  Informal consultation on the supply of and 
demand for opiates for medical and scientific 
purposes 
 
141. At the request of the Governments of India and 
Turkey, the Board convened an informal consultation on 
the supply of and demand for opiates for medical and 
scientific purposes, pursuant to Economic and Social 
Council resolution 2003/40, during the forty-seventh 
session of the Commission on Narcotic Drugs. All major 
producers and importers of opiate raw materials 
participated in the consultation. The Board has convened 
such informal consultations since 1992 to enable the 
participating Governments to be informed of recent 
developments affecting global production of and 
demand for opiate raw materials and to review the 
various policies applied in this respect. The information 
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gathered at such consultations allows the Governments 
of producing countries to adjust the production of opiate 
raw materials to global demand for the opiates derived 
from them and facilitates the monitoring of the situation 
by the Board. The consultations therefore contribute to 
the continued availability of opiates for medical 
purposes while preventing oversupply of the raw 
materials. 
  Meeting of permanent representatives on the 
supply of and demand for opiates for medical and 
scientific purposes  
 
142. In addition to the above-mentioned informal 
consultation, which was of a technical nature, the Board 
convened two meetings with permanent representatives 
to the United Nations (Vienna) on the issue of supply of 
and demand for opiates. Invited to those meetings, 
which were held in May and October 2004, were the 
representatives of countries that are major producers or 
importers of opiate raw materials. The objectives of 
those high-level meetings were to examine the present 
system for balancing the supply of and demand for 
opiates and to raise awareness of the necessity to assess 
the actual medical needs for opiates. 
 
  Consumption of narcotic drugs 
 
143. The low consumption of opioid analgesics for the 
treatment of moderate to severe pain, especially in 
developing countries, continues to be a matter of great 
concern to the Board. Global consumption of morphine 
increased significantly throughout the 1990s; in the past 
20 years, it rose almost 10-fold, from 3 tons in 1984 to 
about 28 tons in 2003. However, the bulk of that 
increase occurred in some, but not all, developed 
countries, which represent a small part of the world’s 
population. In 2003, six countries together accounted for 
79 per cent of global consumption of morphine. 
Developing countries, which represent about 80 per cent 
of the world’s population, accounted for only about 
6 per cent of global consumption of morphine. 
144. Opioid analgesics, such as buprenorphine, 
fentanyl, hydromorphone and oxycodone (which have 
become available in newly developed dosage forms, 
such as transdermal patches and controlled-release 
tablets), have been increasingly used in recent years for 
the treatment of pain in some countries. However, the 
increase in the worldwide consumption of those opioids 
was again much more pronounced in developed 
countries, in particular because of the relatively high 
costs of those drugs, especially the new preparations 
(see also paragraphs 193-197 below). 
 
  Consumption of psychotropic substances 
 
  Consumption of central nervous system stimulants 
 
145. Internationally controlled central nervous system 
stimulants are used for the treatment of attention deficit 
disorder (ADD; called attention deficit/hyperactivity 
disorder (ADHD) in the United States), of narcolepsy 
and as anorectics in the treatment of obesity. Until the 
early 1970s, amphetamine and methamphetamine were 
used in large quantities as anorectics, but that has since 
been discontinued or reduced to the extent that it now 
involves only small quantities. The medical use of 
phenmetrazine has been discontinued worldwide while 
fenetylline is prescribed in only a few countries. 
 
  Stimulants in Schedule II of the 1971 Convention 
used for the treatment of attention deficit disorder 
 
146. The increase in the use of stimulants in Schedule II 
for the treatment of ADD continues unabated. During 
the five-year period 1999-2003, the medical use in the 
United States of all three substances together increased 
by nearly one quarter, to more than 11 defined daily 
doses for statistical purposes (S-DDD) per 
1,000 inhabitants per day. During most of the 1990s, 
methylphenidate was the primary drug used in the 
United States. In recent years, however, amphetamines 
replaced methylphenidate as the drug of first choice in 
the treatment of ADD in that country. In the United 
States, the ratio of the use of methylphenidate to the use 
of amphetamines in 2003 was 5.21 S-DDD to 
6.23 S-DDD. 
147. Apart from the United States, only Australia uses 
more amphetamines than methylphenidate in the 
treatment of ADD. All other countries reported that 
methylphenidate was the predominant (if not the only) 
substance used for such treatment. 
148. The major countries consuming methylphenidate 
include Australia, Canada and the United States, as well 
as European countries. Iceland, which has increased the 
use of methylphenidate by more than 500 per cent over 
the past five years, has become the country with the 
world’s largest per capita consumption of the substance: 
5.98 S-DDD per 1,000 inhabitants per day. A number of 
other European countries, such as Norway, Switzerland 
and the United Kingdom, have shown increasing rates 
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similar to that of Iceland. The Board recognizes that, 
with proper diagnosis, stimulants can be effective in 
treating ADD. The Board urges the competent 
authorities to continue to carefully monitor develop-
ments in the diagnosis of ADD and other behavioural 
disorders and to ensure that amphetamines and 
methylphenidate are prescribed in accordance with 
sound medical practice as required under article 9, 
paragraph 2, of the 1971 Convention. 
149. The Board reiterates its request to the competent 
authorities of the countries concerned to increase their 
vigilance with regard to the diversion of, trafficking in 
and abuse of stimulants in Schedule II used for the 
treatment of ADD and to keep the Board informed of 
any new developments in that area. In a few countries, 
methylphenidate supplies for pupils under treatment for 
ADD can be stored at the school, and medication is 
dispensed by the school nurse during the school day. In 
such cases, control measures, including safety measures 
for storage and distribution, should be enforced. 
 
  Stimulants in Schedule IV of the 
1971 Convention used as anorectics 
 
150. The stimulants in Schedule IV of the 1971 
Convention are amphetamine-type stimulants mostly 
used as anorectics. After the mid-1990s, amphetamine-
like anorexigenic drugs were, in most countries, no 
longer recommended for the treatment of obesity, due to 
their abuse potential and possible adverse reactions. 
151. The Board has closely followed trends in the 
consumption of such anorectics over the past decade. In 
the mid-1990s, high consumption levels recorded in 
countries in the Americas led the Board to investigate 
the matter; since then, global trends and developments 
have been regularly presented in the annual reports of 
the Board. In those reports, the Board has repeatedly 
requested that the Governments concerned give 
adequate attention to the matter of elevated consumption 
levels of anorectics. International and regional 
conferences were organized in cooperation with the 
Board and the impact of concerted action was soon felt 
in a number of countries. Two of the consumer countries 
with the highest consumption levels, Argentina and 
Chile, introduced control measures, which led to a 
reduction of nearly 90 per cent in the consumption of 
those stimulants. 
152. Some countries were less successful in their 
attempts to curb high consumption levels of anorectics. 
Brazil, for example, introduced stricter controls for 
prescriptions between 1994 and 1997 and a reduction of 
consumption of anorectics was observed. However, after 
more lenient legislation was introduced in 1998, the use 
of amfepramone and fenproporex rose by more than 
500 per cent. 
153. As the diversion of those anorectics from 
international trade has decreased, such substances have 
been mainly diverted from domestic distribution 
channels, to be abused locally or smuggled into other 
countries. Over the past decade, the Board has 
repeatedly requested Governments to monitor carefully 
the use of amphetamine-type stimulants used as 
anorectics and to ensure adequate control of domestic 
distribution channels, in order to prevent the diversion 
of such substances. Governments of countries in which 
controlled anorectics had been prescribed in large 
quantities were asked to monitor the situation closely to 
prevent overprescribing, which could lead to the abuse 
of those substances due to their stimulant properties. 
Those Governments were requested to support 
educational campaigns to inform the medical and 
pharmaceutical community, as well as the general 
public, of the dangers involved in the indiscriminate use 
of stimulants. 
154. The experience gained during the past decade in a 
number of countries suggests that the measures most 
successful in curbing inappropriate use of anorectics 
include improved regulatory measures, such as adequate 
control of domestic distribution channels and changes in 
prescription policy, as well as education of medical 
doctors, pharmacists and the general public. The Board 
therefore encourages the authorities of countries 
experiencing problems with high consumption levels of 
anorectics to learn from the experience of their 
counterparts in those countries which have successfully 
dealt with the problem, such as Argentina and Chile. 
 
  Consumption of other psychotropic substances 
 
  Buprenorphine 
 
155. In several countries, mixed agonist/antagonist 
opioid analgesics such as buprenorphine are subject to 
more stringent control measures than other psychotropic 
substances. Buprenorphine, a potent opioid was included 
in Schedule III of the 1971 Convention in 1989. As the 
substance is also used, to an increasing extent, in the 
detoxification and substitution treatment of heroin 
addicts, global manufacture and consumption have 
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increased substantially during the past few years. The 
Board notes that buprenorphine continues to be diverted 
from domestic distribution channels in several countries. 
Taking into account the rapidly expanding licit use of 
the substance, the Board wishes to draw the attention of 
Governments to the potential misuse and diversion of 
the substance from domestic distribution channels. The 
Board reiterates its request to WHO to include informa-
tion on the misuse and diversion of buprenorphine when 
reviewing the control status of the substance and to 
consider reviewing the control status of this class of 
drugs. 
 
  Benzodiazepines 
 
156. Increasing medical availability of benzodiazepines 
has led in a number of countries to their increasing 
abuse. For example, the incidence of benzodiazepine 
abuse among drug addicts in Europe is high, and drug 
traffickers have successfully developed markets for 
specific substances. Widespread availability may indi-
cate loopholes in domestic distribution channels. More-
over, information received by the Board from several 
countries indicates that some general practitioners pres-
cribe benzodiazepines for unnecessarily long periods 
and for symptoms that may not require such treatment. 
157. The Board reiterates its request to Governments of 
countries in which there are high levels of consumption 
of benzodiazepines and increasing abuse of those 
substances to conduct, in cooperation with non-
governmental organizations involved in the treatment 
and rehabilitation of drug abusers, comprehensive 
surveys to determine the size of the population abusing 
those substances. The Board also encourages the 
Governments concerned to monitor consumption levels 
of benzodiazepines and to raise the awareness of 
medical practitioners about the rational use of those 
substances. Noting that in some regions benzodiazepines 
are occasionally supplied by pharmacies without 
prescriptions, the Board requests all Governments to 
ensure adherence to prescription requirements for all 
psychotropic substances, including benzodiazepines. 
158. Adequate availability of benzodiazepines through 
regular distribution channels is not ensured in all regions 
of the world, especially in many developing countries. 
At the same time, it has come to the attention of the 
Board that essential psychotropic substances have been 
distributed through informal markets. The Board 
reiterates its request to Governments to ensure sufficient 
supply of those substances for medical purposes through 
adequately controlled distribution channels with 
appropriate counselling to consumers. 
 
 
 F. Follow-up to missions of the Board 
undertaken in 2001 
 
 
159. Pursuant to the aims of the international drug 
control treaties, the Board reviews, on a regular basis, 
overall compliance by Governments with the provisions 
of the treaties and, in particular, progress made by 
Governments in the implementation of the Board’s 
recommendations following its country missions. 
160. In 2004, the Board reviewed the situation in a 
number of countries to which it had sent missions in 
2001. Those countries include Egypt (see para-
graphs   253-254 below), Jamaica, Serbia and 
Montenegro (see paragraphs 547-549 below) and 
Ukraine (see paragraphs 550-551 below). The 
Governments of those countries were requested to 
provide information on measures taken to implement the 
recommendations of the Board. 
161. The Board notes with concern that, despite 
repeated written requests to do so, the Government of 
Jamaica has not provided any information on measures 
taken to implement the recommendations of the Board. 
The Board calls on the Government of Jamaica to report 
to the Board any measures that it has taken to comply 
with those recommendations and to ensure that the 
provisions of the international drug control treaties are 
fully complied with in its territory. 
162. The Board underlines that it attaches great 
importance to the implementation of its recommenda-
tions and expects the full support and cooperation of 
Governments. In the absence of information provided by 
Governments, the Board finds it difficult to conduct a 
meaningful review and assessment of the drug control 
situations in various countries. 
 
 
 G. Special topics 
 
 
  1972 Protocol amending the Single Convention 
on Narcotic Drugs of 1961 
 
163. The amendments brought by the 1972 Protocol to 
the 1961 Convention reflected two main purposes. The 
first one was to bestow upon the Board additional 
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responsibilities and authority to enable it to perform 
more effectively its role in the supervision of the 
international drug control system. The second purpose 
was to reflect the fact that the control of licit drug 
production, manufacture and trade alone is not sufficient 
to counter increasing drug abuse and illicit trafficking. 
The scope of article 14 of the 1961 Convention, 
regarding the measures by the Board to ensure the 
execution of the provisions of the convention, was 
extended to cover not only situations in which the aims 
of the convention are seriously endangered by reason 
of a country or territory failing to carry out its 
provisions, but also serious drug situations not 
necessarily resulting from the failure of a Government 
to implement the convention. The Board was 
authorized to recommend multilateral technical or 
financial assistance to the Government concerned, if 
appropriate. The 1961 Convention as amended by the 
1972 Protocol gives guidance for parties to establish a 
balanced approach to the drug abuse problem, based on 
a system of administrative controls and penal sanctions 
and, in addition, the prevention of drug abuse and the 
treatment of drug abusers. The added provisions 
stipulate that when drug abusers have committed 
offences under the convention, parties may provide 
treatment, education, aftercare, rehabilitation and 
social reintegration, either as an alternative or in 
addition to conviction or punishment. 
164. The Board notes with appreciation that all States 
that are parties to the 1961 Convention are parties to that 
convention in its amended form, except for the four 
States referred to in paragraph 54 above. The Board 
trusts that those States will soon adhere to the 1972 
Protocol and implement its provisions, thus establishing 
a drug control mechanism in their countries which 
enables them to deal with the drug problem in a 
comprehensive and effective manner. 
 
  Control of cannabis used for medical or 
scientific purposes  
 
165. Cannabis is included in Schedules I and IV of the 
1961 Convention. According to article 3 of the 1961 
Convention, drugs in Schedule IV are those considered 
particularly liable to abuse and to produce ill effects. 
Since the end of the 1990s, scientific research on the 
therapeutic usefulness of cannabis or cannabis extracts 
is in progress in several countries, including Canada, 
Germany, the Netherlands, Switzerland, the United 
Kingdom and the United States. 
166. In 2004, the Board contacted the countries where 
such research was known to take place, asking for the 
findings of the studies in question. The replies received 
so far from the relevant countries indicate that results of 
such research regarding the potential therapeutic 
usefulness of cannabis or cannabis extracts remain 
limited. The Board therefore wishes to voice concern 
about the medical use of cannabis in Canada and the 
Netherlands and in some jurisdictions of the United 
States, in the absence of conclusive results on the 
effectiveness of such use. The Board confirms that it 
welcomes sound scientific research in this respect, as 
stated in previous reports,30 and trusts that the results, 
when available, will be shared with the Board, WHO 
and the international community. 
167. Articles 23 and 28 of the 1961 Convention provide 
for a national cannabis agency to be established in 
countries where the cannabis plant is cultivated licitly 
for the production of cannabis, even if the cannabis 
produced is used for research purposes only. The Board 
notes that the Government of the United Kingdom plans 
to establish a national cannabis agency by the end of 
2004 and that the Government of Switzerland is taking 
steps to provide a legislative basis for the establishment 
of such an agency in that country. 
168. The Board notes with concern that the 
Governments of several countries where research on the 
medical use of cannabis or cannabis extracts is taking 
place or where the medical use of cannabis is permitted 
have had difficulties furnishing in a timely manner 
relevant estimates and statistical reports on production, 
imports, exports and consumption of cannabis or 
cannabis extracts, in accordance with the 1961 
Convention. The Board wishes to remind the 
Governments concerned that the relevant treaty 
provisions must be implemented and reiterates its 
request to those Governments to take the necessary steps 
to ensure their compliance with those provisions. 
 
  Provisions regarding travellers under treatment 
involving the use of medical preparations 
containing controlled substances 
 
169. The Commission on Narcotic Drugs, in its 
resolutions 45/5 and 46/6, encouraged States parties to 
the 1961 Convention, that Convention as amended by 
the 1972 Protocol and the 1971 Convention to notify 
the Board of restrictions currently applicable in their 
territory to travellers under medical treatment with 
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drugs containing narcotic drugs and psychotropic 
substances under international control. The Board has 
requested Governments to provide specific information 
on their legal provisions or administrative measures 
regarding travellers under medical treatment, including 
restrictions and conditions that need to be met by 
travellers entering or leaving their territory and 
carrying medical preparations containing controlled 
substances for personal use. Several Governments have 
already provided the requested information to the 
Board. The Board calls on all Governments that have 
not yet done so to submit such information without 
delay. The information received by the Board will be 
made widely available so that Governments will be 
able to advise travellers on the restrictions. 
 
  Misuse of the Internet 
 
170. Since 1996, the Board has devoted more and more 
attention to the problem of Internet pharmacies illicitly 
selling pharmaceuticals containing internationally 
controlled narcotic drugs and psychotropic substances. 
While the Board recognizes and has acknowledged that, 
in principle, the Internet may facilitate access to medical 
and pharmaceutical services for large segments of 
society, it has also warned that the potential for misuse 
is considerable.31 This concern has been validated by 
developments during the past few years. Narcotic drugs 
and psychotropic substances are increasingly being 
advertised and illicitly sold without required prescrip-
tions by Internet pharmacies; the pharmacies are thus 
not only operating in contravention of international and 
national legislation but also subjecting customers to 
serious health risks. Furthermore, narcotic drugs and 
psychotropic substances with high abuse potential are 
diverted and trafficked through the Internet to the illicit 
market; thus, the Internet has been acting as a substitute 
for trafficking channels that have been successfully 
closed. 
171. The Board, aware of the fact that the problem of 
illicit sales through the Internet requires close co-
operation between countries and international organiza-
tions, organized in Vienna in 2004 an expert group 
meeting for experts from relevant international organiza-
tions and national authorities. The meeting provided 
significant insight into the problem and recommended 
several measures, some of which are presented below. 
172. Available information indicates that the illicit sale 
of pharmaceuticals containing controlled narcotic drugs 
and psychotropic substances via the Internet and the 
illicit distribution of such substances by mail are global 
problems; resolving those problems requires urgent 
action by the international community. Evidence 
collected and analysed by regulatory and law enforce-
ment authorities indicates that several billion doses of 
controlled substances are illicitly sold each year. 
173. Investigations by the United States authorities of 
illicit Internet pharmacies show that the proportion of 
the total sales of pharmaceuticals accounted for by 
prescription drug sales is significantly higher than for 
traditional licensed pharmacies and that the vast 
majority (sometimes more than 95 per cent), of their 
prescription drug sales involve internationally controlled 
narcotic drugs and psychotropic substances. That 
information is confirmed by data analysis and case 
studies undertaken in Asian and European countries. 
Those investigations also confirm that around 90 per 
cent of such sales by Internet pharmacies are conducted 
without the prescriptions required for internationally 
controlled narcotic drugs and psychotropic substances. 
174. Such sales include substances in Schedules I and II 
of the 1961 Convention and substances in Schedules II, 
III and IV of the 1971 Convention. One particular 
concern of the Board is the fact that substances known 
to have a high abuse potential—certain opioids (such as 
oxycodone), stimulants (amphetamines) and benzo-
diazepines (such as alprazolam and diazepam)—are 
among the substances frequently traded by illicit 
Internet pharmacies. In addition, certain substances with 
(possibly fatal) health risks, such as fentanyl and 
secobarbital, are sold by Internet pharmacies. 
175. As the vast majority of Internet pharmacies fulfil 
these orders without requiring a valid prescription or (in 
cases of online doctor consultations) without verifying 
personal details provided by the customer, one special 
concern involves the age of customers. The illicit trade 
over the Internet has been identified as one of the major 
sources for prescription medications abused by children 
and adolescents in certain countries such as the United 
States. At present, there are no mechanisms in place to 
block the access of children and adolescents to those 
Internet sites or to prevent illicit supplies by Internet 
pharmacies from reaching persons in that age group. 
176. Investigations carried out in the United States and 
in a number of European countries revealed that 
purchases from illicit Internet pharmacies are more  
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expensive than purchases from licensed pharmacies. In 
addition, costs will not be refunded by national health 
systems if no prescription has been obtained. 
Therefore, it appears that those customers who order 
pharmaceuticals containing internationally controlled 
substances from illicit Internet pharmacies cannot 
legally obtain the required prescription. Apart from the 
higher costs, customers of illicit Internet pharmacies 
cannot rely on the authenticity and the quality of the 
pharmaceuticals sold, which may even include 
counterfeit drugs, as in a recent case where supplies for 
two Internet pharmacy sites were illicitly manufactured 
in a clandestine laboratory. Customers of illicit Internet 
pharmacies should be aware that such purchases 
constitute a breach of law in almost all countries, as 
prescription requirements are universal. 
177. Given the fact that Internet pharmacies, 
irrespective of the residence of the owner of the Internet 
site, can ship orders from pharmacies operating in all 
regions of the world, meaningful action against such 
illicit activities depends on close international 
cooperation and the political will of all Governments to 
accord importance to the matter. The Board notes with 
appreciation that the United States has identified the 
non-medical use of prescription drugs as one of the top 
three priorities of the 2004 National Drug Control 
Strategy. The Strategy highlights the importance of state 
prescription monitoring programmes, physician training, 
and public education programmes to curb the abuse of 
prescription drugs. It calls upon the pharmaceutical 
industry, the medical community and state governments 
to work in partnership, and it looks for new initiatives 
and technologies to identify, investigate and prosecute 
illicit Internet pharmacies. The Board calls upon all 
Governments to make similar efforts. 
178. Diversions of internationally controlled narcotic 
drugs and psychotropic substances occurring under the 
anonymity of Internet pharmacies constitute new 
challenges for investigative as well as prevention 
efforts. Significant synergies can be achieved through 
concerted national and international action. The 
establishment and monitoring of national legislation and 
regulations involve various government offices and 
agencies. The international character of the transactions 
means that the cooperation of such offices and agencies 
in the countries concerned is called for. The Board plans 
to organize a meeting to mobilize the regional and 
international organizations concerned, such as Interpol, 
the World Customs Organization, WHO and the 
Universal Postal Union. 
179. Action to be taken in a timely manner necessitates 
the efficient sharing of experience and exchange of 
information in specific cases, as well as rapid 
intervention by national authorities. The Board is 
pleased to note that positive examples of successful 
international cooperation show that concerted action can 
have an impact. The Board commends the efforts of the 
authorities of the Netherlands Antilles in 2004, in co-
operation with national authorities in the United States 
and countries in Europe, which prevented the diversion 
of psychotropic substances into illicit channels. 
180. While most countries are willing to support 
investigations involving Internet pharmacies shipping 
illicit consignments from their territory, a lack of 
cooperation by some national authorities has been 
identified as a major impediment to concerted efforts. In 
its annual report for 2003,32 the Board referred to the 
illegal shipments of psychotropic substances from an 
Internet pharmacy in Pakistan to Switzerland and 
requested the competent authorities of Pakistan to 
urgently investigate the matter. The Board notes with 
concern that so far no cooperation has been forthcoming 
and that other countries, such as the Netherlands, are 
also receiving similar illicit shipments from Pakistan. As 
the authorities of Pakistan have received all the details 
of the Internet pharmacies involved, the Board calls on 
the authorities to investigate and prosecute the cases 
without further delay. 
181. There is a need to establish a mechanism that will 
ensure the sharing of experience and the rapid exchange 
of information on specific cases, as well as the 
standardization of data collected. The Board, in 
cooperation with national authorities and international 
organizations, will seek to identify measures to support 
such international cooperation. Urgent action is also 
required with regard to the sharing of information on 
national legislation regarding Internet pharmacies and 
shipments of individual orders by mail. 
182. National legislation needs to be supported by the 
universal application of international regulations. Illicit 
Internet pharmacies dealing with brand products must 
obtain their supplies from established and recognized 
suppliers supervised by the competent authorities of the 
country from which they operate. Implementing and 
enforcing existing laws in all countries, including  
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provisions of the relevant international treaties and 
Economic and Social Council resolutions, would 
significantly contribute to the prevention of diversions 
of internationally controlled narcotic drugs and 
psychotropic substances through the Internet. The 
Board wishes to remind all Governments to implement 
fully all provisions of the three international drug 
control conventions, as well as all relevant measures 
requested by the Council in its resolutions, such as the 
establishment and monitoring of the system of 
assessments for psychotropic substances and the 
system of requirements for import and export 
authorizations. The Board also wishes to bring to the 
attention of all Governments the action plans adopted 
by the General Assembly at its twentieth special 
session, in particular the Action Plan against Illicit 
Manufacture, Trafficking and Abuse of Amphetamine-
type Stimulants and Their Precursors (Assembly 
resolution S-20/4 A), and the Action Plan for the 
Implementation of the Declaration on the Guiding 
Principles of Drug Demand Reduction (Assembly 
resolution 54/132, annex), in which the Assembly 
recognized that the use of the Internet posed new 
opportunities and challenges to international 
cooperation in combating drug abuse and illicit 
production and trafficking. 
183. According to information available to the Board, 
diversions of narcotic drugs and psychotropic substances 
mostly occur when consignments pass from the 
wholesale level to the retail level. Competent authorities 
should, therefore, seek to identify weaknesses in 
national regulatory systems with regard to domestic 
distribution, as well as in reporting and inspection. 
184. The support of national authorities is required to 
increase awareness of problems relating to the diversion 
of pharmaceutical products containing narcotic drugs 
and psychotropic substances. The Board once again calls 
on national authorities to bring to the attention of the 
judiciary, as well as prosecutors, the urgent need to give 
greater importance and adequate penalties to court cases 
involving the diversion of licitly manufactured narcotic 
drugs and psychotropic substances into illicit channels. 
In addition, efforts need to be made to educate the 
general public about the dangers involved in abusing 
pharmaceutical products containing controlled drugs. 
Consumers should be made aware that such purchases 
not only constitute a breach of law but are also poten-
tially dangerous to their health, because there is little or 
no quality control. Countries should cooperate with the 
pharmaceutical industry, as well as with Internet 
service providers, in order to support international 
activities in this area. The Board would like to remind 
all Governments that their political will is necessary if 
all of the above-mentioned initiatives are to be carried 
out. 
 
  Public incitement to drug abuse  
 
185. During the past few years, the Board has noted an 
ambiguity towards drug abuse in some countries in 
Western Europe: while drug abuse prevention campaigns 
call on young people to refrain from abusing drugs, 
authorities have not taken measures against incitement 
to abuse drugs, and drug abuse may even be promoted 
through certain media or other channels.33 
186. The Board calls on all Governments that have not 
yet done so to implement article 3, paragraph 1 (c) (iii), 
of the 1988 Convention, which requires each State party, 
subject to its constitutional principles and the basic 
concepts of its legal system, to establish as criminal 
offences publicly inciting or inducing others to commit 
any of the offences established in accordance with 
article 3 or to illicitly use narcotic drugs or psychotropic 
substances. 
187. The Board notes that the criminalization of 
incitement or inducement to commit drug trafficking 
offences is covered in most national penal codes by a 
general provision on “incitement to commit a crime”, in 
addition to being specifically provided for in the 
national drug control laws of many countries. 
188. The Board notes that most European countries 
have included incitement to illicit drug use as a specific 
offence in their drug control legislation or among the 
drug control provisions of their national penal or health 
code. For example, in France, the Public Health Code 
provides that anyone who in any way induces the illicit 
use of narcotic drugs or substances presented as having 
the effects of narcotic drugs or shows such use in a 
favourable light is considered to have committed an 
offence that carries a penalty of up to five years of 
imprisonment and/or a fine of up to 75,000 euros. In 
Germany, a term of imprisonment of up to five years or 
a fine may be imposed on anyone who publicly, at a 
meeting or by the dissemination of written material, 
calls for the use of narcotics that have not been 
prescribed in the permitted manner. However, it remains 
to be seen how those provisions are being implemented. 
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189. The Board notes with concern that in some 
European countries, in particular Spain, the liberal 
approach towards personal drug consumption appears to 
have been extended to incitement to engage in, or the 
advertisement and promotion of, such activity. 
According to a legal opinion formulated in February 
2003 by the public prosecutor of the Supreme Court in 
Spain, the sale in “grow-shops” of cannabis seeds and 
equipment for the cultivation of cannabis plants for 
personal consumption and the advertisement of such 
seeds and equipment, as well as the dissemination of 
detailed advice on methods of such cultivation in 
specialized magazines available to the general public, do 
not constitute penal offences under current legislation, 
as long as it has not been established that the cultivation 
is for purposes of trafficking. In some countries, while 
there is a provision in the legislation, the liberal 
approach adopted towards personal drug consumption 
and related activities might also extend to enforcement 
of the ban on incitement or on the advertisement and 
promotion of such activities. 
190. The Board stresses that the constitutional 
principles and basic legal concept that have been 
invoked in supporting a non-criminalizing approach to 
dealing with personal drug consumption activities in 
some countries cannot, by analogy, be extended to acts 
such as incitement to use illicit drugs or advertisement 
of such activity. Indeed, inciting or inducing others to 
illicitly use drugs does not belong to the private sphere 
of the individual and it can be clearly associated with 
social harm. Moreover, incitement and advertisement of 
illicit drug use would be contrary to the emphasis on 
prevention and education that often accompanies the 
non-penal treatment of drug abusers in those countries. 
191. The Board notes that the WHO Framework 
Convention on Tobacco Control,34 adopted by the World 
Health Assembly in May 2003, includes various 
provisions on a comprehensive ban of all tobacco 
advertising, promotion and sponsorship. It would be 
inconsistent if countries undertake a ban on the 
advertisement of tobacco, the use of which is licit, but 
deprive themselves of the legal means to prohibit and 
suppress the advertisement of illicit drugs. 
192. The Board is concerned about the situation in 
countries where the current legal regime makes it 
extremely difficult to prosecute persons for publicly 
inciting others to illicitly use drugs or to illicitly 
cultivate drug crops. The Board reiterates that it is 
important for Governments to comply fully with the 
provisions of the international drug control treaties. 
 
  Efforts to improve availability of narcotic drugs 
for relief of pain 
 
193. Pursuant to its mandate, the Board endeavours to 
support the availability of narcotic drugs for medical 
use, including the relief of pain, while preventing their 
diversion for illicit use. 
194. The Board has cooperated with WHO in joint 
efforts to increase the availability of narcotic analgesics 
for the treatment of pain worldwide. In recent years, the 
Board has brought the issue of low availability of opioid 
analgesics to the attention of the international 
community at the World Health Assembly. In its address 
to the Executive Board of WHO in 2004, the Board once 
again made health policy makers aware of that issue. 
The Board notes with appreciation that WHO is 
preparing a comprehensive global strategy against pain, 
which is aimed at providing assistance to countries in 
building capacity and raising awareness in the area of 
using opioids in pain treatment. The Board will 
cooperate with WHO in the implementation of the 
activities related to the strategy. The Board calls on the 
international community to support WHO efforts to 
ensure adequate pain treatment worldwide. 
195. France is one of the countries where the 
availability of opioids has increased significantly during 
the past decade. The increase in the consumption of 
opioid analgesics in France has been linked to the intro-
duction of new medications, the simplification of the 
regulatory system and the adoption of two action plans 
on the fight against pain, aimed at raising the awareness 
of health professionals and the general public. 
196. While consumption of narcotic drugs for the 
treatment of pain continues to be extremely low in many 
countries, particularly countries in Africa and Asia, 
commendable progress has been achieved in some 
developing countries. For example, Uganda, which has 
been active in the field of pain management since the 
1990s, has become the first African country to recognize 
palliative care as an essential clinical service, integrating 
pain treatment strategies into its health services and 
providing morphine free of charge to cancer and 
HIV/AIDS patients. The Government of Uganda has 
changed its national legislation to make opioid 
analgesics (especially morphine) more available. Health-
care professionals and community workers have 
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received training in the proper use of opioid analgesics 
in the management of pain. In 2004, the Government of 
Uganda further modified its policy on narcotics to 
permit nurses with a certificate in specialized palliative 
care to prescribe and supply certain opioid analgesic 
drugs, including morphine. 
197. The Board encourages Governments that have not 
yet done so to examine the extent to which their health-
care systems and laws and regulations permit the use of 
opioids for medical purposes, to identify possible 
impediments to such use and to develop plans of action 
for the development of long-term pain management 
strategies, with a view to facilitating the supply and 
availability of narcotic drugs for all appropriate 
indications. 
 
  Food products and dietary supplements illicitly 
containing controlled substances 
 
198. In its annual reports for 199535 and 1998,36 the 
Board referred to the illicit use of psychotropic 
substances, in contravention of the provisions of the 
1971 Convention, as concealed ingredients in herbal 
medicines and to attempts to market preparations 
containing narcotic drugs and psychotropic substances 
as “food products” and “dietary supplements”. Such 
attempts have recently reoccurred. The covert and 
inappropriate use of those substances has in the past led 
to severe health problems and, in a number of cases, 
death. The Board therefore urges Governments to 
investigate such cases of illicit use of narcotic drugs and 
psychotropic substances without delay and to bring to 
the attention of WHO and the Board all information 
required to alert the international community to such 
potentially dangerous misuse of controlled substances. 
 
  Facilities where persons can abuse illicitly 
acquired drugs 
 
199. The Board notes with concern that facilities where 
persons can abuse drugs that they have illicitly acquired 
remain in operation in a number of countries in several 
regions. The Board reiterates that those facilities 
contravene the international drug control treaties, in 
particular article 4 of the 1961 Convention, which 
obligates parties to ensure that the production, 
manufacture, import, export and distribution of, trade in 
and use and possession of drugs should be limited 
exclusively to medical and scientific purposes. The 
Board urges the Governments concerned to take 
immediate measures to ensure compliance with the 
international drug control treaties. 
 
  Use of narcotic drugs manufactured from seized 
materials 
 
200. Some Governments release seized material (such 
as opium and cocaine) for the manufacture of narcotic 
drugs for medical purposes. That practice is not 
prohibited under the 1961 Convention. However, the 
General Assembly, in its resolution 33/168, invited 
Governments to increase their joint efforts to eradicate 
illicit cultivation of narcotic plants in order to ensure a 
continuing balance between licit supply and licit 
demand, and to avoid unforeseen imbalances caused by 
sales of seized and confiscated drugs. Moreover, the 
Economic and Social Council, in its resolutions on the 
supply of and demand for opiates for scientific and 
medical needs, has repeatedly encouraged all 
Governments to avoid unforeseen imbalances between 
the licit supply of and demand for opiates caused by the 
exportation of products manufactured from seized and 
confiscated drugs, and to restrict the use of such 
products to domestic use only. In order to remove any 
temptation to countries to use seized raw materials for 
the manufacture of products destined for export, the 
Board urges countries that are exporting licitly produced 
raw materials to maintain the standards of quality of 
those raw materials. 
 
  Medical prescription of heroin 
 
201. Heroin is prescribed in a few countries to a small 
proportion of long-term opiate addicts, and in some 
other countries research on prescription of heroin for the 
treatment of such addicts is under way. The Board 
reiterates its reservations concerning the medical 
prescription of heroin. The Board wishes to emphasize 
the importance of formally involving WHO in the 
evaluation of the results of all projects on the medical 
prescription of heroin to addicts. 
 
  Measures to ensure the implementation of the 
international drug control treaties 
 
  Action of the Board taken pursuant to article 14 of 
the 1961 Convention and article 19 of the 
1971 Convention 
 
202. Article 14 of the 1961 Convention and article 19 
of the 1971 Convention describe measures that, in 
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certain circumstances, the Board may take to ensure that 
States implement provisions of the conventions. 
203. The Board has, since 1997, formally invoked 
article 14 of the 1961 Convention and/or article 19 of 
the 1971 Convention with respect to a limited number of 
States parties, in view of the drug control situation in 
those countries and the Governments’ lack of 
compliance with the international drug control treaties. 
The States involved are not named until such time as the 
Board deems it necessary to call the attention of the 
other States parties, the Economic and Social Council 
and the Commission on Narcotic Drugs to the situation, 
as in the case of Afghanistan. 
204. The Board’s objective has been to promote the 
compliance of States with the conventions when other 
means failed. As a result of an ongoing dialogue with 
the Board pursuant to article 14 of the 1961 Convention 
and article 19 of the 1971 Convention, most of the 
States took remedial measures. Consequently, the Board 
decided to terminate any action pursuant to those 
articles vis-à-vis those States. 
 
  Consultation with the authorities of Afghanistan 
pursuant to article 14 of the 1961 Convention 
 
205. The Board invoked article 14 of the 1961 
Convention with respect to Afghanistan in 2000. Since 
then, the Board has maintained a close dialogue with the 
authorities of that country. In addition, the Board has 
undertaken several missions to Afghanistan. In February 
2004, at the request of the Board, a delegation from the 
Government of Afghanistan reported to the Board on the 
drug control situation in the country, as part of the 
continuing consultations under article 14 of the 1961 
Convention. 
206. The Board notes that the Government of 
Afghanistan, in cooperation with the Government of the 
United Kingdom and the United Nations Office on 
Drugs and Crime, has recently developed five action 
plans within the framework of the national drug control 
strategy, covering the areas of law enforcement, 
counter-narcotics judicial reform, alternative liveli-
hoods, drug demand reduction and public awareness. 
The Board considers that development to be an 
important step forward in drug control and hopes that 
the Counter-Narcotics Directorate, the national 
coordinating body for drug control in Afghanistan, will 
work closely with all the government ministries 
concerned to ensure that the implementation of the 
national drug control strategy is well coordinated and 
effectively carried out. 
207. The Board also notes that progress has been made 
in building the capacity of Afghanistan in the area of 
law enforcement. Since the establishment of the Counter 
Narcotics Police of Afghanistan (CNPA) and the Special 
Narcotics Force, there have been a number of successful 
law enforcement operations, resulting in several 
significant drug seizures involving heroin, morphine, 
opium and cannabis resin. The Board encourages the 
Government to continue its efforts in that area, in order 
to address the illicit drug trafficking situation in the 
country in a more effective way.  
208. The Board is seriously concerned, however, that 
the overall drug control situation in Afghanistan appears 
to have deteriorated. In particular, illicit opium poppy 
cultivation continued to expand in 2004, occurring in 
almost all the provinces in the country and involving an 
increased number of farmers. Consequently, illicit 
opium production has reached 4,200 tons, an increase of 
17 per cent compared with 2003, according to the annual 
survey conducted by the United Nations Office on 
Drugs and Crime. That is a clear indication that illicit 
opium production will continue to thrive unless firm 
action is taken to eliminate such production and other 
illicit drug-related activities, including illicit drug 
manufacture and trafficking. 
209. The Board wishes to underline that it is the 
responsibility of the Government of Afghanistan to fulfil 
its obligations under the international drug control 
treaties, to which Afghanistan is a party. The elimination 
of the illicit cultivation of opium poppy should be of the 
utmost importance to the Government, as it is essential 
to the stability of the country, in addition to being in the 
interest of the international community. The Board urges 
the Government to establish law and order in rural areas, 
to extend the enforcement of the ban on opium 
production so that it applies to the entire country and, 
with the assistance of the international community, to 
provide alternative livelihoods to opium poppy growers. 
The Board stresses that counter-narcotics measures 
should be brought into the mainstream of overall 
development assistance. The Board hopes that the 
targets set out in the national drug control strategy will 
be met without further delay. 
210. Afghanistan is faced with not only the serious 
problem of illicit opium poppy cultivation, but also 
growing problems involving illicit manufacture of and 
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trafficking in opiates, as a result of increased opium 
production. Opium and heroin of Afghan origin continue 
to be smuggled on a large scale into other countries in 
West Asia and, through those countries, into Europe. 
That situation hinders national reconstruction efforts and 
also constitutes a serious threat to security and stability 
in the region. The Board calls upon the international 
community, the countries into which Afghan opiates are 
being smuggled, including the neighbouring countries of 
Afghanistan, to continue strengthening their cooperation 
with the Government of Afghanistan. Such cooperation 
should include, whenever possible, the provision of 
technical and financial assistance to the Government 
with a view to enhancing its capacity in law 
enforcement. The full cooperation of the international 
community will be necessary for the country to succeed 
in recovering from its disastrous past. 
211. The Board notes with concern that drug abuse in 
Afghanistan has increased significantly over the past 
few years because of prolonged human deprivation and 
suffering, the breakdown of traditional social controls, 
the return of refugees and the almost unlimited 
availability of opiates within the country. What is 
especially disturbing is that heroin is frequently mixed 
with other controlled substances from unknown sources, 
such as diazepam and phenobarbital. Another major 
concern is the increasing use of injection as a mode of 
administering illicit drugs, particularly among heroin 
abusers. Given the almost total collapse of social and 
physical infrastructure after over two decades of war 
and conflict, there are limited treatment facilities and no 
trained staff to deal with drug abuse problems. 
212. The Board notes with appreciation that a project 
aimed at reducing illicit drug demand in Afghanistan has 
recently been developed by the United Nations Office 
on Drugs and Crime. The Board hopes that, with the 
support of the international community, the Government 
of Afghanistan will successfully implement its action 
plan on demand reduction and achieve the targets 
identified in various areas of demand reduction, 
including public awareness, training, treatment and 
rehabilitation. 
213. There is substantial evidence that a wide range of 
pharmaceutical products containing controlled sub-
stances can be obtained in Afghanistan over the counter 
(without medical prescriptions) from unregulated 
pharmacies, other retail outlets and even roadside stalls. 
Most of the products are adulterated, out of date and 
unregistered and have been illicitly manufactured 
elsewhere and smuggled into Afghanistan. That 
situation, if left unaddressed, will contribute to a 
worsening of the drug abuse problem. The Board urges 
the national authorities responsible for drug control to 
increase adherence to drug control regulations, in order 
to counter the proliferation of such pharmacies and 
identify the sources of the substances involved, and to 
ensure that controlled drugs are used exclusively for 
medical and scientific purposes. In particular, the 
Ministry of Health should, as a matter of urgency, 
establish and promulgate rules and regulations on the 
control of narcotic drugs and psychotropic substances, 
in order to ensure that controlled drugs are distributed 
only through official channels and, at the same time, that 
the legitimate requirements for drugs used for medical 
needs are met. 
214. The Board notes the positive results of a joint 
technical visit of the United Nations Office on Drugs 
and Crime and the Board to Afghanistan in May 2004 to 
accelerate the implementation of the new Afghan drug 
control law. The Board supports the continuation of such 
joint technical visits, as they contribute to the 
strengthening of the national capacity to implement the 
provisions of the international drug control treaties. 
215. The invocation of article 14 of the 1961 
Convention will remain in force until such time as the 
Board is satisfied that Afghanistan is complying with the 
provisions of that convention. The Board, in accordance 
with the 1961 Convention, will continue to maintain 
dialogue with the Government and monitor closely the 
drug control situation in Afghanistan until substantial 
progress is made by the Government in its drug control 
efforts. The recently held election and the firm statement 
by the President-elect that he will accord high priority to 
the matter of illicit drugs are the first steps toward a 
better future for the country. 
 
  Policy of the Government of the Netherlands on 
cannabis 
 
216. In August 2004, the Government of the 
Netherlands officially informed the Board of a crucial 
and significant change in its policy on cannabis. In an 
inter-ministerial policy paper on cannabis, the 
Government acknowledged that “cannabis is not 
harmless”, neither for the abusers nor for the commu-
nity, and stressed the importance of strengthening 
“measures against street dealing, drug tourism and 
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cannabis cultivation” and of continuing “to reduce the 
number of coffee shops”. That is a good example of 
applying objective evaluation of public policies. 
217. The Government of the Netherlands now 
recognizes that coffee shops are “not blameless” in the 
maintenance of the illicit drug trade and are not 
satisfactory in terms of suppressing drug-related crime. 
The Government also notes that coffee shops may 
discredit the drug policy of the country in general. 
218. The Government of the Netherlands is requesting 
local authorities responsible for the implementation of 
the coffee shop policy to assist in tightening the 
cannabis policy. The Government intends to reduce the 
number of coffee shops located near schools and in 
border areas and to take action against uncontrolled 
outlets. Furthermore, the Government, together with the 
local authorities, will take action to ensure that drug 
tourism, in border areas in particular, is kept under 
control. 
219. The Government of the Netherlands also stated 
that it would implement an action plan to discourage 
cannabis abuse, which would include specific drug 
prevention campaigns aimed at high-risk groups, as well 
as an annual mass-media anti-drug campaign over a 
period of three years that would specifically target 
young people between the ages of 12 and 18. The 
Government also plans to enhance efforts to treat 
cannabis abusers. Regarding the illicit cultivation of 
cannabis with a high tetrahydrocannabinol (THC) 
content (“Nederwiet”, “Dutch skunkweed”) in the 
Netherlands, the Government advocates a twin-track 
policy of administrative and criminal law enforcement, 
with a view to using a combination of sanctions to make 
cultivation as unattractive as possible. Specifically, the 
Government noted that new prosecutorial guidelines 
provide a basis for taking more speedy action against 
those involved in the cultivation of cannabis; the 
Government stated that it plans to raise the penalty for 
large-scale illicit cannabis cultivation to at least five 
years of imprisonment. 
220. The Board welcomes the initiative of the 
Government of the Netherlands, which is an important 
step in the right direction—towards full compliance with 
the international drug control conventions concerning 
cannabis. The fact that the Government recognizes 
health and social problems associated with cannabis 
abuse, its cultivation and trafficking is of importance, 
not only for the Netherlands, but also for the entire 
region and beyond. The Board urges the Government to 
take further action to reduce the number of coffee shops, 
which are contrary to the provisions of the international 
drug control treaties. 
221. In view of the emerging evidence of health-related 
consequences of cannabis abuse, the Board requests 
WHO to examine that issue. 
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III.  Analysis of the world situation 
 
 
 A. Africa 
 
 
  Major developments 
 
222. Cannabis remains the major drug of concern 
throughout Africa. In addition, trafficking in and abuse 
of cocaine, heroin and amphetamine-type stimulants 
are increasing in many countries in the region. The 
practice of injecting drug use, which is spreading in a 
number of African countries, could exacerbate by other 
means the already severe HIV/AIDS crisis in Africa. 
The abuse of psychotropic substances is facilitated by 
the absence of adequate licit control measures in most 
African countries. That inadequate drug control, 
together with activities involving organized crime, is 
hindering development efforts in Africa. The Board 
therefore welcomes the adoption of the United Nations 
Convention against Transnational Organized Crime 
(General Assembly resolution 55/25, annex J) and the 
United Nations Convention against Corruption 
(Assembly resolution 58/4, annex) and encourages all 
States to make use of those international instruments in 
their efforts to counter drug trafficking. 
223. The limited institutional and technical capacity of 
African countries to deal with the drug issue in an 
effective and comprehensive manner has had a 
negative impact on national drug control strategies. 
There are not sufficient mechanisms or skilled human 
resources to control and prevent drug trafficking in 
many countries in Africa, and the provision of 
counselling, treatment and rehabilitation facilities for 
drug abusers is inadequate. While Governments of 
African countries are investing increasing resources to 
deal with those problems, the investment appears to be 
inadequate and the continent remains a very weak link 
in international drug control. The Board therefore calls 
upon the international community to provide 
appropriate assistance and support to States in the 
region to enhance their efforts to combat drug 
trafficking and abuse. 
224. In many countries in Africa that are emerging 
from conflict and civil strife, drug abuse continues, in 
particular among child soldiers. The Board encourages 
the Governments concerned to make an assessment of 
the nature and extent of the drug abuse situation in 
their countries and to put in place appropriate 
mechanisms to deal with the problem. 
225. The uncontrolled sale (without appropriate 
prescription) in licensed pharmacies of prescription 
drugs containing narcotic drugs and psychotropic 
substances, the proliferation of illegal retail 
pharmaceutical outlets and the diversion from licit 
distribution channels of such products into street 
markets are all problems that continue to persist in 
many countries in Africa. The Board calls on the 
Governments concerned to establish and/or enhance 
the capacity of their national drug regulatory 
authorities to enforce the licensing, distribution and 
inspection of and trade in pharmaceutical products. 
226. Most countries in Africa have no adequate 
legislative framework and lack the necessary 
administrative mechanisms for the control of precursor 
chemicals. Such a situation may lead to serious 
problems in the international monitoring of trade in 
such chemicals; consequently, African countries are 
increasingly being targeted by traffickers attempting to 
obtain the chemicals they need for illicit drug manu-
facture. The Board therefore urges those Governments 
to establish, as a matter of urgency, appropriate 
mechanisms for the monitoring and control of 
precursor chemicals in order to prevent their diversion. 
 
  Treaty adherence 
 
227. The Board welcomes the accession in March 
2004 of the Congo to the Single Convention on 
Narcotic Drugs of 1961 as amended by the 1972 
Protocol, the Convention on Psychotropic Substances 
of 1971 and the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988. The Board notes that Gabon has 
approved legislation that will allow the Government to 
ratify the 1988 Convention and to deposit its 
instrument of accession with the Secretary-General. 
228. Angola and Equatorial Guinea remain the only 
countries in Africa that are not yet parties to any of the 
three main international drug control treaties. Chad has 
not yet acceded to the 1972 Protocol amending the 
1961 Convention. Liberia has not yet become party to 
the 1971 Convention, and the Democratic Republic of 
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the Congo, Gabon, Liberia, Namibia and Somalia have 
not yet become parties to the 1988 Convention. 
 
  Regional cooperation 
 
229. The Board notes with appreciation the continuing 
commitment of the African Union to drug control. At 
its second Ministerial Conference on Drug Control in 
Africa, to be held in Grande Baie, Mauritius, in 
December 2004, participants will review the progress 
made at the national and regional levels in the 
implementation of the Plan of Action on Drug Control 
in Africa: 2002-2006. The Board also notes the steps 
being taken to create a sustainable drug control 
coordination and advisory capacity within the African 
Union and a system to review and monitor the progress 
made in drug control throughout Africa. 
230. The Fourteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Cairo from 30 May to 3 June 2004. The Meeting, 
which was attended by 27 African States,37 made 
recommendations on the interdiction of drug 
trafficking in countries emerging from conflict; the 
development of a common strategy to combat illicit 
cannabis cultivation, production, trafficking and abuse; 
and effective control over licit pharmaceutical 
medicines and precursor chemicals used in the illicit 
manufacture of amphetamine-type stimulants. 
231. The regional training academy for drug control at 
Jos, Nigeria, held its first international training session 
in April 2004 for participants from Cape Verde, the 
Gambia, Ghana, Nigeria and Sierra Leone. The 
academy is to provide training to drug law enforcement 
officers from Nigeria and other Western African 
countries and to promote cooperation among drug law 
enforcement agencies in the subregion. 
232. A training seminar on licit drug control for 
Eastern African countries was organized jointly by the 
Board and the United Nations Office on Drugs and 
Crime in Nairobi in January 2004 to enable the 
national drug regulatory authorities in Eastern Africa to 
more effectively monitor and exercise control over the 
supply and distribution of narcotic drugs and psycho-
tropic substances while ensuring their availability for 
legitimate medical and scientific purposes. 
233. The Board notes the continuing efforts of African 
countries to enhance regional collaboration in drug 
control through regular meetings of law enforcement 
authorities, such as the fifteenth operational meeting 
on drugs for Eastern African heads of criminal 
investigation departments and anti-narcotic units, held 
in Zanzibar, United Republic of Tanzania, in March 
2004 and the sixth Eastern Africa Police Chiefs 
Cooperation Organization meeting held on Mahé 
Island, Seychelles, in September 2004. Cooperation 
among the law enforcement authorities of the countries 
participating in the West African Joint Operations 
Initiative led to the seizure of over 140 kg of cocaine in 
Cotonou, Benin, in April 2004 (see also para. 246 
below). 
234. The Southern African Development Community 
(SADC) organized a seminar on the monitoring of 
precursors for SADC member States in Johannesburg, 
South Africa, in November 2003. The participants set 
up a more effective system for controlling the 
movement of precursors and established information 
networks to facilitate the seizure of precursors in the 
illicit traffic in Southern Africa. 
235. Activities against money-laundering have also 
been initiated in some subregions in Africa. Following 
a preparatory meeting held in Abuja in November 
2003, the statutory meeting of the Groupe 
intergouvernemental d’action contre le blanchiment 
d’argent en Afrique de l’Ouest (GIABA) was held in 
Dakar from 22 to 25 June 2004. Mauritania and all 
member States of the Economic Community of West 
African States except Liberia, as well as numerous 
international organizations and financial institutions, 
were represented at the statutory meeting, which 
approved the formal establishment of the GIABA 
secretariat and its work plan for the period 2004-2006. 
The secretariat of GIABA was subsequently granted 
observer status with the Financial Action Task Force on 
Money Laundering (FATF) at a meeting of the Task 
Force held in Paris in June 2004. The countries in 
Central Africa officially inaugurated the Action Group 
against Money-Laundering in Central Africa (GABAC) 
in Bangui in March 2004. The Eastern and Southern 
Africa Anti-Money Laundering Group (ESAAMLG)38 
held a meeting in Cape Town in May 2004 to assist its 
member States in the drafting and finalization of 
national plans to counter money-laundering and the 
financing of terrorism; the draft plans were discussed 
during an ESAAMLG meeting held in Grande Baie, 
Mauritius, in August 2004 and will be finalized in 
March 2005. 
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  National legislation, policy and action 
 
236. A new penal code passed by the Parliament of 
Ethiopia increases the severity of the penalties for 
offences ranging from illicit drug manufacture to 
trafficking and organized crime to a minimum sentence 
of 10 years of imprisonment and a maximum sentence 
of 15 years of imprisonment. 
237. In a number of African countries, including 
Algeria, Cape Verde, Madagascar and Mauritius, steps 
have been taken to establish and implement national 
drug control master plans. South Africa is in the 
process of drafting a new five-year master plan that 
will take into account experiences gained from the 
implementation of the master plan for the period 1999-
2004. 
238. The Board notes the progress made by the 
Government of the Libyan Arab Jamahiriya in 
strengthening the national and legal institutional 
capacities for the control of licit drugs, as well as drug 
law enforcement. 
239. The Government of Morocco has proposed new 
legislation against money-laundering that conforms 
with international standards and takes into account the 
FATF recommendations; the Board calls upon the 
Government to enact the draft legislation without 
further delay. The Board notes that, in 2004, the Niger 
and Senegal adopted national laws modelled after 
standardized legislation against money-laundering 
developed by the West African Economic and 
Monetary Union in 2002. In the remaining member 
States of the West African Economic and Monetary 
Union, such legislation is limited or non-existent. 
Legislation against money-laundering that meets 
international standards is also in place in Cape Verde, 
the Gambia, Ghana and Nigeria. In Eastern Africa, 
Madagascar has adopted a new law against money-
laundering. The Board advises States that have not 
adopted legislation against money-laundering to do so 
as soon as possible. 
240. The Board notes with appreciation that the 
Government of Zambia has intensified its interdiction 
efforts. In 2003, 182 tons of cannabis were seized, 
compared with a total of 30 tons seized in 2001 and 
2002.  
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
241. Africa continues to be a major source of the 
cannabis found in illicit markets in the region or 
smuggled out of the region, mainly into Europe. 
Production of and trafficking in cannabis have been 
reported in practically all countries in Africa, while the 
production of cannabis resin is concentrated mainly in 
Morocco. 
242. According to a joint survey carried out by the 
United Nations Office on Drugs and Crime and the 
Government of Morocco in 2003, the total area under 
cannabis cultivation in Morocco was estimated at 
134,000 hectares; the survey estimated that 47,000 tons 
of cannabis plant material was produced, representing 
approximately 3,000 tons of cannabis resin. In the 
same survey, it was estimated that Morocco accounted 
for approximately 40 per cent of global cannabis resin 
production. About 60 per cent of the cannabis resin 
seized in the world continues to be of Moroccan origin; 
most of the Moroccan cannabis is seized in Western 
Europe. Cannabis resin from Morocco is smuggled into 
other African subregions for local consumption and for 
re-routing to illicit markets elsewhere.  
243. There is an urgent need in Morocco for new 
legislation in support of the national drug control 
strategy and institutions monitoring drugs. The Board 
therefore urges the Government of Morocco to develop 
such legislation; the legislation should provide for the 
use of eradication measures and the sanctions 
envisaged in the 1988 Convention, permit the use of 
investigative techniques such as controlled delivery 
and facilitate the development of effective international 
cooperation through, for example, extradition, the 
confiscation of illicit drug consignments in other 
countries, mutual legal assistance and the interception 
of illicit drug consignments in transit. 
244. Cannabis herb has remained the most abused 
illicit drug in most African countries. Several African 
countries are major sources of cannabis. In some of 
those countries, the cultivation of cannabis for 
commercial purposes is reportedly increasing as a 
result of declining prices for other agricultural 
products. In Eastern Africa, in particular in the 
Comoros, Ethiopia, Kenya, Madagascar, Uganda and 
the United Republic of Tanzania, cannabis constitutes a 
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significant commercial crop. The country in Southern 
Africa in which cannabis cultivation is most common 
is South Africa, followed by Malawi. There is evidence 
to suggest that some of the many civil conflicts in 
Africa are partly funded by profits from cannabis 
trafficking. 
245. Weak control measures at seaports, airports and 
land borders, inadequate drug control legislation and 
an increasing number of important airline hubs 
continue to contribute to the growing drug trafficking 
problem in Eastern Africa. Over the years, Western 
Africa, in particular Nigeria, has become a major 
transit area for drug trafficking. 
246. Cocaine originating in South America continues 
to enter Southern and Western Africa before continuing 
on its way to Europe and North America. For 2003, 
several countries in Africa reported increased seizures 
of cocaine. While previously the largest cocaine 
seizures were reported in Nigeria and South Africa, the 
year 2004 saw some record seizures in the Gulf of 
Guinea: in January, about 600 kg of cocaine destined 
for the United Kingdom were seized and an 
international drugs cartel was dismantled in Ghana; 
and in July, some 450 kg of cocaine were seized off the 
coast of Togo in a joint operation conducted by French 
and Togolese officials acting on intelligence provided 
by Spain. Also in July 2004, the authorities of Cape 
Verde seized 200 kg of cocaine and arrested 10 persons 
in connection with that seizure. Those cases clearly 
corroborate an increasing trend in drug trafficking by 
sea, especially in Western Africa. It is believed that 
drug traffickers have moved their operations to the 
coast of Western Africa as a result of effective law 
enforcement measures off the coast of Portugal and 
Spain. According to information provided by the 
Sudanese authorities, there has also been a noticeable 
increase in the smuggling of drugs, in particular 
cocaine, from West Africa through the Sudan to 
countries in the area of the Persian Gulf, including 
Saudi Arabia. There is relatively little abuse of cocaine 
in Africa; the abuse of that drug in the region seems to 
be confined mainly to Nigeria, Senegal and South 
Africa, as well as transit countries, notably Cape 
Verde. 
247. Heroin originating in South-East Asia and South-
West Asia continues to be smuggled into countries in 
Eastern and Western Africa, the ultimate destination 
being Europe and, to a lesser extent, North America. 
While the quantities involved are small compared with 
heroin trafficking in other regions, there is a clear 
upward trend in such trafficking. (Africa accounts for 
only 0.5 per cent of all the heroin seized in the world.) 
Countries in Western Africa account for most of the 
seizures. Seizures of heroin continue to be made at the 
international airport at Nairobi, as well as in Addis 
Ababa. A number of African countries are reporting 
growing abuse of heroin, albeit at a low level; those 
countries include Côte d’Ivoire, Kenya, Mauritius, 
Morocco, Mozambique, South Africa and the United 
Republic of Tanzania. While most heroin is smoked, its 
use by injection is being increasingly reported in 
countries in Eastern and Southern Africa, a 
development that will have serious ramifications for 
the spread of HIV/AIDS. In South Africa, the large 
increase in demand for treatment for heroin abuse, 
which had been observed for a few years, appears to 
have levelled off. 
 
  Psychotropic substances 
 
248. The abuse of pharmaceutical products, in 
particular preparations containing psychotropic 
substances, that are increasingly being sold over the 
counter and without medical prescription continues to 
be a subject of major concern in Africa. Ephedrine and 
diazepam are often sold by street vendors or in 
neighbourhood shops in several Western and Central 
African countries. Particularly worrying is the fact that 
some young people in Eastern Africa have access to 
such diverted drugs. In South Africa, the recent rapid 
increase in the abuse in the Cape Town area of 
methamphetamine hydrochloride (commonly called 
“ice”), which apparently is smuggled into the country 
from China, and the growing availability of 
methcathinone (commonly called “cat”), which is 
clandestinely manufactured in the country, have 
become a cause for concern for the authorities. 
249. The abuse of methaqualone continues to be a 
matter of concern in South Africa, as well as in other 
countries in Southern Africa. Methaqualone is usually 
smoked in combination with cannabis (a combination 
commonly called “white pipe”). Methaqualone 
continues to enter South Africa from India and China, 
and some shipments of the substances pass through 
Mozambique, Swaziland and Zimbabwe and Eastern 
African ports and airports. Methaqualone has also been 
manufactured in clandestine laboratories in countries in 
Southern Africa. The Board notes that the South 
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African law enforcement authorities have, on several 
occasions, been very successful in intercepting some of 
the methaqualone smuggled into their country. In mid-
2004, three major seizures of methaqualone powder 
(totalling 12 tons and apparently originating in China) 
were made in Southern Africa: two of them in Durban, 
South Africa, and one in Maputo. 
250. The abuse of MDMA (Ecstasy) seems to be 
largely confined to South Africa. Most of the substance 
is smuggled into South Africa, but some MDMA is also 
manufactured locally. The first clandestine laboratory 
manufacturing MDMA was identified and dismantled 
in 1996; since then, the police have been making 
seizures of MDMA on a regular basis.  
251. While the illicit manufacture of amphetamine-
type stimulants has remained limited to a few cases in 
Egypt, amphetamine and methamphetamine tablets are 
smuggled from West Africa, via the Sudan, to Saudi 
Arabia and other countries in the area of the Persian 
Gulf. 
 
  Others 
 
252. Khat, which is not under international control, 
continues to be cultivated in Ethiopia and Kenya, as 
well as in the Comoros, Madagascar and the United 
Republic of Tanzania. Khat is abused mainly in 
Djibouti, Ethiopia and Somalia. Though khat 
consumption is associated with health-risk and 
detrimental social consequences, it is only prohibited 
in some countries, such as Eritrea and the United 
Republic of Tanzania. Khat is currently under critical 
review by the WHO Expert Committee on Drug 
Dependence. 
 
  Missions 
 
253. The Board reviewed action taken by the 
Government of Egypt to implement the 
recommendations made by the Board following its 
mission to that country in May 2001. Those 
recommendations included the systematic conducting 
of studies on the extent of drug abuse in Egypt and the 
further development of prevention and treatment 
services; the strengthening of legal provisions against 
money-laundering; and the implementation of effective 
measures in Egypt to prevent controlled psychotropic 
substances from being made available without the 
required prescription. 
254. The Board, while acknowledging some measures 
taken by the Ministry of Health and Population of 
Egypt with regard to the control of licit activities 
related to psychotropic substances and precursors, 
notes with concern that recommendations covering 
other issues of drug control either have not been 
attended to or have not been adequately addressed. The 
Board urges the Government to take the necessary 
steps to ensure that other recommendations of the 
Board are fully implemented in a more effective and 
coordinated manner without further delay. 
255. The Board sent a mission to Madagascar in June 
2004. The Board notes with appreciation that the 
mission was received by government officials at the 
highest political level, including the Prime Minister 
and members of the Cabinet, who clearly expressed the 
firm political will of the Government to fight the drug 
problem. Madagascar adopted in 1997 legislation that 
is in line with the international drug control treaties 
and has recently enacted provisions against money-
laundering. 
256. The Board notes with appreciation that a 
comprehensive national master plan for drug control, 
including measures to deal with licit control, was 
adopted in 2003 by the Government of Madagascar but 
regrets that its implementation has been delayed due to 
financial constraints. As the interministerial 
commission for drug control coordination plays a 
relevant role in all drug control activities in 
Madagascar, the Board encourages the Government to 
assign sufficient technical and financial resources to 
the secretariat of the Commission to enable it to 
implement the plan and perform its functions 
effectively. 
257. The Board is aware that Madagascar, because of 
its strategic location in the Indian Ocean, is at risk of 
being targeted by drug traffickers. In Madagascar, the 
extensive coastline, the development of tourist resorts 
in the north of the country and on nearby islands and 
the shortage of financial and technical resources make 
it difficult to combat drug abuse and trafficking. The 
Board notes the importance attached by the 
Government to improving the current network for the 
collection of data on drug abuse and trafficking, which 
will be used as a tool to realign government priorities 
on prevention measures for the general population, in 
particular the younger members of the population. The 
Board recommends that donor countries and relevant 
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international organizations provide technical and 
financial assistance to the Government in developing 
drug prevention programmes, intelligence services and 
modern detection methods, including law enforcement 
and laboratory detection techniques, that will enhance 
the capacity of law enforcement authorities to intercept 
illicit drug consignments. 
258. During a joint technical visit by the secretariat of 
the Board and the United Nations Office on Drugs and 
Crime to Mauritania in June 2004, the action taken by 
the Government pursuant to the recommendations 
made by the Board after its mission to that country in 
March 1999 was discussed. Consultations with the 
authorities of Mauritania are continuing with regard to 
the improvement of the reporting obligations of 
Mauritania, as required under the international drug 
control treaties. 
259. The Board notes the various difficulties 
encountered by the Government of Mauritania in 
complying with its treaty obligations. However, the 
Board appreciates the efforts of the Government to 
rectify the situation and notes with satisfaction the 
measures taken by the authorities to strengthen the 
current national drug control legislation. The Board 
looks forward to the development of a comprehensive 
national drug control system and hopes that the new 
draft legislation will soon be adopted, thus providing 
for better control of the distribution of pharmaceutical 
products, including internationally controlled 
substances. 
260. The Board notes with appreciation that, despite 
limited technical and human resources, the national 
office for the fight against the illicit traffic in narcotic 
drugs and psychotropic substances is regularly making 
seizures of illicit consignments of cannabis and 
psychotropic substances in Mauritania. However, the 
Board notes that better coordination between the 
different bodies involved in the fight against drug 
trafficking and abuse is required if sustained drug 
control is to be achieved in the country. Therefore, the 
Board strongly encourages the Government of 
Mauritania to reinforce the interministerial commission 
for drug control coordination in order to enable it to 
carry out its functions of coordination and promotion 
of efficient cooperation and the sharing of information 
between the various drug control authorities. 
261. In June 2004, the Board sent a mission to South 
Africa to assess the progress made by the Government 
in implementing the recommendations made by the 
Board following its 1993 mission to that country. 
While the mission did not have the opportunity to 
make full assessment of the drug control situation in 
the country, the Board appreciates the commitment of 
the Government to international drug control. The legal 
framework for drug control in South Africa is 
comprehensive and in compliance with the provisions 
of the 1961 Convention, the 1971 Convention and the 
1988 Convention. Sufficient controls are being 
exercised over licit narcotic drugs, psychotropic 
substances and precursor chemicals. However, 
implementation is hampered by lack of coordination. 
262. The Board notes that the Government of South 
Africa is currently in the process of developing a new 
national drug control master plan, based on an 
evaluation of the results achieved under the master 
plan for the period 1999-2004. The Board urges the 
Government to ensure improved coordination and 
cooperation among the regulatory and law enforcement 
institutions and agencies responsible for drug control 
issues. The Board looks forward to the implementation 
of the new master plan, including at the local level, 
particularly in the areas of prevention and treatment of 
drug abuse. The Board also looks forward to the 
Government of South Africa providing rural 
communities with programmes for sustainable 
development that discourage cannabis cultivation. 
263. The Board notes the active role played by the 
Government of South Africa in fostering cooperation in 
the field of drug control at the international and 
regional levels, in particular among the countries in 
Southern Africa within the framework provided by 
SADC. The Board also notes the continued support 
provided by the Government to the three international 
operations launched by the Board for preventing the 
diversion of key chemicals used in the illicit 
manufacture of heroin, cocaine and amphetamine-type 
stimulants. 
 
 
 B. Americas 
 
 
264. The Inter-American Drug Abuse Control 
Commission (CICAD) of the Organization of American 
States remains the main regional forum for 
coordinating drug control issues in the Americas. 
Under its aegis, the third evaluation round of the 
Multilateral Evaluation Mechanism was launched in 
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December 2003. A total of 34 countries participated in 
that round, the main aim of which is to assess the 
implementation of previous recommendations. The 
information gathered from participating countries is to 
be compiled and evaluated at intergovernmental 
meetings, one of which is to be held in January 2005. 
265. Intergovernmental working groups held a meeting 
under the auspices of CICAD in November 2003. One 
of the working groups presented a report on maritime 
drug trafficking. According to the report, 90 per cent of 
the cocaine manufactured in South America—590 tons 
out of an estimated total of 655 tons in 2003—is 
trafficked by sea, mainly through the Caribbean and 
the Gulf of Mexico; moreover, in many States in the 
region, there is insufficient funding and a lack of 
human and material resources and none of the required 
mechanisms for coordination at the national and 
regional levels to deal with the situation in an effective 
manner. The working group recommended the 
establishment within CICAD of an expert group on 
maritime control to draft model maritime control 
legislation and regulations and to develop best 
practices and strategies for maritime drug control in 
CICAD member States. 
266. A second intergovernmental working group 
reviewed the control over precursors in the Americas 
and concluded that there was a need for several States 
to strengthen their existing legislation and regulations 
in that area. 
 
 
  Central America and the Caribbean 
 
 
  Major developments 
 
267. The region of Central America and the Caribbean 
continues to be affected by large-scale cocaine 
trafficking and abuse; serious drug abuse problems 
have emerged in countries in the region. In the past 
year, law enforcement agencies in several countries 
reported increased seizures of cocaine, as well as 
stricter controls over precursor chemicals. There are, 
however, indications that drug trafficking organizations 
are adapting their methods in order to overcome law 
enforcement efforts.  
268. In countries in Central America, many youth 
gangs have been involved in violent crime and drug 
trafficking. Though there is no agreement on the 
number of persons involved in such gangs, it is 
estimated that at least 70,000 persons are members of 
youth gangs. The majority of them are in El Salvador, 
Guatemala and Honduras. Stringent measures have 
been adopted against youth gangs in several countries, 
including El Salvador, where new legislation 
penalizing membership in a youth gang has been 
widely criticized. At a summit held in March 2004, the 
heads of government of Central American countries 
agreed to cooperate in the fight against youth gangs. 
269. A new Government was formed in Haiti, 
following upheaval and armed conflict in early 2004. 
The drug control situation in Haiti has for many years 
been characterized by ineffective law enforcement and 
widespread corruption, resulting in the country 
becoming a key drug trafficking hub in Central 
America and the Caribbean. The Board urges the new 
Government of Haiti, with the assistance of the 
international community and the United Nations 
Stabilization Mission in Haiti (MINUSTAH), to ensure 
that drug control is a priority in its national 
reconstruction programme and to take the measures 
necessary to combat drug trafficking and the increasing 
drug abuse in the country. 
 
  Treaty adherence 
 
270. All States in Central America and the Caribbean 
are parties to the 1961 Convention, the 1988 
Convention and, with the exception of Haiti and 
Honduras, the 1971 Convention. The Board calls on 
Haiti and Honduras to accede to the 1971 Convention 
and to implement the provisions in that convention 
without delay. The Board also calls on Nicaragua to 
ratify the 1972 Protocol amending the 1961 
Convention without delay, as it remains the only State 
in the region that has not yet done so. 
 
  Regional cooperation 
 
271. Cooperation between law enforcement agencies 
in countries in Central America and the Caribbean and 
elsewhere in the Americas has resulted in the arrest of 
major drug traffickers. For example, in March 2004, 
the leader of a major drug trafficking organization in 
the Dominican Republic was arrested. According to the 
United States Government, the organization had moved 
shipments containing several hundred kilograms of 
cocaine into Puerto Rico and the United States from 
the British Virgin Islands, the Dominican Republic and 
unspecified countries in South America. 
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272. In April 2004, approximately 30 persons were 
arrested in several countries as a result of cooperative 
efforts between the law enforcement agencies of 
Colombia, the Netherlands Antilles and the United 
States. According to the law enforcement officials 
involved, the arrests were the result of unprecedented 
coordinated efforts between the countries involved, 
including joint activities enabling law enforcement 
officials to track down persons involved in all stages of 
the drug trafficking operation, from the sources of 
supply to the wholesale and retail dealers. 
 
  National legislation, policy and action 
 
273. During the past year, steps were taken in several 
countries in Central America and the Caribbean to 
strengthen the control of precursors. In January 2004, 
the Government of Panama recorded a major seizure of 
ephedrine at the international airport in that country. 
Given the importance of Panama as a trans-shipment 
point, the Board encourages the Government of that 
country to pursue its efforts in strengthening precursor 
control, in cooperation with other Governments in the 
region.  
274. In Guatemala, the Government adopted new 
regulations on the control of precursors and established 
a new inter-ministerial committee to coordinate its 
action in that area. In Honduras, the Government 
started to implement the national action plan to 
strengthen precursor control. In Jamaica, the 
Government is implementing stricter controls over the 
shipment of controlled chemical substances at 
authorized ports of entry, including airports and 
container freight stations; however, the Government 
faces serious difficulties in pursuing such operations, 
including a lack of financial and other resources. 
275. In nearly all countries in Central America and the 
Caribbean, national drug control plans have been 
adopted in recent years. The Board notes with 
satisfaction that the Government of the Bahamas has 
adopted a national drug control plan covering the 
period 2003-2008, which the Board called for in its 
report for 2003.39 The Board also notes that, as part of 
that plan, the Government is in the process of 
establishing a national drug observatory and is creating 
minimum standards of care for the treatment of drug 
addicts. The national drug control plan adopted by 
Costa Rica provides for institutional restructuring to 
strengthen efforts in drug control. In El Salvador, a 
newly adopted drug control law strengthens penalties 
for a wide range of drug-related offences. 
276. In February 2004, a select committee of the 
Parliament of Jamaica recommended that national 
legislation be amended so that the possession and 
abuse of cannabis in small quantities in private would 
be minor offences, subject to a moderate fine. The 
committee recommended that cannabis abuse in public 
spaces remain subject to criminal sanctions. The 
committee also recommended that other measures be 
taken to reduce the abuse of cannabis, including an 
intensive demand reduction campaign directed at 
young persons and the strengthening of efforts to 
eradicate the illicit cultivation of cannabis. The 
recommendations of the committee were sent to the 
Parliament for adoption. 
277. The Board wishes to stress that cannabis is a 
harmful drug, requiring strong control under the 1961 
Convention. The Board urges the Government of 
Jamaica to ensure that a clear and correct message is 
sent to the public regarding the dangers of cannabis 
abuse.  
278. The Government of Belize has developed a 
national programme for alternative sentencing, 
whereby, in cases involving drug abuse, first-time and 
juvenile offenders are given sentences of community 
service in conjunction with drug treatment or 
counselling.  
279. The Government of Antigua and Barbuda has 
recently conducted a national survey of drug abuse in 
schools and is currently in the process of analysing the 
results. A similar survey in Guatemala indicated that 
abuse of illicit drugs, including cannabis and cocaine, 
had increased over the previous five years. Such 
surveys have also been conducted in Costa Rica and 
Panama. 
280. A national survey conducted on drug abuse in 
El Salvador was completed in June 2004. The survey 
indicated that 16 per cent of the population had abused 
an illicit drug at least once and 7 per cent had done so 
in the previous year. The survey also showed that the 
age of initial use of crack and cannabis was 
approximately 13 years, which indicated a need to 
ensure adequate drug abuse prevention programmes for 
children 12 years old and younger. 
281. Concrete information on drug abuse in many 
countries in Central America and the Caribbean 
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remains scarce. The Board encourages Governments of 
countries in the region to continue their efforts to 
collect and analyse data in that area. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
282. Cocaine is trafficked in large quantities 
throughout Central America and the Caribbean. The 
authorities of the Netherlands Antilles and Aruba 
seized almost 5,000 kg of cocaine in 2003, an increase 
from approximately 2,000 kg in 2002. There are 
indications that drug trafficking organizations in the 
Netherlands Antilles are increasingly paying individual 
drug carriers (“mules”) not in cash but in MDMA or 
cocaine, thereby increasing the level of drug abuse and 
drug-related crime and exacerbating the adverse social 
situation in the territory. 
283. In Honduras, the total amount of cocaine seized 
increased from an average annual level of 
approximately 1,500 kg in the period 1997-2000 to 
over 5,000 kg in 2003. In August 2004, a truck 
containing 1,600 kg of cocaine was seized by the 
authorities in Nicaragua near the border of that country 
with Honduras. 
284. In 2003, the Government of Bahamas seized a 
total of over 4,000 kg of cocaine, the highest level 
recorded since 1997. The amount of cocaine seized in 
Guatemala totalled over 9,000 kg in 2003, reaching 
previous high levels of 1998 and 1999. The 
Government of Costa Rica seized a total of 2,900 kg of 
cocaine in 2002, 4,200 kg in 2003 and 4,300 kg in the 
first six months of 2004 alone. 
285. In response to rigorous efforts by law 
enforcement agencies, drug trafficking organizations in 
some countries are changing their modus operandi. In 
Honduras, there appears to have been an increase in the 
use of air and sea routes for drug trafficking. In 
Jamaica, drug traffickers are increasingly using small 
boats to transport illicit consignments, and drug 
trafficking organizations were making reconnaissance 
flights with small aircraft to ensure that sea lanes were 
clear before dispatching their boats. 
286. Cocaine abuse appears to be increasing in Central 
America and the Caribbean. In Panama, the annual 
prevalence rate is 1.4 per cent, though that figure is 
based on data collected in 1997. Barbados, Guatemala, 
Nicaragua and Saint Lucia are all estimated to have an 
annual prevalence rate of 1 per cent. In the Dominican 
Republic and Haiti, cocaine abuse, though still 
minimal, is also increasing. 
287. Cannabis cultivation takes place in most 
countries in Central America and the Caribbean; most 
of the cannabis produced is abused locally or smuggled 
into neighbouring countries. Governments in the 
subregion have continued their cannabis eradication 
programmes.  
288. Jamaica has reported considerable success in the 
elimination of illicit cannabis cultivation, the total area 
under such cultivation in that country having fallen 
from 900 hectares in 1999 to 400 hectares in 2003. The 
total amount of cannabis seized by the authorities in 
Jamaica in the same period fell from 74,000 to 
36,000 kg. Despite those successes, Jamaica continues 
to be a major source of cannabis in the region. The 
Board encourages Jamaica to continue its efforts, 
including the collection of data to assist in monitoring 
the situation. The Board calls on Jamaica’s partners to 
support those efforts through financial and technical 
assistance. 
289. Heroin abuse in Central America and the 
Caribbean is relatively low, but the situation is 
changing as drug trafficking throughout the region is 
increasing. An increase in heroin abuse has been 
reported in the Dominican Republic and El Salvador. 
290. Females account for an increasing proportion of 
drug abusers in Central America and the Caribbean. 
The Board urges Governments in the region to ensure 
that, in efforts to combat drug abuse, adequate 
programmes are in place to ensure that special 
attention is given to female drug abusers. 
 
  Psychotropic substances 
 
291. Surveys indicate that the abuse of pharmaceutical 
medications containing psychotropic substances is at a 
high level in certain countries in Central America and 
the Caribbean. One study shows that psychotropic 
substances, in particular flunitrazepam and diazepam, 
are the main drugs of abuse among street children in 
Port-au-Prince, the capital of Haiti. Those substances 
are diverted from the licit market or international 
donations or are smuggled from Costa Rica, the 
Dominican Republic, the Netherlands Antilles, Panama 
and Venezuela. CICAD has noted that the control of 
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psychotropic substances remains problematic in several 
countries in Central America and the Caribbean. The 
Board urges Governments of countries in the region to 
ensure that adequate controls are in place for 
pharmaceutical medications, in accordance with the 
provisions of the international drug control treaties. 
 
 
  North America 
 
 
  Major developments 
 
292. The North American region is, collectively, the 
largest market in the world for illicit drugs. Large-scale 
trafficking and illicit manufacture of drugs are also a 
grave concern, and the abuse or misuse of prescription 
drugs appears to be a growing phenomenon. At the 
same time, the countries in the region devote a large 
amount of resources to deal with their drug problems, 
both within and beyond their individual countries. 
Collaboration between the countries of the region, in 
particular in the field of law enforcement, is excellent.  
293. The first national survey on drug abuse since 
1994 was launched in Canada in December 2003. The 
survey represents the first step in ensuring that 
comprehensive data on current trends are available, as 
recommended by the Board. Debate continued in 
Canada regarding proposed legislation that would 
reduce the sanctions for possession of small amounts 
of cannabis from criminal prosecution to a fine. 
294. The Government of Mexico continued its law 
enforcement efforts against drug trafficking, recording 
several major successes, including the arrest of high-
ranking members of drug trafficking organizations. 
Mexico also acted as host to the High-level Political 
Conference for the Purpose of Signing the United 
Nations Convention against Corruption, held in Merida 
in December 2003. 
295. The United States, the world’s largest single 
market for illicit drugs, continued to be a major partner 
in international drug control efforts, in particular in the 
area of law enforcement. As a result of law enforce-
ment efforts, including joint operations involving the 
United States and other countries, eight major 
international drug trafficking organizations were 
dismantled during the past year and seven others were 
severely disrupted. The United States also continued its 
efforts to address the high level of drug abuse on its 
territory; consequently, there was a significant decline 
in drug abuse among secondary-school students. 
However, the abuse of some pharmaceutical 
medications containing narcotic drugs and psycho-
tropic substances appears to be an increasing problem 
in the country.  
 
  Treaty adherence 
 
296. All three States in North America are parties to 
the three international drug control treaties. 
 
  Regional cooperation 
 
297. The three countries in North America continued 
their excellent cooperation in the area of law 
enforcement and achieved a number of successes 
against international drug trafficking organizations. In 
March 2004, Canada and the United States dismantled 
an organization that had been engaged in illicit drug 
manufacture and trafficking on a large-scale; as a result 
of that operation, more than 130 persons in the United 
States and 50 persons in Canada were arrested. In May 
2004, the authorities of Canada, Colombia, the United 
Kingdom and the United States dismantled a large-
scale money-laundering ring, which had laundered 
millions of United States dollars of proceeds from the 
sale of Colombian cocaine.  
298. A large number of high-ranking members of drug 
trafficking organizations were also arrested in Mexico, 
often as a result of joint operations and the sharing of 
intelligence with other countries in Central America 
and/or North America. Mexico extradited 31 persons to 
the United States, 19 of whom had been charged with 
drug- related offences. Prosecutors in Mexico and the 
United States participated in a cooperation programme 
to identify practical methods to improve extradition 
procedures. 
299. All three States in North America are members of 
CICAD and participate in the Multilateral Evaluation 
Mechanism. The thirty-fourth regular session of 
CICAD was held in Montreal, Canada, in November 
2003 and the thirty-fifth regular session was held in 
Washington, D.C., in April 2004. The Board 
encourages the three States in North America to con-
tinue their active participation in that regional forum. 
 
  National legislation, policy and action 
 
300. The Board welcomes that, pursuant to its 
recommendation, in December 2003, the Government 
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of Canada commenced the first national survey on drug 
abuse since 1994. Until the current survey, information 
on drug abuse in Canada had been incomplete. The 
Board hopes the findings of the survey will be utilized 
by the Government of Canada in developing 
programmes to combat drug abuse in that country.  
301. The Board notes that legislation proposed by the 
Government of Canada to revise penalties for 
cannabis-related offences remains the subject of 
debate. While, under the proposed legislation, the 
possession of cannabis would remain a criminal 
offence, the possession of small amounts of that 
substance would not result in a criminal record. The 
Board is concerned that any revision should not 
contribute to the mistaken perception that cannabis is a 
harmless substance. The proposed legislation would 
also increase penalties for the production of cannabis 
in certain cases. 
302. Mexican law enforcement authorities arrested 
high-ranking members of major drug trafficking 
organizations in the past year. For example, in April 
2004, members of the Mexican police force arrested a 
Guatemalan national alleged to have been the head of 
one of the largest drug trafficking organizations in 
Central America and, in August 2004, Mexican 
authorities arrested the leader of an organization 
alleged to be responsible for having trafficked 
approximately half of the cocaine entering the United 
States from Mexico. The Government of Mexico also 
continued its efforts against corruption, which in many 
cases was connected to drug trafficking. For example, 
in April 2004, the Government took action in a state in 
central Mexico against a large number of police 
officers who had been accused of transporting cocaine 
in police vehicles. 
303. In July 2004, the Government of Mexico 
indicated that some of the main drug trafficking 
organizations had been significantly weakened. The 
Board encourages the Government to continue its 
efforts against drug trafficking, especially as there are 
indications that drug trafficking organizations are 
becoming more decentralized, with a larger number of 
smaller organizations.  
304. The Board notes that cannabis and opium poppy 
illicitly cultivated in Mexico, though not on a large 
scale, have posed problems in North America for some 
years. As part of its demand reduction efforts, the 
Government of Mexico continued to establish 
municipal committees against drug addiction. The 
Board notes that the large amount of drugs trafficked 
through Mexico leaves the country vulnerable to the 
spillover effect, which has already taken place in other 
countries. In addition, the Board notes that there are 
high rates of abuse for some drugs in the northern 
part  of the country. The Board encourages the 
Government to continue strengthening its efforts in 
demand reduction, and it hopes that the municipal 
committees will prove to be a useful tool in combating 
drug abuse.  
305. The Government of the United States continued 
to give top priority to combating drug trafficking and 
drug abuse. Besides its efforts on its own territory, the 
United States is also a major partner in international 
drug control, having allocated US$ 731 million for the 
year 2005 to support drug control efforts in countries 
in South America, including support for law 
enforcement, the eradication of illicitly cultivated 
crops, institution-building, alternative development and 
demand reduction programmes. The Government also 
plays a leading role in Project Prism, a global 
operation initiated by the Board in 2002 to address the 
diversion of precursors used in the manufacture of 
amphetamine-type stimulants.  
306. Though recent official data show that the rate of 
drug abuse among the general population of the United 
States has remained stable since 2002, there has been a 
significant decrease in the abuse of illicit drugs among 
secondary-school children, the first such decline in 
more than a decade. The perception of the risks 
involved in the abuse of drugs, in particular cannabis, 
among young persons also appears to have increased—
a development that may be attributed in part to the 
effectiveness of media campaigns. 
307. The Board notes with concern that, despite the 
above-mentioned positive developments, the rate of 
drug abuse in the United States remains disturbingly 
high: the prevalence of illicit drug abuse in the past 
month is 8.2 per cent. The Board encourages the 
Government to continue its efforts in drug abuse 
prevention. The Board notes that the rate of drug abuse 
varies widely among the major ethnic groups in the 
country, and it encourages the Government to take 
those differences into account in formulating and 
implementing demand reduction programmes.  
308. The Board notes that experience in several 
countries and jurisdictions has shown that drug courts 
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may be effective in ensuring that non-violent drug 
offenders undergo treatment, and it encourages 
countries to continue exploring that option in 
addressing drug abuse and related problems. The Board 
welcomes the significant increase in the funding 
available for drug courts in the United States, which 
was announced by the Government. The Board also 
notes the efforts by the Government to establish 
mandatory minimum standards for drug addiction 
treatment in the country and encourages it to continue 
those efforts.  
309. In July 2004, law enforcement authorities in the 
United States closed down several web sites that had 
been used to sell controlled psychotropic substances. 
The web sites had made it possible for such drugs to be 
sold to thousands of customers worldwide. The Board 
has repeatedly expressed concern about the growing 
phenomenon of the sale of controlled substances over 
the Internet, and it urges Governments to take adequate 
measures to ensure compliance with the international 
drug control treaties. The Board convened an expert 
meeting on the subject in October 2004, the major 
conclusions and recommendations of which are 
reflected in paragraphs 170-184 above. 
310. A panel of experts convened by the Government 
of the United States concluded in February 2004 that 
the increase in methadone-related emergency room 
visits and deaths in the period 1995-2002 had not been 
attributable to any diversion from methadone substitu-
tion treatment but had been associated mainly with the 
use of methadone as medication prescribed for pain. 
 
  Cultivation, production, trafficking and abuse 
 
  Narcotic drugs 
 
311. Cannabis remains the most abused drug in North 
America and is produced in significant amounts in all 
three countries in the region. The Government of the 
United States estimates that approximately 2,500 tons 
of cannabis is produced in that country; over 
3.3 million cannabis plants were eradicated by the 
Government in 2002, which represents a slight increase 
over the level of the previous year.  
312. Law enforcement agencies in all provinces of 
Canada report that illicit cannabis cultivation is one of 
their main drug law enforcement problems; in several 
provinces, such cultivation has reached levels that 
could be deemed epidemic. Despite some reports 
regarding the widespread cultivation of high-potency 
cannabis in Canada, the Royal Canadian Mounted 
Police points to research indicating that the potency of 
cannabis cultivated in Canada remains stable. As noted 
in paragraph 317 above, the Government of Mexico is 
currently establishing a mechanism for the estimation 
of illicit drug crop cultivation on its territory. 
313. Cocaine is trafficked in large quantities 
throughout North America; that is largely a result of 
the fact that the United States is by far the world’s 
largest market for the drug. The abuse of cocaine also 
takes place in Canada and, to a lesser extent, Mexico. 
According to the assessment of the Government of 
Canada, much of the cocaine entering the country from 
the United States appears to be connected to the 
smuggling of Canadian cannabis into the United States, 
indicating that drug trafficking organizations are 
engaging in a form of barter trade. 
314. The total amount of cocaine seized by the 
Government of Mexico increased significantly, from 
12,600 kg in 2002 to approximately 21,000 kg in 2003. 
There are indications that drug trafficking 
organizations are using Mexico as a transit point for 
cocaine destined for Europe. The Board urges the 
Government of Mexico, in cooperation with other 
Governments, to make every effort to deal with that 
new development. The Board is also concerned about 
recent indications that drug trafficking organizations 
are beginning to change their methods in Mexico, 
perhaps targeting the country as an emerging market. 
That is perhaps evidenced by the recent seizure of a 
large amount of stored cocaine and the dismantling of a 
large laboratory for cocaine manufacture, both in 
Mexico City.  
315. A recently published national household survey 
shows that the rate of cocaine abuse in Mexico, which 
is concentrated mainly in the states in the northern part 
of the country, decreased slightly in the period 1998-
2002, after having increased for roughly a decade. The 
Board encourages the Government to continue its 
efforts in demand reduction. 
316. In the United States, cocaine (in powder or crack 
form) continues to be regarded as the drug that poses 
as the greatest threat and that most contributes to 
violent crime.  
317. The Government of Mexico estimates that opium 
poppy cultivation has remained stable in 2003. 
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According to estimates of the Government of the 
United States, 4,800 hectares of illicit opium poppy 
were cultivated in Mexico in 2003. The Board notes 
that the Government of Mexico is in the process of 
establishing a system for estimating the quantity of 
drugs illicitly produced in Mexico. The Board 
encourages the Government to continue its efforts to 
obtain an accurate estimate of the scope of illicit crop 
cultivation on its territory. 
318. Data released in 2004 in the United States show 
an increasing problem involving the abuse or misuse of 
some prescription drugs under international control, 
including oxycodone and hydrocodone. Those drugs, 
which are used for pain treatment, are also abused by 
young persons. The majority of prescription drugs 
abused in the country are diverted from the licit market 
and obtained through Internet pharmacies.  
319. Recent research indicates that drug abuse in 
Mexico is increasing at a faster pace among women 
than among men: while there were 13 male drug 
abusers for every female drug abuser in 1998, there 
were four male drug abusers for every female drug 
abuser in 2002. 
 
  Psychotropic substances 
 
320. The illicit manufacture of methamphetamine in 
North America has continued on a large scale and 
appears to be increasing. In 2003, over 9,000 clandes-
tine laboratories used for methamphetamine manu-
facture were dismantled in the United States—more 
than in any other country in the region; in the same 
year, 37 such laboratories were dismantled in Canada 
and 20 were dismantled in Mexico.  
321. The abuse of methamphetamine remains at a high 
level in the United States, though recent research 
indicates a gradual decline in the abuse of this drug 
among young people. In Canada, the abuse of 
amphetamine-type stimulants, including MDMA 
(Ecstasy) and methamphetamine, is increasing 
among  young people. There are also indications of 
increasing use of those drugs among adults. The total 
amount of MDMA (Ecstasy) seized by Canadian 
authorities has increased dramatically in recent years, 
and the number of clandestine MDMA (Ecstasy) 
laboratories dismantled by the Government has also 
increased. 
 
 
  South America 
 
 
  Major developments 
 
322. Significant positive developments have occurred 
in South America during the past year. Drug control in 
South America continues to be an issue of considerable 
political importance, not only to the region itself, but 
also to the rest of the world. That is evidenced by the 
ongoing discussion on how to maintain the assistance 
provided by the United States for alternative 
development and to strengthen institutions and develop 
social infrastructure in countries in the Andean 
subregion. Those issues were addressed at the sixth 
high-level meeting of countries in Latin America and 
the European Union, held in Dublin in May 2004; at 
the meeting, Peru was elected President of the 
coordination and cooperation mechanism in drug 
matters between the European Union, Latin America 
and the Caribbean. In South America, the total area 
under illicit coca bush cultivation was reduced during 
2003 for the third consecutive year. The Governments 
of several countries in the region have had 
considerable success against drug trafficking networks, 
as evidenced by, among other things, increased drug 
seizures. Strengthened regional and bilateral 
cooperation in interdiction efforts have contributed to 
that success. Most notably, in June 2004, as a result of 
a joint operation involving national law enforcement 
agencies and the United States and other countries 
outside of the region, the head of one of the largest 
drug cartels in Colombia was arrested (see para. 330 
below). In Colombia, the Government has made 
progress in combating drug trafficking and guerrilla 
and paramilitary groups involved in drug trafficking.  
323. At the same time, heightened social disturbances 
and violence related to illegal drugs have continued, 
particularly in Peru in the first half of 2004. Although 
there are numerous effective alternative development 
schemes currently under way, there are still far too 
many coca bush farmers in Bolivia and Peru who are 
dependent on income from such illicit cultivation. 
Insufficient support and implementation of sustainable 
alternative development programmes in some coca 
bush cultivation areas might have contributed to this. 
Drug trafficking, and the money-laundering and 
corruption associated with it, continues to endanger 
stability in the region. As in the recent past, drug 
traffickers have attempted to intimidate public 
prosecutors, demonstrating once again the close links 
E/INCB/2004/1  
 
50  
 
 
between drug trafficking and organized crime. Drug 
traffickers have responded to interdiction efforts by 
using different trafficking routes, by entering into new 
strategic alliances with trafficking organizations from 
other regions (such as the alliance involving 
Colombian and Moroccan organizations) and by 
merging organizations previously concentrating only 
on either cocaine or heroin.  
324. Open clashes between farmers who cultivate coca 
bush and the Government, which has made an effort to 
reduce such cultivation, continue in Bolivia; in Peru, 
the frequency and the level of violence of such clashes 
have increased. In Peru, where, in 2003, 40 per cent of 
the reduction in coca bush cultivation was undertaken 
voluntarily, some federations of coca bush growers are 
demanding new legislation that would make such 
cultivation completely legal and would contain no 
more provisions for drug crop eradication or 
alternative development. The Government of Peru has 
found such demands to be unacceptable. The Board 
urges the Governments of Bolivia and Peru to ensure 
that the provisions of the 1961 Convention concerning 
illicit crop cultivation and illicit drug production and 
trafficking are fully implemented in their countries.  
325. The Board is concerned about recent 
developments in the cultivation of coca bush and the 
manufacture of cocaine, since a reduction in the total 
area under cultivation might be offset by increasing 
yields in most producing countries. At the same time, 
coca bush cultivation is being moved to areas 
previously not affected. The increasing seizures of 
cocaine in and outside the region and the 
diversification of trafficking routes indicate that there 
is no shortage of that drug in illicit markets, despite the 
significant reduction in coca bush cultivation and other 
achievements of interdiction efforts. 
326. Since coca bush cultivation is often found in 
areas where poverty prevails, the Board is convinced 
that measures to alleviate poverty are extremely 
important to achieve a continuous reduction in the 
production of coca leaf and other narcotic drugs in 
South America. 
 
  Treaty adherence 
 
327. All States in South America are parties to the 
1961 Convention as amended by the 1972 Protocol, the 
1971 Convention and the 1988 Convention. 
 
  Regional cooperation 
 
328. In South America, countries continue to 
participate actively in multilateral cooperation 
mechanisms of CICAD. For example, in a pilot project 
in South America undertaken by CICAD, Uruguay has 
been chosen to develop activities related to a 
programme on estimating the human, social and 
economic costs of illicit drugs in America (see also 
para. 336 below). In addition, many States with 
common geographical characteristics or shared borders 
have entered into bilateral or multilateral agreements 
and have continued to adhere to those agreements; for 
instance, the third meeting of the Executive Committee 
of the Andean Cooperation Plan for the Control of 
Illegal Drugs and Related Offences was held in 
Cuenca, Ecuador, in April 2004. Other examples 
include the cooperation between Argentina, Bolivia, 
Chile, Peru and Uruguay in a subregional system for 
the prevention and treatment of drug abuse. In 
February 2004, the military forces of Brazil, Colombia 
and Peru signed an agreement aimed at suppressing 
drug trafficking and arms smuggling; it was the first 
agreement of its kind and involved three countries in 
the Amazon area. 
329. At the Thirteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and 
the Caribbean, held in Salvador, Brazil, in October 
2003, representatives expressed their Governments’ 
concern over the increased manufacture of 
amphetamine-type stimulants, in particular 
methamphetamine, and the increasing abuse of such 
stimulants in the region. The Meeting noted that the 
use of postal and courier services in drug trafficking 
had been increasing. The Meeting agreed that 
Governments should strengthen cooperation with 
postal and courier services to facilitate the detection 
and prevention of the use of the postal system for drug 
trafficking and, where appropriate, to facilitate 
controlled delivery operations. 
330. In June 2004, a joint operation involving the law 
enforcement agencies of the Bahamas, Canada, 
Colombia, Jamaica, Panama and the United States led 
to the arrest of the head of one of the largest drug 
cartels in Colombia, as well as over 50 members of the 
cartel. The operation also resulted in the seizure of 
6,539 kg of cocaine, 1,209 kg of cannabis and more 
than US$ 25 million in currency and seized assets. 
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331. The United States and countries in Europe 
continue to provide resources for drug control in South 
America through bilateral and multilateral agreements 
in various fields, such as law enforcement, criminal 
and fiscal investigation and judiciary matters, 
alternative development and educational programmes 
for drug abuse prevention. 
 
  National legislation, policy and action 
 
332. In Bolivia, the integrated strategy to fight drug 
trafficking for the period 2004-2008 was approved by 
the Government in September 2004. The strategy 
includes promotion of sustainable alternative 
development, eradication of illicit crop cultivation and 
control of precursor chemicals, prevention of the 
diversion of coca leaf into illicit channels, prevention 
of illicit drug manufacture and trafficking and 
prevention of laundering of proceeds obtained from 
illicit activities involving drugs. The strategy also 
introduces a new focus on the prevention of drug abuse 
and the treatment and social reintegration of addicts. 
The national plan for alternative development for the 
period 2004-2008, which is based on the principles of 
sustainability, integrity and social participation, was 
approved by the Government of Bolivia in May 2004. 
In Peru, the national drug control strategy for the 
period 2002-2007 was approved in January 2004. In 
Ecuador, the new decree on the national policy to fight 
drugs strengthens the role of the competent authority, 
the Consejo Nacional de Control de Sustancias 
Estupefacientes y Psicotropicas, and provides for a 
balanced approach between activities aimed at 
reducing the demand for and supply of illicit drugs. 
333. In Colombia, a reform of the criminal procedure 
code will enter into force on 1 January 2005 as part of 
the overall reform of the criminal justice system; 
during 2003, an updated law on controlled substances, 
covering narcotic drugs, psychotropic substances and 
precursors, was issued and judges were trained in 
legislative measures relevant to their work in the 
prevention of trafficking in drugs and precursors. In 
Brazil, a new law amending Act No. 6.368 of 
21 October 1976 is currently awaiting adoption by the 
Federal Senate; if adopted, the new law would remove 
mandatory prison sentences for drug abuse offences, 
directing addicts to treatment, and would increase 
penalties for drug trafficking. The Board trusts that the 
new law will be in line with the provisions of the 
international drug control treaties. 
334. With regard to action taken to prevent money-
laundering, the Board notes that, in Chile, Law 
No. 19.913 on money-laundering was enacted in 2003, 
establishing a financial intelligence unit and replacing 
or strengthening laws against money-laundering dating 
back to 1995. In Colombia, according to the 
Government, stricter measures to facilitate forfeiture of 
property originating from illegal activities have 
resulted in a significant increase in such forfeitures 
since mid-2002. The Government of Paraguay reported 
law enforcement successes vis-à-vis illegal foreign 
exchange providers and in strengthening judicial and 
fiscal units; a draft law against money-laundering is 
still being examined by the parliament. In Peru, the 
parliament adopted a law strengthening the role of the 
newly created financial intelligence unit in July 2004. 
A national strategy to combat money-laundering was 
adopted in Brazil in January 2004.  
335. For precursor control, activities aimed at 
controlling and combating the use of chemicals for the 
manufacture of cocaine and heroin continued under 
Operation Seis Fronteras, a regional initiative 
involving Bolivia, Brazil, Colombia, Ecuador, Peru and 
Venezuela, as well as the United States. Governments 
also cooperated in Operation Purple, the international 
tracking programme for prevention of the diversion of 
potassium permanganate (used for the illicit 
manufacture of cocaine) and Operation Topaz, the 
international tracking programme for prevention of the 
diversion of acetic anhydride (used for the illicit 
manufacture of heroin). In Peru, a new precursor law 
was adopted in July 2004, strengthening controls and 
providing for stricter sanctions in the event of non-
compliance.  
336. Programmes for the prevention and treatment of 
drug abuse, including relevant training, are coordinated 
among countries of the Southern Cone (Argentina, 
Chile, Paraguay and Uruguay). Those programmes 
include giving special attention to raising awareness 
about the risks of injecting drug abuse, which might 
result in the spread of HIV/AIDS, and drug abuse by 
pregnant women. In Chile, an interim report on the 
implementation of the national strategy covering the 
period 2003-2008 shows that prevention programmes 
have been carried out according to plan in schools, 
public enterprises, places of work, large communities 
and the armed forces. The Board notes that the 
Government of Uruguay is undertaking a survey on 
drug abuse among persons detained by the police; in 
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addition, drug abuse prevention activities at schools 
and correction centres are being evaluated with a view 
to developing a new consolidated prevention strategy 
for the country. 
 
  Cultivation, production, manufacture, 
trafficking and abuse  
 
  Narcotic drugs 
 
337. Illicit cultivation of cannabis mainly to be used 
locally or in other countries in South America 
continues to be detected in most countries in the region 
and appears to be increasing in several of those 
countries. For example, cannabis is cultivated in the 
north-eastern part of Brazil. In Paraguay, more than 
5,500 hectares are under cannabis cultivation, and most 
of the cannabis produced is destined for the Brazilian 
market. Operation Aliança, a campaign to eradicate 
illicit cannabis cultivation in the border area between 
Brazil and Paraguay, is carried out jointly by those two 
countries on a yearly basis. The eradication of cannabis 
cultivation has also been reported in Ecuador. Seizures 
of cannabis have increased in the region. 
338. In 2003, the total area under coca bush 
cultivation in Bolivia, Colombia and Peru decreased by 
11 per cent compared with 2002, to 154,000 hectares, 
the lowest level in a decade. However, as stated in 
paragraph 325 above, recent developments in coca 
bush cultivation indicate that reduction in the total area 
under cultivation in South America appears to be offset 
by increasing agricultural yields. Although the total 
area under coca bush cultivation decreased more in 
Colombia than elsewhere in the region, from 
102,000 hectares in 2002 to 86,000 hectares in 2003, 
such cultivation actually increased in certain parts of 
that country and is no longer confined to remote areas 
with no infrastructure. In addition, a shift towards 
smaller plots has been identified, possibly in an 
attempt to make it more difficult to carry out 
eradication efforts involving crop spraying. Moreover, 
it appears that high-yield varieties of coca bush have 
been introduced in Colombia.  
339. In Peru, it has been found that the reduction of 
the area under coca bush cultivation in 2003 by 
5 per cent compared with 2002, to 44,200 hectares, 
was at least partly offset by higher yields resulting 
from improved farming techniques such as increased 
plant density and the use of fertilizers. According to 
estimates by the United Nations Office on Drugs and 
Crime, there were 23,600 hectares under coca bush 
cultivation in Bolivia in 2003 and there are worrying 
signs that such cultivation might have increased during 
that year. The use of irrigation and fertilizers to 
cultivate coca bush is now common in Bolivia; for that 
reason, the agricultural yield of coca leaf in that 
country was also higher in 2003 than in previous years.  
340. In addition, illicit coca bush cultivation continues 
to be reported in Ecuador and in Venezuela, close to 
those countries’ borders with Colombia; however, the 
extent of coca bush cultivation in those countries is 
small compared with that of the major producing 
countries. In Venezuela, such cultivation is reportedly 
partly attributable to farmers who leave Colombia as a 
result of conflict in that country. The Board reiterates 
its appeal to all States in South America to cooperate 
with each other in order to prevent the displacement of 
illicit crop cultivation. 
341. In all the above-mentioned countries in South 
America, illicit coca bush cultivation is being 
eradicated, mostly manually; only in Colombia is it 
being eradicated mainly through crop spraying. In 
Colombia, the reduction in illicit coca bush cultivation 
is believed to be mainly due to strict law enforcement 
and crop spraying, since in 2003 spraying activities 
reached a record high level, although bad weather 
impeded crop spraying at the end of 2003. In contrast, 
in Bolivia and Peru, such eradication is carried out, to 
a great extent, voluntarily. The Board wishes to re-
emphasize that continued reduction of illicit coca bush 
cultivation, either on a voluntary basis or as a result of 
interdiction efforts, will depend on the ability to offer 
sustainable alternative livelihood to farmers in the 
producing countries. It is therefore essential for the 
international community to continue to support and 
expand alternative development initiatives in those 
countries.  
342. Based on the estimated cultivation of coca bush, 
the potential total manufacture of cocaine in South 
America in 2003 was estimated at 655 tons, compared 
with 800 tons in 2002. It should be noted that the 
figure for 2003 has been calculated according to past 
agricultural yields, which may no longer be valid at 
times of increasing agricultural yields. In addition, 
there are indications that cocaine manufacture from 
coca leaf has also become more effective, since 
traffickers have begun using better methods for 
extracting cocaine from coca leaf and have become 
 E/INCB/2004/1
 
 53 
 
more experienced in the use of precursors. The bulk of 
the cocaine continues to be manufactured in Colombia, 
but illicit manufacture of cocaine is known to take 
place or to have taken place in recent years also in all 
other countries in South America except Paraguay and 
Uruguay. In Colombia, strengthened law enforcement 
efforts during 2003 and 2004 resulted in increased 
detection and dismantling of clandestine laboratories 
used for cocaine manufacture.  
343. Seizures of coca leaf, predominantly reported in 
the countries in South America where illicit coca leaf 
production exists, doubled in 2003 compared with 
2002, due to strengthened interdiction efforts. Cocaine 
trafficking in the region continues to consist mainly of 
transit trafficking: the transport of cocaine 
consignments destined for the United States or, 
increasingly, Europe. Brazil, Ecuador and Venezuela 
are the countries in South America most affected by 
cocaine trafficking, although transit trafficking has 
increased in other countries in the region, such as 
Argentina and Chile. Increasing amounts of cocaine 
from Brazil and Colombia are smuggled through 
Portugal into Portuguese-speaking countries in Africa, 
primarily Angola and Mozambique, and into South 
Africa. There are also reports that cocaine from South 
America is being trans-shipped via several African 
countries to Europe. During 2003 and the first half of 
2004, seizures of cocaine increased or remained stable 
in most countries in South America; increased cocaine 
seizures were reported in a number of countries in the 
region, in particular, in Colombia and Venezuela. In 
Suriname, 341 kg of cocaine were seized from a 
clandestine airstrip in November 2003. 
344. In the recent past, the low level of oxidation of 
the cocaine seized was evidence of the success of 
Operation Purple, the international tracking 
programme for the prevention of the diversion of 
potassium permanganate. Governments of countries 
participating in that operation were identifying the 
legitimacy of end-users and determining the actual 
requirements of those companies, in order to ensure 
that no diversion from domestic distribution channels 
was taking place. In 2003, as in 2002, clandestine 
laboratories used for the manufacture of potassium 
permanganate continued to be detected and dismantled 
in Colombia, indicating that traffickers had found other 
ways to obtain the chemical in the quantities that they 
needed. It is not surprising that an increase in the 
purity of seized cocaine has been reported in Colombia 
and Paraguay, although the purity level is not yet 
comparable to the levels attained in the mid-1990s.  
345. While possible methodologies for making sound 
estimates of the illicit cultivation of opium poppy and 
the illicit production of opium in South America are 
still being explored, the Government of Colombia 
believes that around 4,000 hectares were used for that 
purpose in 2003, based, inter alia, on the total area of 
opium poppy eradicated, which amounted to almost 
3,000 hectares. It is assumed that the total area under 
opium poppy cultivation has not changed much in 
recent years, despite eradication efforts involving crop 
spraying. Eradication efforts targeting illicit opium 
poppy cultivation also continue to take place in Peru 
and Venezuela. 
346. Heroin manufacture continues to take place in 
South America, mainly in Colombia; the majority of 
the heroin manufactured is destined for the United 
States. Seizures of heroin in the region have been 
increasing; the country most commonly reported to be 
the source of the heroin seized is Colombia. While, in 
2003, Colombia continued to report the highest level of 
heroin seizures in South America, the level of such 
seizures in Venezuela increased significantly in 2002 
and has remained high since then, which may be an 
indication that that country is on one of the main 
transit routes used for smuggling heroin out of the 
region.  
347. According to the Government of Colombia, more 
than 95 per cent of the chemicals used in illicit drug 
manufacture in that country have been smuggled into 
the country and only 5 per cent have been diverted 
from domestic licit distribution; that highlights the 
need for neighbouring countries to remain vigilant and 
prevent the smuggling of those chemicals into 
Colombia. The Governments of many countries in 
South America, including that of Colombia, indicated 
that in 2003 they had effected an increased number of 
seizures of such chemicals and in 2003 and 2004 had 
dismantled several clandestine laboratories used in 
illicit drug manufacture. The Board is greatly 
concerned that Colombia did not submit to it 
information on seizures of such chemicals or any 
information related to the origin or destination of the 
chemicals in question. The Board wishes to re-
emphasize that seizures of precursors should be 
investigated with a view to identifying the trafficking 
routes used. The results of such investigations should 
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then be shared with the Board, in order to alert other 
Governments, where necessary.  
348. Although cannabis herb and resin are widely 
abused in South America, they are not necessarily the 
primary drugs of abuse. In Venezuela, for example, 
cannabis abuse is reported to be second only to cocaine 
abuse, whereas in Brazil cannabis abuse ranks second 
after the abuse of benzodiazepines. Cannabis and 
cocaine, in that order, were identified as the main drugs 
of abuse in a national survey on drug abuse conducted 
in Uruguay in 2003. While several countries in the 
region have reported increasing drug abuse, in Chile 
the prevalence of drug abuse continues to be 
decreasing or stable, as indicated by a national survey 
on secondary-school students undertaken during 2003 
and a study conducted during 2002. According to data 
collected by CICAD for a comparative study of the use 
of illicit drugs in selected countries in Latin America, 
there are considerable differences in the perceived 
accessibility of such drugs among the selected 
countries; the accessibility of such drugs is considered 
to be more difficult in Ecuador and Uruguay than in 
Paraguay and Venezuela. 
 
  Psychotropic substances 
 
349. There is limited illicit manufacture of 
psychotropic substances in South America. In 2003, 
clandestine laboratories used to manufacture MDMA 
(Ecstasy) were dismantled in Argentina and Suriname; 
illicit manufacture of MDMA (Ecstasy) has also been 
reported in Venezuela. Seizures of stimulants, mainly 
smuggled out of Europe, continue to be effected in 
countries in the region. The diversion and over-
prescription of a variety of psychotropic substances 
continue, reflecting the need for Governments to 
strengthen control over the prescription of controlled 
pharmaceuticals and to inspect records relating to the 
sales of such pharmaceuticals, as requested repeatedly 
by the Board.40 Seizures of diverted pharmaceuticals 
were reported for 2003 only by Brazil and Chile, 
indicating that law enforcement authorities in other 
countries in the region may have to pay more attention 
to that area. 
 
  Missions  
 
350. The Board sent a mission to Brazil in December 
2003 and found that the Government had made efforts 
to implement the provisions of the international drug 
control treaties. At the same time, the mission found a 
number of areas of concern about the current status of 
the government policies on countering drug abuse and 
trafficking. The Board encourages the Government to 
continue to attach high priority to drug control issues 
and, in particular, to ensure that all bodies involved in 
drug-related issues have adequate resources to enable 
them to carry out their functions.  
351. The most recent epidemiological study on drug 
abuse undertaken in Brazil shows that prescription 
medicines such as benzodiazepines or medications 
containing codeine are frequently abused in Brazil. In 
order to learn more about that problem and to be in a 
position to address it properly, the Board strongly 
encourages the Government to monitor and analyse 
prescription patterns more closely in order to establish 
the reasons behind that high rate of abuse of such 
drugs. The Board recommends that a nationwide initia-
tive be launched to educate members of the medical 
profession, as well as the public, on the rational use of 
narcotic drugs and psychotropic substances and to 
promote sound medical prescription practices.  
352. While efforts have been made to strengthen 
control of chemicals that are often used in the illicit 
manufacture of drugs, the competent authorities for 
precursor control have not established a working 
relationship and there is no coordination or exchange 
of information between those entities. The Board 
wishes to emphasize that an effective system for 
precursor control requires active cooperation and a 
good working relationship between the different 
regulatory and enforcement authorities involved. The 
Board therefore urges the Government to ensure 
cooperation between the regulatory and law 
enforcement authorities involved in the control of 
precursors and to request all those authorities to 
establish functioning channels for exchanging 
information on a regular basis.  
353. The Board notes both the efforts made by Brazil 
to fight drug trafficking and the recent increase in 
cocaine seizures in that country. Nevertheless, the 
absence of cooperation between federal and state 
police forces seriously limits the effectiveness of those 
efforts. The Board therefore encourages Brazil to 
continue to intensify cooperation and exchange of 
information between state and federal police forces, in 
order to be able to address drug trafficking in a more 
coordinated and effective manner. 
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 C.  Asia 
 
 
  East and South-East Asia 
 
 
  Major developments 
 
354. In South-East Asia illicit opium poppy production 
continued to decline. In 2004, illicit opium poppy 
cultivation was significantly reduced in the Lao 
People’s Democratic Republic and Myanmar. The 
average yield of illicit opium production was also 
reduced. Thailand is no longer a major source of illicit 
opium and heroin. Some small-scale opium poppy 
cultivation took place in the remote and mountainous 
areas in the northern part of Thailand. There was no 
opium production reported in Viet Nam. 
355. The illicit manufacture of, trafficking in and 
abuse of amphetamine-type stimulants, especially 
methamphetamine, remain a major concern in East and 
South-East Asia. Large quantities of crystallized 
methamphetamine were seized in Japan, Myanmar and 
the Philippines. Thailand also reported large seizures 
of methamphetamine, mainly in the form of tablets. 
The majority of countries in the region reported a 
significant increase in seizures of MDMA (Ecstasy) in 
2003. 
356. In several countries in East and South-East Asia, 
namely Cambodia, China, Myanmar, Thailand and Viet 
Nam, the abuse of opiates appears to have shifted away 
from opium and towards heroin. In Cambodia, China, 
the Lao People’s Democratic Republic, Myanmar, 
Thailand and Viet Nam, data on admissions to drug 
abuse treatment centres show that heroin is the primary 
reason that drug abusers are receiving treatment. 
Heroin is also the main drug used by injecting drug 
abusers, raising concern about HIV/AIDS transmission 
in many countries in the region. 
357. Injecting drug abusers who share syringes 
continue to account for the largest percentage of new 
HIV/AIDS cases in China and Viet Nam. The rate for 
sharing syringes has been reported to be as high as 
50 per cent in parts of Malaysia, Myanmar and 
Thailand. The Board notes with satisfaction that 
Governments, non-governmental organizations and 
international organizations have shown a sustained 
commitment to addressing the issue. The 
XV International AIDS Conference was held in 
Bangkok from 11 to 16 July 2004. The theme of the 
Conference was access to education, information and 
medication for all infected and affected groups. The 
Board encourages the relevant countries to continue to 
strengthen their efforts to deal with the double 
epidemic of injecting drug abuse and HIV/AIDS. 
 
  Treaty adherence 
 
358. In East and South-East Asia, Cambodia and the 
Democratic People’s Republic of Korea have not yet 
become parties to any of the international drug control 
treaties. The Board calls on those States to ratify the 
treaties without further delay. The Board also 
encourages Timor-Leste to ratify the treaties as soon as 
possible. 
359. The Board welcomes the accession of the Lao 
People’s Democratic Republic to the 1988 Convention 
in October 2004. The Board calls on that State to 
become a party to the 1972 Protocol amending the 
1961 Convention without further delay. 
 
  Regional cooperation 
 
360. The Board notes that a number of regional 
meetings on precursor control have recently been held 
in Thailand. The first Senior Officials Meeting and first 
Ministerial Meeting of Pentalateral Cooperation on 
Drug Control among China, India, the Lao People’s 
Democratic Republic, Myanmar and Thailand were 
held in Chiang Rai, Thailand, in July 2003, and the 
Second Senior Officials Meeting of Pentalateral 
Cooperation on Drug Control among China, India, the 
Lao People’s Democratic Republic, Myanmar and 
Thailand was held in Pattaya, Thailand, in April 2004. 
361. The Board welcomes the continued cooperation 
of the Association of South-East Asian Nations 
(ASEAN) and China under the ASEAN and China 
Cooperative Operations in Response to Dangerous 
Drugs (ACCORD) Plan of Action. In January 2004, a 
memorandum of understanding was signed by ASEAN 
and China to develop practical strategies for combating 
transnational crime, including drug trafficking, 
terrorism and money-laundering. Under the 
memorandum of understanding, the States agreed to 
exchange information, conduct personnel exchange and 
training, cooperate in the field of law enforcement and 
conduct joint research. They also agreed to hold an 
annual meeting to review the implementation of the 
memorandum of understanding and discuss future 
plans. At the first ASEAN Plus Three (ASEAN plus 
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China, Japan and the Republic of Korea) Ministerial 
Meeting on Transnational Crime, held in Bangkok on 
19 January 2004, views were exchanged on joint 
efforts to tackle regional political and security issues 
such as terrorism, which has been associated with other 
forms of transnational crime such as drug trafficking 
and money-laundering. 
362. The Board notes that the annual meeting of senior 
officials of the signatories of the 1993 memorandum of 
understanding on drug control between the countries in 
the Mekong area (Cambodia, China, the Lao People’s 
Democratic Republic, Myanmar, Thailand and 
Viet Nam) was held in Krabi, Thailand, from 17 to 
19 May 2004. The meeting agreed to continue 
strengthening regional cooperation and establishing 
institutional links in order to share innovative 
approaches and best practices in the areas of 
community-based alternative development and the 
elimination of illicit opium poppy cultivation. The 
meeting also endorsed stronger measures to deal with 
the abuse of amphetamine-type stimulants and HIV 
vulnerability in custodial and community settings, as 
well as judicial and prosecutorial capacity-building. 
The Board commends the signatory States of the 
memorandum of understanding for contributing 
financially to the project “Support for MOU 
partnership in East Asia”. 
363. The Board commends the various bilateral efforts 
in East and South-East Asia to combat illicit drug 
production and trafficking. 
 
  National legislation, policy and action 
 
364. In April 2004, China launched a five-month 
campaign against drug trafficking, focusing mainly on 
Yunnan Province, from where it is suspected that most 
of the drugs from the Golden Triangle are smuggled 
into the country. Over the past three years, seizures in 
Yunnan Province of heroin reportedly originating in 
Myanmar have accounted for 80 per cent of all seizures 
of heroin in China. A total of 8,000 kg of heroin was 
seized in Yunnan Province in 2003. Following the 
success of its first five-year drug elimination plan, 
covering the period 1999-2004 Myanmar has launched 
a second five-year drug elimination plan, covering the 
period 2004-2009. The Board notes the progress made 
in Myanmar thus far and encourages the Government 
to continue its efforts. 
365. The Board notes with concern that Indonesia, 
Myanmar and the Philippines remain on the list of 
countries and territories considered by FATF to be 
“non-cooperative” in efforts to counter money-
laundering or having critical deficiencies in their 
systems for countering money-laundering. However, 
the Board notes the progress made in those countries in 
addressing weaknesses in their systems and encourages 
them to continue their efforts. The Board reiterates that 
it is important for each country to implement relevant 
legislation to prevent money-laundering as an integral 
part of the fight against drug trafficking. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
366. Cannabis continued to be cultivated throughout 
East and South-East Asia. Most countries and areas in 
the region, namely the Hong Kong Special 
Administrative Region of China, Indonesia, Mongolia, 
Myanmar and the Republic of Korea, reported a large 
decrease in seizures of cannabis in 2003 compared with 
the previous year. However, a significant increase in 
such seizures was reported by a few countries, 
including Japan, the Lao People’s Democratic Republic 
and Malaysia. 
367. Cannabis continues to be abused in many 
countries in East and South-East Asia, namely Brunei 
Darussalam, Indonesia, Malaysia, Mongolia, the 
Philippines and the Republic of Korea. 
368. As in the previous year, a significant reduction in 
illicit opium poppy production was seen in the Lao 
People’s Democratic Republic and Myanmar in 2004. 
As a result of continued government efforts to 
eliminate opium poppy production in the Lao People’s 
Democratic Republic the total area under such 
cultivation in the country declined by a further 45 per 
cent, from 12,000 hectares in 2003 to 6,600 hectares in 
2004. In Myanmar, the total area under illicit opium 
poppy cultivation was reduced by 28 per cent, from 
62,200 hectares in 2003 to 44,200 hectares in 2004. 
Compared with the previous year, total production of 
raw opium in 2004 was reduced by approximately 
64 per cent in the Lao People’s Democratic Republic 
and by 54 per cent in Myanmar.  
369. Seizures of opium were reported in several 
countries in East and South-East Asia, including Japan, 
 E/INCB/2004/1
 
 57 
 
the Lao People’s Democratic Republic, Malaysia, 
Myanmar, the Republic of Korea and Viet Nam. In 
2003, seven clandestine heroin laboratories were 
dismantled in Myanmar and three were dismantled in 
the Hong Kong Special Administrative Region of 
China. 
370. Opiates are the most often abused drugs in East 
and South-East Asia. The highest prevalence of abuse 
of opiates has been reported in the Lao People’s 
Democratic Republic, Myanmar and Thailand. The 
Hong Kong Special Administrative Region of China, 
Malaysia and the Republic of Korea reported increased 
abuse of opium in 2003. In the same year, 70 per cent 
of registered drug addicts in China were registered for 
heroin abuse. Cambodia, Japan, Malaysia, Myanmar, 
Thailand and Viet Nam have reported increased abuse 
of heroin. 
371. Increased cocaine abuse has been reported in a 
few countries in East and South-East Asia; in the 
region as a whole, however, cocaine trafficking and 
abuse continue to be limited. 
 
  Psychotropic substances 
 
372. A significant amount of amphetamine-type 
stimulants appears to be illicitly manufactured in the 
border areas of Myanmar; the chemicals required to 
manufacture those synthetic drugs are being smuggled 
into Myanmar from its neighbouring countries. The 
Board encourages the Governments concerned to 
continue their close cross-border cooperation and 
strengthened control on precursors in those areas. 
373. Most of the countries in East and South-East 
Asia, including China, Japan, Malaysia, Myanmar, the 
Philippines and the Republic of Korea, reported a 
significant increase in the total amount of 
amphetamine-type stimulants seized in 2003, compared 
with 2002. In 2003, 11 clandestine laboratories used to 
manufacture amphetamine-type stimulants were 
dismantled in the Philippines and 6 were dismantled in 
Indonesia. Although a total of 490 kg of amphetamine-
type stimulants were seized in Japan in 2003, a figure 
slightly higher than in the previous year, when 446 kg 
were seized, seizures of such stimulants have generally 
been declining in that country since 1999. 
374. Asia accounts for over two thirds of the world’s 
amphetamine abusers, and East and South-East Asia 
accounts for approximately 95 per cent of the 
amphetamine abusers in Asia. In East and South-East 
Asia, only opiates are abused more than amphetamine-
type stimulants. The highest prevalence of abuse of 
such stimulants was reported in Thailand, followed by 
the Philippines and the Macao Special Administrative 
Region of China. In 2003, Viet Nam reported a large 
increase in the total amount of amphetamine-type 
stimulants seized and in the abuse of such stimulants. 
375. The Lao People’s Democratic Republic is 
emerging as an important transit country for traffickers 
of amphetamine-type stimulants illicitly manufactured 
in the border areas of Myanmar and destined for 
Thailand. Cambodia is also increasingly being used as 
a transit country by traffickers of drugs illicitly 
manufactured in East and South-East Asia. 
376. Methamphetamine continues to be illicitly 
manufactured in China, Myanmar and, to a lesser 
extent, the Philippines. 
377. Nearly 90 per cent of all methamphetamine 
seizures in the world take place in East and South-East 
Asia. In 2002, a total of 13,760 kg of meth-
amphetamine were seized in the region. China seized 
5,830 kg of crystallized methamphetamine in 2003, 
considerably more than in 2002, when 3,190 kg of that 
substance were seized. In February 2004, police in 
Japan seized a large amount of crystallized meth-
amphetamine that had been smuggled out of Taiwan 
Province of China. While methamphetamine illicitly 
manufactured in Myanmar is mostly in tablet form, one 
clandestine laboratory manufacturing crystallized 
methamphetamine was also dismantled in that country 
in 2003. 
378. Several countries in East and South-East Asia 
appear to be major sources of 3,4-methylene-
dioxyphenyl-2-propanone and safrole, two precursors 
used in the illicit manufacture of MDMA (Ecstasy). 
379. A significant increase in the total amount of 
MDMA (Ecstasy) seized was reported in the majority 
of countries and areas in East and South-East Asia in 
2003, including the Hong Kong Special Administrative 
Region of China, Indonesia, Japan and Malaysia. One 
clandestine MDMA (Ecstasy) laboratory was reported 
to have been dismantled in the Hong Kong Special 
Administrative Region of China in 2003. 
380. While the prevalence of abuse of MDMA 
(Ecstasy) has remained relatively low compared with 
that of methamphetamine, increased abuse of MDMA 
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(Ecstasy) has been reported in several countries in East 
and South-East Asia, namely Cambodia, China, 
Thailand and Viet Nam. 
381. The abuse of ketamine, especially among youth, 
which is a recent phenomenon in East and South-East 
Asia, has remained low. Its abuse has been reported in 
a few countries and areas in the region, namely 
Cambodia, the Hong Kong Special Administrative 
Region of China, Malaysia, Singapore, Thailand and 
Viet Nam. 
382. Authorities in South-East Asia have made notable 
progress in addressing the trafficking in ephedrine and 
pseudoephedrine in the region, where the illicit 
manufacture of methamphetamine is of major concern. 
More importantly, analysis of seizure data indicates 
that Governments are now working in a coordinated 
manner to seek practical solutions to the common 
problem of chemical diversion. Successes have been 
noted in South-East Asia, where, during the past few 
years, illicit methamphetamine manufacture in 
Myanmar has been fuelled by ephedrine diverted from 
domestic distribution channels in China and 
subsequently smuggled into Myanmar. In addition to 
the control mechanisms that China has in place to 
prevent diversions from domestic distribution 
channels, regional efforts have helped the 
Governments concerned to identify practical working 
mechanisms for preventing cross-border trafficking in 
precursors. The Board trusts that those Governments 
will continue with their working-level tripartite 
meetings and that further successes will be reported in 
those regions. 
383. A decrease in the total amount of precursors 
seized in 2003 was reported in most countries in East 
and South-East Asia, including China and Myanmar; 
the exception was the Philippines, which reported a 
major increase in the amount of precursors seized. The 
precursor of amphetamine-type stimulants most often 
seized in the region continued to be ephedrine, 
followed by phenylacetic acid. In 2003, 300 kg of 
ephedrine were seized in Myanmar. In China, the 
amount of ephedrine seized has been increasing over 
the past few years; that trend continued in 2003, when 
5,800 kg of ephedrine were seized in that country. In 
2004, 5,650 kg of ephedrine and 1,500 kg of 
pseudoephedrine were seized in three clandestine 
laboratories in the Philippines. In April 2004, over 
400,000 tablets of pseudoephedrine, another precursor 
of amphetamine-type stimulants, were seized in 
Australia; the tablets had been transported from 
Malaysia. In response to more effective controls over 
ephedrine and pseudoephedrine, traffickers are 
attempting to divert other chemicals for use in the 
illicit manufacture of amphetamine-type stimulants, 
with phenylacetic acid and 1-phenyl-2-propanone 
being the chemicals of choice. The Board therefore 
notes with satisfaction that Governments of countries 
in South-East Asia have introduced appropriate control 
mechanisms for those substances and, as a result, have 
identified attempts to divert phenylacetic acid from 
China to India, as well as attempts to divert 1-phenyl-
2-propanone from China, via the Hong Kong Special 
Administrative Region of China, to Viet Nam in 2004. 
 
  Missions 
 
384. A mission of the Board visited Indonesia in 
March 2004. The Board notes with appreciation the 
commitment of the Government of Indonesia to 
tackling drug abuse and trafficking and welcomes the 
special measures taken by the authorities to strengthen 
the current legal framework for the control of 
precursors. The Board trusts that taking the adequate 
legislative and administrative measures will enable the 
authorities to better comply with the provisions of the 
1988 Convention. 
385. However, the Board notes that the continued lack 
of reporting by Indonesia on issues related to the 
seizure of illicit drugs may be the result of a lack of 
coordination between the National Narcotics Board and 
the National Agency for Food and Drug Control of 
Indonesia. The Board is of the opinion that the 
Government should initiate, as soon as possible, 
consultations among relevant departments involved in 
drug control activities, in particular the National 
Narcotics Board and the National Agency for Food and 
Drug Control, with a view to introducing the necessary 
revisions in the current working mechanisms, clearly 
defining the respective functions and establishing 
and/or reinforcing the necessary links between those 
departments. The Board believes that, by doing so, the 
Government will ensure that in future, internal 
coordination will be improved, its reports to the Board 
will be as complete as possible and that all the 
necessary information will be included. 
386. While drug abuse and trafficking have increased 
in Indonesia, the Government has taken significant 
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measures to reinforce facilities for the treatment and 
rehabilitation of drug abusers; the Board appreciates, 
in particular, the considerable efforts being made by 
the Indonesian authorities to combat the alarming 
incidence of HIV/AIDS among injecting drug users. 
387. Finally, the Board notes that the Government of 
Indonesia is taking measures to comply with 
international money-laundering standards. The Board 
welcomes the establishment of the Indonesian 
Financial Transaction Reports and Analysis Centre. 
The Board encourages the Government to provide the 
Centre with the resources necessary for it to achieve 
the expected results. 
388. The Board sent a mission to Thailand in May 
2004, mainly to assess the efforts of the Government 
during the “war on drugs”, an ongoing nationwide 
campaign against drug trafficking and abuse. In 
particular, the Board had noted reports that killings had 
taken place during the “war on drugs” and it wished to 
gather comprehensive information regarding the 
campaign and the measures and action that had 
subsequently been taken. The mission received detailed 
information from the Government regarding special 
committees established to investigate those cases and 
was informed that certain cases had already been the 
subject of judicial procedures. In addition, the mission 
was informed that criminal proceedings had been 
initiated against a significant number of government 
officials accused of corruption. The Board appreciates 
those efforts and trusts that the Government will 
continue to provide information to it regarding the 
progress of those investigations. 
389. The Board was also informed that, subsequent to 
the “war on drugs”, the problem of methamphetamine 
abuse had been reduced. The Board received detailed 
information on the treatment of drug addicts in 
Thailand. The Board notes the efforts of the 
Government and urges it to undertake sustainable 
measures to address the drug abuse problem in 
Thailand. 
390. The Board also received information from the 
Government of Thailand regarding the growing 
problem of ketamine abuse in the country. The Board 
shares the concern of the Government regarding that 
development; the Board notes that increasing ketamine 
abuse can be observed elsewhere, both within and 
outside the region of East and South-East Asia. The 
Board encourages the international community to give 
serious consideration to initiating the procedure, 
outlined in the 1971 Convention, for placing ketamine 
under international control. 
391. In March 2004, the Board made a technical visit 
to Timor-Leste, which is not yet a party to any of the 
three international drug control treaties. The objective 
of the technical visit was to introduce the Board and its 
work in promoting the implementation of the 
international drug control treaties and to obtain 
information on the drug control situation in 
Timor-Leste, assessing existing mechanisms and 
structures for the prevention of drug trafficking. 
392. The Board is concerned that the geographical 
situation of Timor-Leste and the insufficient protection 
of its borders and coasts could lead to it being regarded 
by drug traffickers as an ideal transit country. The 
authorities have acknowledged that drug abuse and 
trafficking exist in Timor-Leste but on a very low 
scale. While the current situation in Timor-Leste with 
regard to drug trafficking and abuse may not be 
comparable to that of its neighbouring countries, little 
else is known about that situation; therefore, the Board 
encourages the authorities of Timor-Leste to consider 
initiating a national survey to evaluate the extent of 
drug abuse and trafficking and to consider preventive 
action. 
393. The Board notes with satisfaction that the 
authorities of Timor-Leste are initiating the drafting of 
comprehensive legislation for the control of medical 
supplies, including narcotic drugs and psychotropic 
substances, and encourages the authorities to draft such 
regulations in accordance with the provisions of the 
international drug control treaties. 
394. Finally, the Board notes the efforts of the United 
Nations Mission of Support in East Timor (UNMISET) 
in providing assistance to core administrative 
structures and assist in the development of various 
services in Timor-Leste. 
 
 
  South Asia 
 
 
  Major developments 
 
395. South Asia continues to experience increased 
drug availability and abuse because of its proximity to 
the major opiate production areas, the Golden Crescent 
and the Golden Triangle, widespread domestic 
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cultivation of cannabis and increasing diversion of 
pharmaceutical products. 
396. The flow of heroin from Afghanistan, the world’s 
largest illicit opium producer and heroin manufacturer, 
towards South Asian countries continues to increase. 
One concern of Indian law enforcement officials has 
been the recent discovery of areas under illicit opium 
poppy cultivation in the south of India, close to the 
heroin trafficking routes leading to Maldives, 
Sri Lanka and countries in West Asia. Licitly 
manufactured but diverted pharmaceutical preparations 
containing narcotic drugs and psychotropic substances 
are smuggled out of India and into Bangladesh, 
Maldives, Nepal and Sri Lanka. Maritime drug 
trafficking routes leading from India to Sri Lanka and 
from Pakistan to India have been partially replaced by 
air and land routes. 
397. The Board notes that India carried out its first 
national survey on the extent, patterns and trends of 
drug abuse. In the survey, the high rate of abuse of 
opiates and, in particular, the increasing popularity of 
injecting drug use were identified as major areas of 
concern. The survey also revealed an increase in the 
abuse of various pharmaceutical products, ranging 
from codeine-based cough syrups to anxiolytics in 
tablet form and injectable analgesics. 
398. HIV infection associated with injecting drug use 
is increasing as a result of a shift from opium abuse to 
heroin abuse, most notably in India and Nepal, and the 
increasing abuse of injectable analgesics such as 
buprenorphine and propoxyphene. Indian authorities 
have noted with concern the re-emergence of illicit 
manufacture of and trafficking in methaqualone and, 
quite recently, limited abuse of MDMA (Ecstasy). 
 
  Treaty adherence 
 
399. All six States in South Asia are parties to the 
1988 Convention. Bhutan is not yet a party to the 1961 
Convention and the 1971 Convention, and Nepal is not 
yet a party to the 1971 Convention. The Board urges 
both of those States to take speedy action to remedy 
the situation. 
 
  Regional cooperation 
 
400. The “Roadmap for Peace” outlined by the 
Government of India calls for renewed cooperation and 
dialogue between India and Pakistan on terrorism and 
other forms of cross-border crime such as trafficking in 
narcotic drugs. To that end, the authorities of India and 
Pakistan have identified focal points for sharing 
information and operational intelligence on drug 
trafficking. Senior-level customs officers from India 
and Sri Lanka have adopted operational-level strategies 
to combat drug smuggling. As part of activities 
undertaken within the framework of a bilateral 
agreement on customs cooperation between India and 
Maldives, senior-level customs officials from both of 
those countries held a meeting in Male in May 2004. 
The officials at the meeting decided to establish 
contact points for law enforcement activities to prevent 
various types of crime, including drug smuggling. The 
customs authorities of India also agreed to assist their 
counterparts in Maldives in drug law enforcement 
training. 
401. At its twenty-fourth session, held in Islamabad in 
January 2004, the Council of Ministers of the South 
Asian Association for Regional Cooperation (SAARC) 
established high-level working groups, one of which 
relates to health and population activities, including 
drug-related matters. In May 2004, a memorandum of 
understanding between SAARC and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) was 
signed to support South Asian countries in HIV/AIDS 
prevention efforts. The Board welcomes the initiative 
to enable the SAARC Drug Offences Monitoring Desk 
in the regional precursor control project for SAARC 
member States to play a more active role in the 
management of information relating to precursor 
control in South Asia. The Board notes with 
appreciation the strengthened cooperation between 
Bhutan and the Drug Advisory Programme of the 
Colombo Plan for Cooperative Economic and Social 
Development in Asia and the Pacific, especially in drug 
prevention activities. A workshop on drug abuse 
prevention, organized with the support of the 
Government of Bhutan, recommended the development 
of policies and programmes aimed at schools, health 
care, the workplace, the community, law enforcement 
and other relevant areas. 
 
  National legislation, policy and action 
 
402. In Sri Lanka, draft legislation that would allow 
limited and controlled cultivation of cannabis for use 
by the estimated 16,000 locally registered Ayurvedic 
practitioners is currently under discussion. At present, 
the practitioners use powdered cannabis processed 
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from seized cannabis and sold to them by the 
Ayurvedic Drugs Corporation. As the use of powdered 
cannabis does not conform to traditional methods, the 
proposed legislation would allow the Commissioner of 
Ayurveda of the Department of Ayurveda of Sri Lanka 
to grow cannabis in one central location, after having 
estimated the quantities required and taking into 
account the necessary protection and control measures. 
The Board trusts that, if the draft legislation is adopted, 
all provisions of the 1961 Convention (including those 
of articles 23 and 28) will be fully adhered to. 
403. The National Assembly of Bhutan is considering 
the introduction of draft legislation that would include 
a listing of drugs termed “illicit” and would determine 
sanctions for the abuse of and trafficking in those 
drugs. In addition, the Assembly has recommended the 
identification of a central focal point to coordinate 
drug control activities. 
404. From the reports submitted by India it is clear 
that control over imports and exports of internationally 
controlled substances is well implemented. However, 
controls over the licit manufacture of, trade in and 
distribution of narcotic drugs and psychotropic 
substances in India have been found to be inadequate, 
as evidenced by the Government’s incomplete 
reporting to the Board and the diversion of 
pharmaceutical products manufactured in India. The 
control of domestic distribution channels for narcotic 
drugs and psychotropic substances needs to be 
strengthened as controlled drugs are easily available in 
India. The Board calls on the Government of India to 
step up its law enforcement activities, especially at the 
retail level, and to carry out education and information 
campaigns to increase the awareness of pharmacists 
and the general public regarding the abuse liability of 
narcotic drugs and psychotropic substances. The 
Government’s plan to include information on drug 
abuse in the school curriculum, in addition to existing 
awareness-raising programmes conducted by non-
governmental organizations on the prevention of drug 
abuse, is a positive development. 
405. In Sri Lanka, a national volunteer project aimed 
at formulating a long-term action plan for the 
prevention of substance abuse and the rehabilitation of 
substance abusers has been set up under the 
government programme for the control of crime and 
drug-related offences. Under the project, officials from 
civil society and the Government will participate in 
prevention activities and awareness-raising 
programmes. The officials include representatives from 
the police, government departments, schools, health-
care institutes (including doctors and nurses), Grama 
Niladharis (government officials familiar with certain 
village areas and people), Samurdhi officials (officials 
responsible for alleviating poverty by promoting 
prosperity) and religious dignitaries.  
406. In Maldives, the first national awareness-raising 
campaign was launched in April 2004. In addition, 
teachers and members of clubs are trained in order to 
provide awareness-raising programmes for students 
and youths. 
407. The Governments of a number of countries in 
South Asia are paying more attention to the treatment 
of drug addicts. The national survey carried out in 
India has revealed that enrolment in drug abuse 
treatment facilities is low because of the poor quality 
of the treatment services and the paucity of information 
on the services available. The Government of India has 
developed minimum service standards for programmes 
for the prevention of alcoholism and substance abuse. 
The standards are to serve as guidelines for improving 
the quality of services delivered by non-governmental 
organizations. The Government has also established the 
National Centre for Drug Abuse Prevention and eight 
regional resource training centres to enhance the 
technical capabilities of service providers in the area of 
drug demand reduction. 
408. In Nepal, a project office established by the 
Government implements the sectoral plans for the 
treatment and rehabilitation of drug addicts and other 
demand reduction activities envisaged in the national 
master plan for drug abuse control. The Government of 
Maldives has established a scheme for the treatment 
and rehabilitation of drug addicts facing trial because 
of substance abuse. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
409. Cannabis continues to be produced and abused in 
large quantities in South Asia. Bangladesh and India 
are important source countries for cannabis herb. Nepal 
is a major source country for cannabis resin, which is 
smuggled into countries in Asia and the Pacific and 
Europe, as well as to the United States. The largest 
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seizures of cannabis resin from Nepal have been 
reported in India; cannabis resin in India is sold locally 
on the illicit market or smuggled into Europe. 
410. In India, certain quantities of licitly produced 
opium continue to be diverted into illicit channels 
despite intensified law enforcement activities. Most 
seizures of opium are made within the opium poppy 
cultivation and opium production areas. The diverted 
opium is abused locally or processed into heroin in 
clandestine laboratories, to be sold on illicit markets 
outside the production areas. The Board is pleased to 
note that a survey of licit opium poppy cultivation was 
undertaken jointly by the Governments of India and the 
United States; the results of the survey are to be used 
to determine the minimum-qualifying yield, a measure 
to support the efforts required from the government to 
eliminate diversion of licitly produced opium. 
411. Indian officials have continued to detect and 
destroy illicitly produced opium, as well as to 
prosecute those engaged in illicit opium production in 
northern and north-eastern states. 
412. In India, opium is processed into heroin in 
clandestine laboratories; the laboratories generally 
produce a low-quality heroin base known as “brown 
sugar” that is sold locally on the illicit market or 
smuggled into Maldives and Sri Lanka. The total 
amount of heroin seized in India has been decreasing 
since 2001, averaging less than 1 ton per year. 
413. The international airports at Mumbai, New Delhi, 
Trivandrum, Cochin and Chennai continue to be used 
by trafficking groups to ship heroin to countries in 
Eastern and Western Africa, West Asia and Europe, as 
well as to Sri Lanka. However, in recent years there 
has been a decrease in heroin trafficking along the air 
route from India to Sri Lanka; the majority of the 
heroin seizures are now made along the sea route 
leading from southern India to Sri Lanka. Heroin from 
Pakistan is smuggled into Bangladesh, India and 
Sri Lanka. 
414. There is widespread trafficking in pharma-
ceuticals containing narcotic drugs in South Asia. In 
Bangladesh, the number of seizures of codeine-based 
cough syrups from India is equal to the number of 
seizures of cannabis herb. An individual seizure often 
consists of several hundreds of litres of such cough 
syrup. The abuse of pharmaceuticals containing 
narcotic drugs, such as codeine, remains widespread in 
the region. In addition, because of its lower price and 
easy availability, the abuse of propoxyphene by 
injection in India is as prevalent as heroin abuse by 
injection. 
415. India’s large chemical industry manufactures a 
wide variety of precursors and essential chemicals, 
including acetic anhydride and potassium 
permanganate. In India, the Narcotic Drugs and 
Psychotropic Substances (NDPS) Act, 1985, and the 
Narcotic Drugs and Psychotropic Substances 
(Regulation of Controlled Substances) Order, 1993, 
provide for stringent controls over notified precursors 
and essential chemicals. Acetic anhydride as well as 
methyl ethyl ketone and potassium permanganate, are 
subject to import-export controls. India also follows a 
policy of sending pre-export notifications with regard 
to the export of all the 23 chemicals scheduled in the 
1988 Convention.  
416. There are 11 manufacturers of acetic anhydride in 
India with an annual output of 30,000 to 40,000 tons 
for various industrial and pharmaceutical uses. Acetic 
anhydride is subject to a special customs regime, 
according to which its storage and transportation 
within 100 km of the Indo-Myanmar border and 50 km 
of the Indo-Pakistan border are subject to special 
controls. Traffickers have tried alternative methods 
such as exporting acetic anhydride in misdeclared sea 
cargo consignments using Dubai as a trans-shipment 
point. Acetic anhydride has continued to be seized by 
local law enforcement authorities. The acetic anhydride 
seized had been intended for use mainly in the illicit 
manufacture of low-grade heroin in India. 
 
  Psychotropic substances 
 
417. Pharmaceutical preparations containing psycho-
tropic substances, notably benzodiazepines and 
analgesics, are diverted from licit distribution 
channels, transported through South Asia and 
smuggled into countries outside the region, such as the 
Russian Federation and Scandinavian countries. 
Pharmacies in India are identified as supply sources for 
such trafficking and for their local abuse. The abuse of 
analgesics, anxiolytics and sedative hypnotics has 
increased in the region. Because of the lower price and 
easy availability of pharmaceutical preparations and 
needles and syringes, the abuse of buprenorphine in 
injectable form has increased significantly in India. 
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418. There are indications of the abuse of and 
trafficking in MDMA (Ecstasy) in an emerging “rave” 
culture in New Delhi. 
419. India is the world’s largest illicit manufacturer of 
methaqualone (Mandrax); South Africa is the principal 
destination of the methaqualone illicitly manufactured 
in India. Illicit manufacture of and trafficking in 
methaqualone had become less significant following a 
series of successful law enforcement operations. 
Recently, however, the methaqualone problem has re-
emerged. Illicit drug manufacturing units are 
controlled  and funded by criminal groups based 
outside of India. 
420. India manufactures a wide variety of precursor 
chemicals, including ephedrine, pseudoephedrine, 
N-acetylanthranilic acid, ergotomine, methylendioxy-
phenyl-2-propanone and phenyl acetone. So far 
N-acetylanthranilic acid, ephedrine, pseudoephedrine 
and anthranilic acid have been placed under special 
controls under the NDPS Act.  
421. Laboratories illicitly manufacturing methaqua-
lone are also used for the illicit manufacture of other 
psychotropic substances, notably MDMA (Ecstasy) and 
amphetamines. Small consignments of amphetamine 
enter India through its border with Myanmar. 
422. Almost all ephedrine seized in India is destined to 
be smuggled across the Indo-Myanmar border to 
Myanmar, where significant illicit manufacture of 
amphetamine-type stimulants occurs. Arrangements 
already exist for cooperation between drug law 
enforcement agencies in India and Myanmar at various 
levels. The Board encourages these quick exchanges of 
information, coordinated enforcement action and 
coordinated joint investigations as an efficient means 
to curb illicit drug manufacture in the region. 
 
  Substances not under international control 
 
423. The abuse of ketamine, an anaesthetic, has been 
noted in India in the tourist area of Goa. Although 
ketamine should be sold only with a prescription, it has 
been bought freely in Goa at pharmacies and, 
reportedly, in beach bars. Indian authorities have 
actively tried to curb this illicit trade in Goa by raiding 
unauthorized suppliers and searching European 
tourists. The abuse of inhalants by the poorer segments 
of society and street children is widespread in the 
region. 
  West Asia 
 
 
  Major developments 
 
424. Opium production in Afghanistan and its impact 
on peace and security remain the central elements of 
the drug situation in West Asia. In Afghanistan itself, 
illicit drug production and related activities reached an 
unprecedented level in 2004 and are threatening the 
stability of the country. In other countries in the region, 
drug trafficking and abuse are rapidly increasing, 
undermining social and economic stability. In Central 
Asia, injecting drug abuse is becoming the main factor 
contributing to the spread of HIV/AIDS. 
425. Despite efforts made by the Government of 
Afghanistan, with the assistance of the international 
community, the drug control situation in Afghanistan 
continued to deteriorate in 2004. Widespread 
cultivation of opium poppy and the processing of and 
trafficking in opiates have transformed Afghanistan 
into a country in which the economy, the culture and 
the political life are dominated by the illicit drug trade, 
which is threatening reconstruction efforts and 
undermining legitimate economic activities and the 
establishment of the rule of law. The Board calls upon 
the Government of Afghanistan and the international 
community to continue to accord drug control the 
highest priority and to strengthen efforts to address the 
drug problem in a comprehensive manner, within the 
framework of overall development plans and 
programmes to establish law and order throughout the 
country and make alternative development in areas 
under drug crop cultivation more effective. The Board 
notes that the President-elect of Afghanistan has 
expressed his strong commitment to the 
implementation of drug control measures. 
426. In Central Asia, concerns continue to be raised 
over trafficking in and abuse of Afghan opiates, as well 
as the illicit movement of acetic anhydride, a chemical 
used in the manufacture of heroin. It is estimated that 
one third of Afghanistan’s opium crop in 2004 will 
pass through countries in the region, in particular 
Kazakhstan and Tajikistan. The large quantities of 
Afghan heroin being transported towards the Russian 
Federation and other countries in Europe are rapidly 
escalating the illicit drug problems in that subregion. 
427. Countries on the Arabian peninsula are more 
frequently used as transit points for heroin and 
cannabis destined for Europe, while precursors are 
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smuggled in the opposite direction. The abuse of 
opiates, especially heroin, is increasing, as is the 
already widespread abuse of synthetic drugs. 
428. The Board is concerned that the drug situation in 
Iraq may deteriorate further because of the 
disintegration of the drug control structure in the 
country, given its geographical location and the current 
political and economic instability in the country. The 
complex interlinkage of terrorism, organized crime, 
corruption and drug trafficking poses an unprecedented 
threat, raising concerns that the overall situation may 
worsen. 
 
  Treaty adherence 
 
429. All of the 24 States in West Asia are parties to the 
1961 Convention, the 1971 Convention and the 1988 
Convention. As for the 1972 Protocol amending the 
1961 Convention, Afghanistan remains the only State 
that has not yet become a party to that instrument. The 
Board encourages the authorities of Afghanistan to take 
appropriate action to accede to the 1972 Protocol. 
 
  Regional cooperation 
 
430. During the past year, numerous agreements, 
cooperative mechanisms and joint law enforcement 
operations were among the activities undertaken or 
approved by Governments of countries in West Asia to 
promote regional cooperation efforts to fight drug 
trafficking and related criminal activities. The Board 
welcomes those initiatives and encourages all countries 
in the region to participate in future cooperative 
efforts. 
431. At the Berlin Conference on Afghanistan, held on 
31 March and 1 April 2004, the Transitional Authority 
of Afghanistan and its six neighbouring countries, 
namely China, the Islamic Republic of Iran, Pakistan, 
Tajikistan, Turkmenistan and Uzbekistan, adopted the 
Berlin Declaration on Counter-Narcotics within the 
Framework of the Kabul Declaration on Good-
Neighbourly Relations, which provided, among other 
things, for increased collaboration in the fight against 
narcotics and the establishment of a security belt 
around Afghanistan. In particular, the Islamic Republic 
of Iran and Pakistan proposed to train Afghan experts 
in countering trafficking in narcotic drugs. 
432. In April 2004, senior law enforcement officers 
from Afghanistan, the Islamic Republic of Iran, 
Kuwait, Pakistan, Qatar, Saudi Arabia and the United 
Arab Emirates at the Regional Gulf Cooperation 
Meeting held in Pakistan agreed to strengthen their 
cooperation in the fight against criminal organizations 
engaged in illicit drug trafficking and cross-border 
organized crime. The countries decided to nominate 
national focal points and exchange operational staff 
with a view to improve the sharing of information and 
joint operations. 
433. In July 2004, representatives of Afghanistan 
participated for the first time in the Intergovernmental 
Technical Committee meeting, a forum for the 
exchange of drug law enforcement information in the 
region. The meeting, held in Islamabad, was also 
attended by representatives of the Islamic Republic of 
Iran and Pakistan. The Committee agreed to revise the 
existing memorandum of understanding, in order to 
admit Afghanistan as a regular member of the 
Intergovernmental Technical Committee meetings and 
to establish a committee for the analysis of intelligence 
and the exchange of information on narcotics that 
would meet every six months. 
434. On 3 and 4 August 2004, the Government of 
Pakistan hosted a seminar in Islamabad for SAARC 
member States to review progress made towards 
achieving the goals related to precursor control set in 
1988 by the General Assembly at its twentieth special 
session. The participants shared information with 
regard to legislative developments in precursor control 
and agreed to facilitate the rapid exchange of 
information on precursor transactions and monitoring 
measures (see para. 401 above). 
435. Two workshops organized under the auspices of 
the Economic Cooperation Organization (ECO) to 
discuss drug supply reduction issues were held in 
Dushanbe in August 2004 and in Ankara in February 
2004. In addition, a network of drug demand reduction 
experts was established to promote regular exchange of 
information among ECO member States. Furthermore, 
at a conference held in Kish, Islamic Republic of Iran, 
in October 2004, all ECO member States except 
Turkmenistan exchanged information on the 
consequences of drug abuse, evidenced-based 
strategies for the reduction of illicit drug demand and 
harm reduction practices. 
436. Officials from Armenia, Azerbaijan, Georgia, 
Kazakhstan, Kyrgyzstan, Tajikistan, Turkey, 
Turkmenistan and Uzbekistan held a meeting in 
 E/INCB/2004/1
 
 65 
 
Antalya, Turkey, from 23 to 25 February 2004 to 
discuss measures to promote international cooperation 
against terrorism and transnational organized crime. 
Participants stressed the need to share information and 
exchange governmental experts in order to share 
experiences in the development of legislation and the 
implementation of activities against terrorism and 
transnational organized crime. 
437. The consultative mechanism known as the Paris 
Pact,41 initiated in 2003 for countries affected by 
trafficking in opiates originating in Afghanistan, held 
several expert round-table meetings at the regional 
level in 2003 and 2004 to discuss the situation 
regarding drug trafficking through Central Asian 
countries, the Russian Federation, the Islamic Republic 
of Iran and the Balkan countries. A meeting of the 
Paris Pact policy group was held in Vienna in October 
2004 to discuss the outcome of previous regional 
meetings. The Board notes that the meeting 
recommended the establishment of a task force on 
precursors. The Board wishes to encourage the group 
to take full advantage of the task forces with similar 
objectives that are currently operating under Operation 
Topaz, Operation Purple and Project Prism. Those task 
forces, whose members include countries participating 
in the Paris Pact, are functioning well. The Board urges 
the group to make full use of existing task forces in 
order to make the best use of resources and avoid 
duplication of efforts. The Board notes the pivotal role 
of the United Nations Office on Drugs and Crime as 
catalyst of the Paris Pact initiative and encourages the 
countries involved in that consultative mechanism to 
continue their cooperation aimed at the elimination of 
the threat posed by Afghan opiates. 
438. The Board notes with satisfaction that all 
countries neighbouring Afghanistan, including 
Turkmenistan, are now participating in Operation 
Topaz, an international operation to prevent diversions 
of acetic anhydride. The Board trusts that the 
Government of Turkmenistan will take vigorous action 
against drug trafficking through Turkmen territory and 
will give high priority to participating actively in other 
international events aimed at promoting regional 
cooperation in drug and precursor control. 
439. Within the framework of the Organization of 
Central Asian Cooperation, the Shanghai Cooperation 
Organization, the Collective Security Treaty 
Organization and the Southern Caucasus Anti-Drug 
Programme (a joint project of the European Union, the 
United Nations Development Programme and the 
Government of Azerbaijan), bilateral and multilateral 
agreements were adopted by the Governments of 
Armenia, Azerbaijan, China, Georgia, Kazakhstan, 
Kyrgyzstan, the Russian Federation, Tajikistan and 
Uzbekistan, with a view to intensifying cooperation 
between national drug control agencies, promoting 
joint law enforcement operations, harmonizing national 
drug control legislation and building capacities. 
440. Central Asian States continue to receive 
international assistance to combat illicit drug 
trafficking and abuse. In 2004, international assistance 
was directed towards local and regional initiatives to 
strengthen border controls, improving the collection 
and sharing of data and addressing the health 
consequences of injecting drug use. One beneficiary of 
international assistance was the Drug Control Agency 
of Kyrgyzstan. In another development, the Board 
notes that cooperation involving the deployment in 
Tajikistan of border guards from the Russian 
Federation, which has proved to be a success, will 
cease in 2005. The Board urges the Governments of 
countries in the region to work out mutually beneficial 
arrangements that guarantee effective border control in 
countries in Central Asia.  
441. At a seminar on precursor control organized 
jointly by the Board and the United Nations Office on 
Drugs and Crime in Amman from 29 to 31 August 
2004, representatives of Egypt, Jordan, Lebanon, Saudi 
Arabia, the Syrian Arab Republic, Turkey and the 
United Arab Emirates agreed to set up a network for 
the exchange of information and to promote inter-
agency cooperation, in order to prevent the diversion 
of precursors. It was the first time that representatives 
of most of the countries on the Arabian peninsula 
discussed precursor control at the regional level. 
442. In June 2004, the Governments of Kazakhstan, 
Kyrgyzstan, Tajikistan and Uzbekistan signed a 
regional cooperation agreement aimed at preventing 
the further spread of HIV/AIDS in the region. 
Countries agreed on joint activities, including activities 
aimed at raising awareness of drug abuse and 
HIV/AIDS. 
 
  National legislation, policy and action 
 
443. The Board continues to be concerned about the 
unstable political situation in Afghanistan, which 
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hampered efforts by the Government to secure power 
throughout the country. The lack of control, especially 
at the provincial level, has been a major obstacle to 
implementing country-wide drug control regulations. 
The drug control situation in the country has further 
deteriorated, despite efforts made by the Afghan 
authorities with the support of the international 
community. The United Kingdom continues to hold the 
coordination role for counter-narcotics in Afghanistan, 
and other donor countries and international 
organizations have also become involved in providing 
support in drug control matters. The Board calls upon 
all parties involved to continue their cooperation and 
provision of technical and financial support in a well-
coordinated manner, in order to establish law and order 
throughout the country and find sustainable solutions 
for drug control in Afghanistan. In view of the 
magnitude of the problem, greater determination is 
necessary to make a significant impact on efforts 
targeting illicit crop cultivation and illicit drug 
production, trafficking and abuse. 
444. The Board notes that there have been a number of 
developments in Afghanistan to improve drug control 
capacities. Based on the national drug control strategy, 
which was approved by the Government in 2003, 
activities have been initiated in the areas of institution-
building and advocacy, judicial reform, law 
enforcement, alternative livelihoods and demand 
reduction.  
445. In continuing efforts at institution-building, the 
Counter-Narcotics Steering Group, chaired by the 
National Security Adviser and run by the Counter-
Narcotics Directorate, the national drug control 
coordinating body, was established in May 2004. To 
implement law enforcement operations, several bodies 
were created. The Central Eradication Planning Cell 
and the Central Poppy Eradication Force were 
established in 2004 within the Ministry of the Interior 
to plan and launch opium poppy eradication 
campaigns. Based on targeted and uncompensated 
eradication, the campaigns were only marginally 
effective (see para. 455 below). The establishment of 
the Counter Narcotics Police of Afghanistan and the 
Special Narcotics Force, responsible for conducting 
interdiction operations, have resulted in the destruction 
of clandestine laboratories and the seizure of opiates 
and cannabis resin. Progress has also been made in the 
development of the judicial system in Afghanistan. To 
facilitate the implementation of the drug control law 
approved in 2003, legal workshops were conducted in 
May 2004 with the support of the United Nations 
Office on Drugs and Crime and the Board. 
Consultations resulted in the classification of drugs and 
the establishment of a framework for licit drug control, 
as well as the definition of penal provisions and 
procedures. The law does not yet cover money-
laundering offences. However, the preparation of new 
legislation against money-laundering has been 
initiated. 
446. The development of alternative livelihoods in 
opium-producing areas in Afghanistan continues to 
lack long-term and sustainable solutions. The Board 
emphasizes the need to address that situation in a 
comprehensive manner, with support from the 
international community, providing alternative 
development in opium-producing areas and 
mainstreaming drug control issues into overall 
development assistance. The implementation of 
demand reduction activities has been initiated in some 
provinces and there are plans to expand those activities 
to include other provinces. Programmes have focused 
on the provision of resources and training to partner 
agencies and organizations involved in health care, 
education and social services. Activities have 
continued in the area of monitoring opium poppy 
cultivation in Afghanistan. The annual opium poppy 
survey was conducted with the support of the United 
Nations Office on Drugs and Crime and the results 
have been published, providing data on the extent and 
location of opium poppy cultivation in Afghanistan and 
monitoring the expansion of cultivation into new areas. 
The collection of additional drug-related statistics has 
also started. Though information remains fragmented, 
some data have become available on the illicit drug 
supply, including data on seizures, arrests, prices and 
the destruction of clandestine drug laboratories, as well 
as on the illicit drug demand, including data on drug 
abuse among certain population groups. 
447. Pakistan, which has built up a comprehensive law 
enforcement system in recent years, has continued its 
narcotics control activities. Legislation against money-
laundering, drafted in 2003, has been presented to the 
relevant authorities for approval. The drug control 
master plan for the period ending in 2003 is being 
extended to 2007, providing an operational framework 
for drug control activities. To counteract the resurgence 
of illicit opium poppy cultivation in Pakistan in 2003, 
intensive eradication efforts were made in 2004. The 
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Board notes the commitment by the Government to 
eradicate opium poppy cultivation and appreciates the 
activities carried out in the fight against drug 
trafficking. However, the Board continues to be 
concerned about the lack of control for prohibited 
goods entering Pakistan via the port of Karachi and 
passing through the country towards Afghanistan. 
448. Demand reduction activities in Pakistan are the 
responsibility of the Anti-Narcotics Force, the 
coordinating body for drug law enforcement. 
According to government authorities, the success of 
community-based awareness-raising campaigns and 
far-reaching drug abuse prevention programmes is 
reflected in the decreased level of heroin abuse in the 
country. In addition, 73 drug treatment centres have 
been set up throughout the country in recent years, 
many of which are run through a network in close 
cooperation with non-governmental organizations. The 
decentralization of demand reduction activities to the 
district level is, for the most part, working well. With 
regard to the collection of data on drug abuse, the 
Board encourages the Government of Pakistan to 
ensure the continuation of the monitoring mechanism 
set up pursuant to the national survey carried out in 
2000.  
449. The Islamic Republic of Iran remains a major 
transit country for drugs originating in Afghanistan and 
continues to be committed to combating the illicit drug 
transit traffic and drug trafficking in general. It also 
has increasingly recognized the dangers posed by 
domestic consumption. In addition to the intensified 
efforts made in the area of drug law enforcement, 
demand reduction activities have recently been 
initiated, including the assessment of drug abuse trends 
and the establishment of a national institute for drug 
abuse research and training. Furthermore, on the basis 
of studies undertaken in recent years, amendments on 
controlled delivery, mutual judicial cooperation and 
extradition have been proposed. The list of illicit drugs 
and other controlled substances has also been reviewed 
and updated in the draft amendment, taking into 
account the relevant provisions of the international 
instruments and the latest available scientific data. In 
addition, a bill against money-laundering has been 
prepared and is awaiting final approval. The Board 
welcomes those initiatives and stresses the need to 
continue to enhance activities in the field of demand 
reduction, with particular emphasis on strengthening 
cooperation with non-governmental organizations. It is 
hoped that comprehensive legislation against money-
laundering will be adopted and institutional structures 
will be established to counter money-laundering 
effectively. 
450. Drug control activities in Turkey focus on 
combating illicit drug transit traffic and drug 
trafficking in general. Law enforcement training 
conducted by the Turkish International Academy 
against Drugs and Organized Crime (TADOC) 
continued. TADOC, established in 2000 with the 
cooperation of the United Nations Office on Drugs and 
Crime, has conducted more than 50 training courses 
related to drug control at the national level and about 
20 at the regional level. The findings of a national drug 
abuse assessment study, carried out in 2003, were 
published in a report42 in 2004 (see para. 486 below). 
451. A number of countries in West Asia, including 
Israel, Kuwait, Qatar, Saudi Arabia and the United 
Arab Emirates, have continued their efforts to combat 
money-laundering. Recent initiatives in this area 
include the development of a system for monitoring 
and following up money transactions, the introduction 
of a regulatory structure for the system of informal 
overseas money transfers know as hawala, the 
establishment of special financial intelligence units and 
the introduction of new laws against the financing of 
terrorism. The Board encourages the Governments of 
all countries in the region that have not yet done so to 
ensure the adoption of comprehensive legislation 
against money-laundering that fully complies with 
international standards and norms and to put in place 
the necessary institutional framework and mechanisms 
for its implementation.  
452. While the system of law enforcement has been 
well developed in many countries in West Asia over the 
past decade, the Board appreciates the increased 
attention given by some Governments to drug abuse 
and demand reduction in recent years. The knowledge 
and information about the nature and extent of drug 
abuse, though still fragmented, has improved in several 
countries as a result of a number of surveys and 
assessment studies conducted in recent years. In 
addition, efforts have been made in some countries to 
introduce drug abuse prevention programmes and 
establish drug abuse treatment facilities. The Board 
strongly encourages all countries in the region to 
strengthen their efforts to develop drug abuse 
monitoring systems and to expand their demand 
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reduction activities. It is noted that the adoption of 
relevant legislation, the allocation of sufficient 
resources and the participation of local communities, 
as well as cooperation with non-governmental 
organizations, continue to be lacking in many countries 
in the region. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
453. Cannabis continues to be the most widely 
available drug in West Asia. Cannabis is illicitly 
cultivated in several countries in the region; however, 
cannabis also continues to grow wild in some 
countries, including Afghanistan, Kazakhstan and 
Pakistan. Cannabis continues to be widely abused in 
West Asia. Given the widespread growth of cannabis 
with a high THC content in Kazakhstan, the 
Government of that country has continued to develop 
new strategies to deal with the issue of preventing the 
illegal harvesting of cannabis, including the massive 
industrial use of wild-growing hemp from the Chu 
valley.  
454. The Board notes with great concern that in 
Afghanistan the illicit cultivation of opium poppy 
continues unabated. In 2003, Afghanistan experienced 
its second largest opium harvest since 1999, estimated 
at 3,600 tons of opium, accounting for more than three 
quarters of the world’s illicit opium production. 
Despite efforts made to counter the trend, opium 
production in 2004 reached 4,200 tons. The total area 
under opium poppy cultivation increased from 
80,000 hectares in 2003 to over 130,000 hectares in 
2004. Illicit opium poppy cultivation has spread to 
inaccessible areas. Opium prices in Afghanistan 
decreased considerably during 2003 and 2004, which is 
seen as a positive development in terms of providing 
less incentive for farmers to grow opium poppy. 
However, prices for opium are still above US$ 100 per 
kilogram, compared with an average range of about 
US$ 50-70 per kilogram during the late 1990s. In 
addition, prices for opiates in neighbouring countries 
remained stable, thus increasing the profit margin for 
traffickers. 
455. Opium poppy eradication in Afghanistan, which 
was planned by the Central Eradication Planning Cell 
within the Ministry of the Interior, was initially 
implemented through provincial governors but with 
limited success. When the Central Poppy Eradication 
Force joined those activities, much of the opium poppy 
had already been harvested. Thus, the eradication 
remained limited; it took place in only one province. 
The Board urges the Government of Afghanistan to 
enforce the ban on opium poppy cultivation and ensure 
the effectiveness of eradication efforts, in coordination 
with alternative development activities. 
456. The Board is concerned about the fact that illicit 
cultivation of opium poppy continued in Pakistan 
throughout 2004. Illicit opium poppy cultivation had 
been reduced to almost nil during the late 1990s, when 
it had been eradicated from the last traditional poppy-
growing areas of the Dir district and other districts in 
the North-West Frontier Province. However, opium 
poppy cultivation re-emerged in Pakistan in 2003 and 
continued in 2004. The total area under illicit opium 
poppy cultivation has been estimated at approximately 
6,700 hectares. Most of the illicit opium poppy 
cultivation occurred in non-traditional growing areas, 
such as the Khyber Agency within the North-West 
Frontier Province and in Baluchistan Province. Both 
provinces are on Pakistan’s border with Afghanistan. 
About 78 per cent of the illicit opium poppy cultivation 
in Pakistan was eradicated in 2004.  
457. Though small-scale cultivation of opium poppy is 
also taking place in Central Asia, annual eradication 
campaigns have virtually eliminated the risk of such 
cultivation proliferating in the subregion. The Board 
encourages the Governments of Central Asian 
countries to continue their efforts aimed at identifying 
and eradicating illicitly cultivated drugs. 
458. The processing of opium into heroin has 
continued on a large scale in many countries in West 
Asia, including, to an increasingly large extent, in 
Afghanistan, the main producer country. Large 
quantities of the precursor acetic anhydride are 
smuggled into Afghanistan from East and South Asia, 
as well as from Europe. A number of countries in West 
Asia have recorded seizures of acetic anhydride in 
recent years. Pakistan, however, reported that no 
significant seizures of acetic anhydride have been 
made since 1999 and no laboratories for heroin 
manufacture have been found in that country since the 
late 1990s. Nevertheless, it is assumed that precursor 
chemicals are smuggled into Pakistan via the seaport of 
Karachi, to be transported into Afghanistan. Although 
countries in Central Asia have not reported any 
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detection of illicit manufacturing activities in their 
territories, precursors reportedly continue to be 
smuggled through that subregion in large quantities. 
Furthermore, Turkey has regularly reported the 
detection of clandestine heroin laboratories in recent 
years. Law enforcement authorities in West Asian 
countries need to address the flow of precursors, in 
particular acetic anhydride, which is used for 
processing opium into heroin. The Board is concerned 
about the extent of precursor smuggling in West Asia 
and stresses the importance of international 
cooperation initiatives such as Operation Topaz. 
459. Trafficking in opiates from Afghanistan, as well 
as cannabis resin originating in various countries in 
West Asia, to (or through) other countries in the region 
and to Europe, continues on a large scale. Synthetic 
drugs and precursors are frequently smuggled in the 
opposite direction. The main transit countries continue 
to be the Islamic Republic of Iran and Pakistan. The 
use of the southern border area between Afghanistan, 
the Islamic Republic of Iran and Pakistan (in particular, 
Baluchistan Province), which has always been used as 
a major transit area for illicit drug consignments, has 
intensified further. Another route, which has been 
increasingly used in recent years, is through countries 
in Central Asia. Tajikistan, for example, ranks third in 
global heroin seizures. In addition, countries in the 
area of the Persian Gulf, namely Kuwait and the 
United Arab Emirates, are being used more frequently 
as transit countries for drug trafficking. Furthermore, 
Turkey continues to be used as a transit country 
because it is situated between Western Europe and 
South-West Asia. 
460. Drug seizures continue to reflect trafficking 
routes and patterns. In Pakistan, opium seizures have 
been decreasing in recent years, while seizures of 
morphine and heroin have been increasing 
considerably. That is related to the increasing 
manufacturing capacities in Afghanistan, which allows 
traffickers to smuggle morphine or heroin instead of 
larger quantities of opium, thus limiting the risks. The 
Islamic Republic of Iran continues to record enormous 
seizures of opiates, though its seizure figures in recent 
years have been lower than during the late 1990s, 
particularly the figures for opium and morphine 
seizures. Those trends may also be related partly to 
increased manufacturing activities in Afghanistan and 
partly to the shift in trafficking routes through Central 
Asia. However, since 2003, seizures in the Islamic 
Republic of Iran have been rising again. Afghanistan 
has submitted seizure data since 2003, but the 
quantities of drugs seized in that country continue to be 
much lower than those reported by its neighbouring 
countries. Some countries on the Arabian peninsula 
that are increasingly being used as drug trafficking 
hubs have reported an increase in seizures of cannabis 
resin, heroin and amphetamine-type stimulants.  
461. Seizures of opium, heroin and cannabis resin in 
Central Asia reflect a deteriorating situation with 
respect to illicit drug trafficking. Partly due to 
improved interdiction capacities, seizures of opium in 
Tajikistan increased in 2003 by 45 per cent, grew 
14-fold in Kazakhstan and doubled in Uzbekistan. 
Seizures of cannabis resin also grew significantly. 
Similar increases were observed with respect to heroin 
seizures, which increased by 44 per cent in Tajikistan, 
29 per cent in Uzbekistan and more than four times in 
Kazakhstan. That trend continued in 2004. The Board 
urges the Governments concerned to reinforce their 
border control and interdiction capacity, especially 
along the borders with Afghanistan and the Russian 
Federation.  
462. Drug abuse has become a serious concern in 
many countries in West Asia. For example, the Islamic 
Republic of Iran reported an increase in heroin 
consumption, including injecting drug use; opium 
remains the most widely used drug in that country. 
Pakistan continues to have one of the highest 
prevalence rates for heroin abuse in the world, though 
the trend has reportedly been decreasing recently. 
Cannabis continues to be widely abused in Pakistan. 
Both countries also reported an increase in HIV/AIDS 
among drug users. Drug abuse has also risen in 
Afghanistan in recent years, where an increase has also 
been noted in injecting drug use among heroin abusers.  
463. The recently published national assessment on 
drug abuse, conducted in 2003 and based on studies 
conducted in six major cities, confirmed that the 
prevalence of drug abuse in Turkey is lower than in 
other countries in West Asia, though an increasing 
trend was noted. Cannabis and inhalants are the most 
commonly abused substances. In addition, heroin and 
MDMA are increasingly being abused. The results 
further suggest a relatively young population of drug 
users. A sizeable percentage of drug abusers also 
reported having recently injected drugs. Heroin was the 
main substance associated with injecting drug use. 
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Furthermore, countries in the eastern Mediterranean 
area and on the Arabian peninsula have experienced an 
increase in the abuse of opiates, especially heroin, in 
addition to widespread abuse of synthetic drugs.  
464. As a consequence of large quantities of illicit 
drugs being trafficked throughout Central Asia, there 
has been a rising incidence of drug abuse in recent 
years. The abuse of heroin, opium and cannabis is a 
serious problem in the subregion, and it is growing in 
importance. The number of registered drug users in 
Kazakhstan stood at almost 50,000 people at the start 
of 2004, which represents an increase of 6 per cent 
over the previous year. A similar rate of increase was 
reported in Uzbekistan, with about 22,000 individuals, 
mostly heroin addicts, registered in treatment and 
prevention institutions in 2004. In Kyrgyzstan, the 
number of officially registered drug users (of which 
65 per cent were heroin and opium addicts) totalled 
5,600 in 2003, an increase of 10 per cent compared 
with 2002.  
465. In Central Asia, the number of HIV/AIDS-
infected people continues to increase, fuelled by 
injecting drug use. The latest estimates of the United 
Nations Office on Drugs and Crime suggest a total of 
46,000 injecting drug users in this subregion, of whom 
over 9,000 are HIV-infected. While approximately 
10 per cent of HIV/AIDS infections worldwide are 
caused by injecting drug use, this mode of transmission 
accounts for 60-90 per cent of new HIV/AIDS cases in 
Central Asia. In 2004, HIV/AIDS prevalence was 
highest in Kazakhstan (4,000 persons, or 2.5 per cent 
of all injecting drug abusers, were reported to be 
HIV-positive), followed by Kyrgyzstan (1.9 per cent). 
During the past two years, the number of HIV cases 
has doubled in Uzbekistan, bringing the total number 
of persons infected with HIV to 3,600 in 2004. The 
Board notes with concern the increasing proportion of 
HIV/AIDS infection among young people, and the 
reported spread of HIV in the prison systems. 
Reportedly, two thirds of prison inmates abuse drugs in 
Kazakhstan. The Board urges the Governments to take 
measures, with the support of all concerned, to prevent 
the further spread of HIV among all segments of the 
population. 
 
  Psychotropic substances 
 
466. The Board notes with concern the increasing 
abuse of psychotropic substances, mainly 
benzodiazepines and barbiturates, in tablet form, 
particularly among women, in West Asia. Such 
substances are often freely available and obtained 
without a doctor’s prescription. The Board is 
particularly concerned about the extent of that problem 
in Afghanistan, Pakistan, Turkey and other countries in 
the region. The Board urges the Governments of 
countries in the region to strengthen regulations on 
drug control, including at the retail level, while 
ensuring that sufficient controlled medicines are 
available for medical purposes. 
467. Of increasing concern in many countries in West 
Asia is also the abuse of inhalants, which has been 
noted in the assessments carried out in Pakistan and 
Turkey and which is mainly associated with young 
people and adolescents, especially street children. 
468. The abuse of amphetamine-type stimulants 
continues to be limited in West Asia. However, in the 
last two years, the availability and increasing use of 
MDMA (Ecstasy) or party or designer drugs have been 
noted in several countries in the region, including the 
Islamic Republic of Iran, Pakistan and Turkey. 
Trafficking in and abuse of other illicitly manufactured 
stimulants (often reported as Captagon) also continues 
and is of particular concern in countries on the Arabian 
peninsula. 
 
  Missions 
 
469. The Board sent a mission to Pakistan in July 2004 
and notes the significant efforts made by the 
Government of Pakistan in combating illicit drug 
production, trafficking and abuse. For more than two 
decades, the country had been heavily affected by drug 
trafficking and had had a high prevalence of drug 
abuse. As a result, the law enforcement and demand 
reduction systems have been built up and considerable 
expertise has been accumulated in the suppression of 
illicit drug production, trafficking and abuse. The 
Board welcomes recent initiatives launched to develop 
legislation against money-laundering and encourages 
the Government of Pakistan to investigate incidents 
involving corruption. 
470. The Ministry of Narcotics Control of Pakistan 
was established in 2003 to coordinate drug control 
activities. The Board hopes that the importance given 
to drug control within the institutional framework in 
Pakistan will contribute to the effective coordination of 
efforts by all authorities involved in the control of licit 
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and the countering of illicit drug-related activity, 
including at the federal and provincial levels. 
471. The Board notes with concern the resurgence of 
illicit opium poppy cultivation in Pakistan in 2003, 
which continued in 2004. The Board recognizes the 
commitment by the Government of Pakistan to 
eradicate illicit crop cultivation areas. Trafficking in 
opiates originating in Afghanistan, as well as cannabis, 
which is also produced throughout Pakistan, continues 
unabated in Pakistan. The Board encourages the 
Government of Pakistan to continue to expand its 
demand reduction activities related to drug abuse 
prevention and treatment and to periodically 
investigate the extent and patterns of drug abuse. The 
abuse of heroin has reportedly been declining recently, 
but the abuse of some psychotropic substances is 
rapidly increasing. 
472. In Pakistan, control over the licit distribution of 
pharmaceutical products has been found to be 
inadequate; that is reflected in the fact that controlled 
drugs are easily obtained without prescription through 
pharmacies. The Board is also concerned about 
incomplete reporting by Pakistan to the Board. The 
Board urges the Government to take the necessary 
steps to monitor the domestic manufacture and 
distribution of narcotic drugs and psychotropic 
substances, while ensuring sufficient availability of 
and accessibility to controlled drugs for medical 
purposes. Finally, the Board encourages the 
Government of Pakistan to decide as soon as possible 
about the future of the Opium Alkaloid Factory and, if 
it is continued, to integrate it into the existing licit drug 
control mechanism with a view to providing better 
laboratory and treatment services, as well as improve 
the reporting to the Board. 
473. A mission of the Board visited Turkmenistan in 
December 2003. Particularly in view of its proximity to 
Afghanistan, it is important that Turkmenistan 
complies with all its obligations under the international 
drug control treaties, takes more vigorous efforts 
against illicit drug trafficking through its territory and 
gives high priority to cooperating actively with the 
international community in the fight against illicit drug 
trafficking. 
474. The Government of Turkmenistan has provided 
only limited information on drug abuse, illicit drug  
 
trafficking and seizures in that country. The Board 
requests the Government to ensure the systematic 
collection, analysis and use of information on drug 
abuse and the illicit drug traffic. The Government 
should share such information with the relevant 
international organizations and the Board, in 
conformity with the requirements of the international 
drug control treaties. The Board recommends that the 
Government carry out regular epidemiological studies 
on drug abuse.  
475. In Turkmenistan, the legislative basis for the 
implementation of several provisions of the 
international drug control treaties has not yet been 
established. The Board urgently requests the 
Government to enact and implement such legislation, 
including the provisions concerning money-laundering 
and the control of precursors.  
476. The Board encourages law enforcement 
authorities in Turkmenistan to intensify their efforts to 
curtail the illicit drug traffic and requests the 
Government to strengthen the capacity of those 
authorities to prevent the smuggling of illicit drugs into 
Turkmenistan as well as the use of the country as a 
transit area for consignments of illicit drugs and 
precursors. The Board encourages the Government to 
closely cooperate with the Governments of its 
neighbouring countries and to actively participate in 
regional drug control cooperation efforts. The 
Government should establish an effective system to 
monitor the manufacture and distribution of and 
international trade in precursors and should regularly 
furnish the required reports to the Board.  
477. While data from official sources are not 
available, there are some reports that the number of 
drug addicts in Turkmenistan is increasing. The Board 
invites the Government to ensure that adequate 
treatment facilities are provided for drug addicts, in 
line with good medical standards. The Board 
recommends that the Government promote the rational 
use of narcotic drugs and psychotropic substances for 
medical treatment. The authorities should monitor the 
consumption levels of narcotic drugs and psychotropic 
substances and ensure that they are available in 
sufficient quantities to those who need them, while 
enforcing the strict observance of the prescription 
requirement. 
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 D. Europe 
 
 
  Major developments 
 
478. Cannabis continues to be trafficked throughout 
Europe. Cannabis herb is increasingly being cultivated 
locally, particularly in member States of the European 
Union. It is estimated that more than 200 tons of 
cocaine are smuggled into Europe every year, entering 
the region mainly via Belgium, the Netherlands, Spain 
and the United Kingdom. After three successive years 
of bumper harvests of opium poppy in Afghanistan, 
heroin trafficking has regained some momentum in 
Europe. There continues to be a significant illicit 
manufacture and abuse of amphetamine-type 
stimulants, in particular MDMA (Ecstasy) and 
amphetamines, in the region.  
479. The abuse of cannabis has shown an upward 
trend in almost all countries in Europe over the past 
10 years. According to the United Nations Office on 
Drugs and Crime, Europe currently accounts for an 
estimated 20 per cent of all cannabis abuse in the 
world. The number of people in Europe seeking 
treatment for cannabis abuse has also increased. 
According to the European Monitoring Centre on 
Drugs and Drug Addiction, 12 per cent of all drug 
abusers in treatment and 25 per cent of new drug 
abusers in treatment in member States of the European 
Union list cannabis as the primary drug of abuse. 
Cannabis has the highest prevalence figure in most 
countries in the region. However, the public debate 
over cannabis use is dominated more by its alleged 
potential benefits than by its risks. The above-
mentioned upward trend in cannabis use seems to be 
related to the efforts by some to promote the notion 
that cannabis use is not harmful. 
480. Whereas the abuse of heroin is stable or declining 
in most countries in Western Europe, the abuse of 
heroin in countries in Eastern Europe and in member 
States of the Commonwealth of Independent States 
(CIS) continues to increase. The abuse of heroin has 
overtaken the abuse of “kompot” (concentrate of poppy 
straw) in the Russian Federation, which is becoming 
the largest heroin market in Europe.  
481. Although methamphetamine accounts for the bulk 
of the amphetamine-type stimulants manufactured in 
the world, in Europe the clandestine manufacture of 
methamphetamine and its abuse appear to be limited to 
a few countries only. While the levels of abuse in 
Western Europe appears to have stabilized, Eastern 
Europe is becoming increasingly important in terms of 
the manufacture, as well as the abuse potential, of 
amphetamines and MDMA (Ecstasy), which are 
rapidly becoming popular drugs of choice. In the 
Czech Republic and Poland, as well as the Baltic States 
(Estonia, Latvia and Lithuania), the incidence of the 
clandestine manufacture of amphetamines and MDMA 
(Ecstasy) has increased, as the number of detected 
illicit manufacturing factories and laboratories and the 
quantity of drugs seized continue to grow; such drugs 
are increasingly being manufactured on a large scale. 
Increased domestic demand has resulted in a shift 
towards illicit manufacture of synthetic drugs, while 
local illicit manufacture has fuelled the spread of their 
abuse in the region. 
482. The use of contaminated injection equipment 
among drug users continues to fuel the spread of 
HIV/AIDS; the Baltic States and the CIS member 
States have the highest growth rate of HIV cases 
among injecting drug abusers. About 80-90 per cent of 
new HIV cases in those countries are the result of 
injecting drug abuse, and the prevalence of injecting 
drug abuse among the adult population (persons 
15-64 years old) is estimated to be as high as 
2.5 per cent in Estonia, 2 per cent in the Russian 
Federation and 1.2 per cent in Ukraine. Furthermore, 
the observed spread of injecting drug abuse among sex 
workers and in prisons has exacerbated the situation, 
keeping the growth rate of registered HIV cases high or 
climbing. In 2003, 4 per cent of the prison population 
in the Russian Federation (or 37,240 persons) were 
infected with HIV: 95 per cent of the persons infected 
were injecting drug abusers. The proportion of the 
prison population infected with HIV was 3 per cent in 
the Republic of Moldova, 2 per cent in Belarus and 
1 per cent in Ukraine.  
483. The number of member States of the European 
Union increased from 15 to 25 on 1 May 2004; that 
development has resulted in the removal of border 
controls at many more borders of European Union 
member States. Several member States of the European 
Union are therefore in the process of reorganizing their 
customs services and significantly reducing their staff. 
The Board emphasizes that such adjustments should 
not have any adverse impact on the control of illicit 
drugs and precursors and the capacity to act against 
drug trafficking. Similarly, in many of the States that 
acceded to the European Union in 2004, controls over 
 E/INCB/2004/1
 
 73 
 
chemicals used in the illicit manufacture of drugs have 
been stricter than those required by European 
Commission regulations. The Board is concerned that 
the enlargement of the European Union membership 
may lead to a weakening of existing import or export 
controls throughout Europe. The Board calls on 
Governments of European countries to continue to 
enforce provisions relating to international trade in 
controlled substances. 
484. Countries along the Balkan route continue to be 
vulnerable to illicit crop cultivation, the illicit 
production or manufacture of and transit trafficking in 
cannabis, heroin and synthetic drugs and the spread of 
organized crime, as a result of the continued unstable 
security situation, poor coordination of law 
enforcement efforts, lack of resources and widespread 
corruption in the public sector. The northern and 
southern branches of the Balkan route continue to 
supply up to 80 per cent of the heroin distributed in 
Europe.  
485. The availability of treatment for drug addicts has 
increased steadily over the past few years, particularly 
in the member States of the European Union. Drug 
abuse treatment has also become more diverse: 
whereas, in the past, such treatment was largely for 
opiate dependence, more individuals are now seeking 
treatment for the abuse of other substances, such as 
cannabis and cocaine. In countries with economies in 
transition, however, drug abuse treatment services 
continue to face the consequences of restructuring and 
may, as a result, have to reduce their services or 
compete with private treatment providers, to the 
detriment of the increasing number of drug abusers 
seeking treatment. The Board urges Governments to 
allocate adequate resources and expand treatment 
services for drug addicts.  
486. The Board welcomes the publication of initial 
results from one of the largest international studies 
ever to be carried out on drug abuse. The quadrennial 
European School Survey Project on Alcohol and Other 
Drugs (ESPAD), which has been carried out under the 
auspices of the Pompidou Group of the Council of 
Europe since 1995 in some 30 European countries, is a 
cross-sectional survey undertaken in the school 
environment, covering more than 90,000 middle-school 
and secondary- school students aged 15-16. The results 
provide valuable information to policy makers about 
the development attitudes and opinions regarding drugs 
over time. 
 
  Treaty adherence 
 
487. Of the 44 States in Europe, 43 are parties to the 
1961 Convention and the 1971 Convention and 
41 States and the European Community are parties to 
the 1988 Convention. 
488. Andorra remains the only State in Europe that is 
not a party to the 1961 Convention or the 1971 
Convention. The Board invites Andorra to accede to 
both conventions as soon as possible.  
489. The Board strongly encourages the Holy See, 
Liechtenstein and Switzerland to become parties to the 
1988 Convention and reiterates that the 1988 
Convention is the basis for effectively addressing illicit 
trafficking in narcotic drugs and psychotropic 
substances and other related issues such as money-
laundering. 
 
  Regional cooperation 
 
490. In March 2004, the European Parliament 
approved the proposal for a Council of the European 
Union framework decision laying down minimum 
provisions on the constituent elements of criminal acts 
and penalties in the field of illicit drug trafficking. In 
accordance with that decision, member States of the 
European Union must take the necessary measures to 
ensure that serious trafficking offences are punishable 
by effective, proportionate and dissuasive criminal 
penalties, ranging from 1 to 10 years of imprisonment. 
The decision further requires member States to take the 
necessary measures to make incitement to commit, 
aiding and abetting or attempting illicit drug trafficking 
a criminal offence. The Board notes that possession 
and related offences of small quantities of drugs for 
“personal use” are excluded from the scope of the 
decision. 
491. In July 2004, the Council of the European Union 
adopted a resolution on cannabis. The resolution calls 
for a variety of measures to be undertaken by member 
States of the European Union to address the problems 
of abuse of and trafficking in that substance. The 
resolution also calls for further research on cannabis 
and invites member States of the European Union to 
encourage new and ongoing research activities  
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involving cannabis, especially regarding its 
dependency and health risks. Furthermore, in its 
resolution, the Council encourages member States of 
the European Union, in accordance with their national 
legislation, to consider taking measures against 
Internet sites providing information on cannabis 
cultivation and promoting the abuse of cannabis.  
492. Under the European Commission framework 
programme for police and judicial cooperation in 
criminal matters the European Conference on Money 
Laundering was held in Santander, Spain, from 26 to 
29 April 2004. Organized by the Government of Spain, 
the event brought together customs and police service 
representatives from all member States of the European 
Union, as well as the European Commission, the 
United Nations Office on Drugs and Crime, FATF, 
Interpol, the European Police Office (Europol) and the 
European Monitoring Centre for Drugs and Drug 
Addiction. Participants explored how illicit drug 
demand and market data could contribute to a better 
understanding of the magnitude of the phenomenon of 
money-laundering. They also exchanged views on 
international intelligence-sharing, implementing legal 
frameworks and dealing with methods used by those 
engaged in money-laundering.  
493. Regional cooperation remains strong with the 
eastward expansion of the European Union; countries 
in Southern Europe and CIS member States are 
becoming increasingly open to regional partnerships, 
especially in the areas of information exchange, law 
enforcement and supply and demand reduction. In 
2004, the Russian Federation joined Operation Purple, 
which provides for international control over 
shipments of potassium permanganate, and Serbia and 
Montenegro joined Operation Topaz, which facilitates 
cross-border tracking of consignments of acetic 
anhydride. Ukraine participates in Project Prism and 
Operation Purple and takes part in Operation Topaz as 
an observer; furthermore, Ukraine continues to 
participate actively in the activities of the Southeast 
European Cooperative Initiative and other regional 
operations, such as the second phase of Operation 
Containment, Operation Redoubt and Operation 
Channel. The Board notes the openness to international 
cooperation of the Government of Ukraine and, given 
the importance of establishing adequate controls over 
acetic anhydride, urges Ukraine to become a full 
participant in Operation Topaz. 
494. The drug control authorities of the new member 
States of the European Union have continued their 
cooperation within the framework of the Phare 
programme (which will be phased out by 2006 for 
eight of the new European Union member States), 
workshops of the Council of Europe, and projects of 
the European Union, FATF and Interpol. Joint efforts 
have been undertaken in such areas as implementing 
measures against the illicit drug supply and money-
laundering, emphasizing drug abuse prevention and 
treatment components of national strategies and 
integrating drug control activities of the national 
competent authorities of the new member States of the 
European Union into the framework of the European 
Monitoring Centre for Drugs and Drug Addiction.  
495. The Russian Federation continues to make efforts 
to contain the threat of opiate trafficking following 
another massive harvest of opium in Afghanistan. The 
competent authorities of the Russian Federation, 
jointly with the other CIS member States in the 
Collective Security Treaty Organization and the 
Shanghai Cooperation Organization, undertook 
measures to disrupt international drug trafficking, 
including by using the technique of controlled 
delivery; those efforts resulted in significant drug 
seizures. Operation Channel, conducted in September 
2004 by the competent authorities of Armenia, Belarus, 
Kazakhstan, Kyrgyzstan, the Russian Federation and 
Tajikistan within the framework of the Collective 
Security Treaty Organization, effectively improved 
interdiction capabilities and communication and 
coordination arrangements among participating law 
enforcement agencies. Particular attention was paid to 
the links between drug production and trafficking, 
involvement of banks in money-laundering schemes, 
financing of terrorist activities and the need to step up 
drug control operations.  
496. The Republic of Moldova and Ukraine, within the 
framework of activities of the GUUAM States 
(Azerbaijan, Georgia, the Republic of Moldova, 
Ukraine and Uzbekistan), have continued to strengthen 
their cooperation in pursuing the common objectives of 
strengthening regional security and combating 
international drug trafficking, money-laundering and 
international terrorism. The activities of the GUUAM 
States are aimed at enhancing the ability of CIS 
member States in Eastern Europe, the Caucasus and 
Central Asia to respond effectively to new challenges 
and threats. The Board notes that the GUUAM States 
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are establishing a virtual law enforcement centre and 
an inter-State information analysis system that will 
foster the exchange of data and the coordination of 
border and customs control measures for tackling illicit 
drug trafficking. 
 
  National legislation, policy and action 
 
497. In May 2004, the Government of the Russian 
Federation adopted a decree amending the criminal 
code and administrative regulations, which, inter alia, 
establish average single doses of narcotic drugs and 
psychoactive substances for the purpose of defining 
penalties for possession for personal use of and 
trafficking in illicit drugs. The decree stipulates that 
possession of illicit substances and related offences 
involving amounts of less than 10 average single doses 
will no longer be considered a criminal violation; 
instead it will be treated as an administrative 
infraction. The amendments will contribute to placing 
the emphasis of law enforcement efforts on pursuing 
drug traffickers rather than on drug abusers, while 
promoting the use of medical and social intervention 
programmes to mitigate the negative consequences of 
drug abuse. The Board notes that the amendments will 
allow heavier penalties to be imposed for trafficking in 
narcotic drugs and psychotropic substances, which is 
appropriate in view of the fact that there has been a 
significant increase in illicit drug trafficking in the 
Russian Federation.  
498. In an effort to further align national legislation 
with the provisions of the international drug control 
treaties, the Government of the Russian Federation 
adopted in September 2004 a decree addressing the 
problem of domestic production of plant-based 
narcotics. The new decree makes it illegal to cultivate 
any plants containing narcotics, including cannabis, 
coca bush, all varieties of opium poppy, khat, 
psilocybin (hallucinogenic mushroom) and mescaline 
(peyote).  
499. In France, a new government plan against illicit 
drugs, tobacco and alcohol for the period 2004-2008 
was launched in July 2004 to ensure more 
homogeneous application of the law of 31 December 
1970 on measures against drug abuse and drug 
trafficking, which makes possession of illicit drugs for 
any purposes a criminal offence. The Board notes that 
the Government of France decided against a change in 
the law itself, as that might have given the wrong 
signal to the population regarding the danger of drugs, 
leading to a further increase in drug abuse. The new 
policy foresees the introduction of sanctions that are to 
have a deterrent effect, thereby reducing recidivism.  
500. In Switzerland, the Parliament rejected a draft 
drug bill in June 2004 that, inter alia, would have led to 
the decriminalization of cannabis possession and 
related offences. 
501. Several countries in Europe have taken measures 
aimed at reducing the demand for cannabis. In 
Switzerland, an action plan for the period 2004-2007 
was launched to reduce cannabis abuse, particularly 
among young people, and to direct heavy cannabis 
abusers to counselling and treatment centres; each year, 
1 million Swiss francs will be allocated to the action 
plan, which will make use of primary prevention 
measures, information campaigns and counselling 
services for adolescents and young adults, as well as 
their parents. In September 2004, “Realize it”, a 
project to reduce cannabis abuse and cannabis 
dependence, was launched jointly by the Governments 
of Germany and Switzerland. The project involves 
using a 10-week counselling session to motivate young 
people who are regular or heavy cannabis abusers to 
reduce the amount of cannabis that they abuse or to 
stop abusing the drug altogether. In Germany, three 
drug counselling centres in cities close to the Swiss 
border are participating in the project. The Board 
welcomes the above-mentioned initiatives in the area 
of cannabis abuse prevention. The Board encourages 
the Government of the Netherlands to conclude its 
action plan against cannabis abuse, which is currently 
being developed. 
502. In Ireland, the second phase of the National Drug 
Awareness Campaign was launched in January 2004. 
The campaign is an important component of the 
National Drugs Strategy of Ireland, which involves 
making a concerted effort in the areas of supply 
reduction, prevention, treatment and research in order 
to achieve the overall aim of reducing significantly the 
harm caused to individuals and society. One of the 
keys to achieving the overall aim of the campaign is to 
promote throughout society greater awareness, 
understanding and clarity about the dangers of drug 
abuse.  
503. For the past two years, countries in Central and 
Eastern Europe have been actively strengthening their 
legislative base and action plans for addressing illicit 
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drug abuse and trafficking. The Government of the 
Czech Republic has presented its new national drug 
control strategy for the period 2005-2009, aimed at 
shifting the focus of competent authorities and 
institution in the field of drug control from supply 
reduction to the prevention and treatment of drug 
abuse, in particular among adolescents. The 
Governments of Latvia and Lithuania have continued 
to implement their new drug control strategies for the 
period 2004-2008, which have a common objective: 
promoting drug abuse prevention initiatives involving 
local authorities and civil society. In February 2004, 
the Parliament of Slovenia approved a new national 
drug control programme for the period 2004-2009, 
which envisages further strengthening of programmes 
for the reduction of illicit drug demand and supply, the 
development of drug control information systems, the 
coordination of prevention, evaluation and research 
programmes at the interministerial level and the 
promotion of international cooperation. 
504. The restructuring of the competent drug control 
authorities of the Russian Federation continues. In July 
2004, the State Committee of the Russian Federation 
on Narcotics and Psychotropics Control 
(Gosnarkokontrol), established in March 2003, was 
transformed into the Federal Drug Control Service and 
given a broad mandate to fight illicit drug trafficking, 
control the licit movement of narcotic drugs and 
psychotropic substances and promote inter-agency 
cooperation in the area of drug abuse prevention. The 
Board notes, however, that the legislative and 
operational aspects of the national drug control 
system need to be strengthened further to ensure co-
operation among the newly structured competent 
authorities and government institutions involved in 
drug control.  
505. Governments of the CIS member States continued 
strengthening their capacity to counter money-
laundering by improving national legislative bases and 
institutional structures. An agreement was reached in 
October 2004 to create an FATF-type regional body in 
Moscow that would coordinate the efforts of CIS 
member States to combat money-laundering and 
financial crime. The Board notes that, in Belarus, 
following a revision of the relevant legislation, a 
financial investigation unit which is to facilitate 
cooperation with international agencies, as well as 
regional and bilateral partners, became operational. 
506. In March 2004, the Government of Italy set up a 
national department for drug control policy in the 
Office of the Prime Minister to coordinate initiatives to 
deal with drug problems and to develop a three-year 
national drug control action plan.  
507. In Spain, Royal Decree No. 1555/2004 was 
adopted in June 2004, making the Plan Nacional Sobre 
Drogas a part of the Ministry of Health and Consumer 
Affairs. Previously, the National Plan on Drugs had 
been an organizational entity of the Ministry of the 
Interior.  
508. The Netherlands continues to implement an 
action plan against MDMA (Ecstasy). In March 2004, a 
progress report indicated that the implementation of 
the action plan, which is to run until 2006, had led to 
an increase in the quantity of raw materials seized and 
in the number of suspects detained. Furthermore, the 
formation of specialized investigative teams yielded 
positive results, such as the dismantling of an 
internationally drug trafficking network in December 
2003.  
509. According to the European Monitoring Centre for 
Drugs and Drug Addiction, the availability of drug 
substitution treatment in 15 European Union member 
States and Norway has increased by 34 per cent over 
the last five years. Some 400,000 people currently 
receive such treatment. Over 60 per cent of the 
treatment facilities are in France, Italy and Spain. The 
biggest increase in the availability of drug addiction 
treatment has been in countries that initially had few 
facilities for such treatment. The Board urges 
Governments of member States of the European Union 
to assess the impact of such programmes on the illicit 
market for and the abuse of heroin. 
510. The establishment of rooms for drug injection, 
consumption and/or inhalation or other facilities where 
illicit drugs are administered continues to be a 
contentious issue, particularly in the member States of 
the European Union. While it is sometimes argued that 
drug injection rooms have some positive effects, such 
as establishing contact between social services and the 
hard-to-reach population of injecting drug abusers, the 
provision of such facilities raises legal and ethical 
issues. Drug injection rooms are legal facilities for the 
purpose of facilitating behaviour that is both illegal 
and damaging. The drugs used in those facilities come 
from the illicit market. The Board notes that the 
Governments of many European countries with drug 
 E/INCB/2004/1
 
 77 
 
control policies as diverse as those of Denmark and 
Portugal have opted against the establishment of drug 
injection rooms, and the Board strongly supports their 
decisions. The Board also reiterates that drug injection 
rooms are against the central principle embodied in the 
international drug control treaties, namely that the use 
of drugs should be limited to medical and scientific 
purposes only.  
511. The Board notes with concern that cannabis seeds 
and drug abuse paraphernalia continue to be sold over 
the Internet, often through advertisements specifically 
targeting young people. Moreover, drug abuse is 
presented as a desirable activity in magazines, other 
printed matter and on Internet sites. The Board notes 
that article 3, paragraph 1 (c) (iii), of the 1988 
Convention requires States parties to establish as a 
criminal offence, inter alia, public incitement or 
inducement of others to engage in illicit drug use or 
drug trafficking. The Board appeals to Governments to 
apply that provision of the 1988 Convention, especially 
when minors are involved. 
 
  Cultivation, production, trafficking and abuse 
 
  Narcotic drugs 
 
512. Albania and other countries in the area of the 
Balkans (Bulgaria, Croatia, Serbia and Montenegro and 
the former Yugoslav Republic of Macedonia) as well as 
the Russian Federation and Slovenia, remain the main 
suppliers of cannabis in Eastern Europe. In 2002, a 
total of 35 tons of cannabis were seized in Eastern 
Europe and an additional 30 tons were seized in the 
Russian Federation. Cannabis continues to be 
cultivated in Western Europe, mainly in the 
Netherlands and, to a lesser extent, in its neighbouring 
countries as well as in Switzerland. The Board 
appreciates the action of Switzerland against the illicit 
cultivation of cannabis, such as Operation Indoor, 
which resulted in the dismantling of 60 cannabis 
cultivation sites and the closure of 70 hemp shops in 
Switzerland; in addition, 4.2 tons of cannabis were 
seized.  
513. Morocco remains a major source of cannabis 
resin abused in Western Europe. Cannabis resin from 
Morocco is smuggled into Spain in freight or other 
motor vehicles by ferry or on small boats. The drug is 
then transported by land to Belgium, France, the 
Netherlands and the United Kingdom. The Russian  
 
Federation continues to be an important supplier of 
cannabis resin, reporting in 2002 the largest amount of 
cannabis resin seized in Eastern Europe—a total of 
over 1.4 tons. A total of over 2 tons of cannabis resin 
were seized in Eastern Europe in 2002. 
514. Cannabis is the most widely abused illicit drug in 
Europe (and in all other regions). In Europe, an 
estimated 28.8 million people, or 5.3 per cent of the 
total population, abused cannabis during the last 
12 months. Cannabis abuse continued to increase in 
2003 and 2004 in Eastern Europe, where 3.6 per cent 
of the adult population, or about 8.5 million people, 
reportedly abuse cannabis. In the Czech Republic, the 
average annual prevalence rate for cannabis abuse is 
11 per cent. In Eastern Europe, the average annual 
prevalence rate for cannabis abuse among persons 
15-16 years old has doubled in the last decade. 
515. Portugal and Spain continue to be used as main 
points of entry for cocaine consignments from South 
America, accounting for 5 per cent of the cocaine 
seized worldwide. There was an increase in the total 
amount of cocaine seized in some Western European 
countries (Belgium, France and Italy); that figure also 
increased in some Eastern European countries, albeit 
from a lower level. In Estonia, 30 kg of cocaine were 
seized in 2003, the largest figure ever recorded in that 
country. 
516. In Europe, cocaine abuse has increased since 
1998, with a tendency towards stabilization. In Eastern 
Europe, cocaine abuse is still at a level well below that 
of Western Europe. Cocaine abuse appears to be 
increasing in the United Kingdom and, to a lesser 
extent, in Denmark, Germany, the Netherlands, Spain 
and Switzerland. Data show that 1-9 per cent of 
persons aged 15 to 34 have abused cocaine in their 
lifetime. 
517. The illicit cultivation of opium poppy is at a low 
level in countries in Central and Eastern Europe and in 
the CIS member States; however, reported seizures of 
opiates indicate that the trafficking volume is high. In 
2002, almost 2.5 tons of opium were seized in Eastern 
Europe. A total of 1,505 kg of opium were seized in the 
Republic of Moldova, 445 kg in the Russian 
Federation, 261 kg in Lithuania and 170 kg in Estonia. 
Over 2.7 tons of heroin and morphine were seized in 
Eastern Europe in 2002; 844 kg of heroin and 
morphine were seized in the Russian Federation. 
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518. After a recent decline, heroin seizures have 
increased again in Europe. Some 90 per cent of the 
opiates destined for illicit drug markets in Europe are 
estimated to have come from Afghanistan. Examination 
of the European seizures indicates that the so-called 
southern branch of the Balkan route, leading to Italy 
via Greece, Albania or the former Yugoslav Republic 
of Macedonia, decreased in importance in 2003. The 
traditional northern branch of the Balkan route, a land 
route that passes through Turkey, Bulgaria, Romania, 
Hungary and Austria, is playing a more significant role 
than it did in 2002. Partly as a result of improved law 
enforcement measures, the total volume of heroin 
seized is reported to have increased in most countries 
on the traditional route; the total quantity of heroin 
seized in Bosnia and Herzegovina doubled in 2003 and 
an increase in heroin trafficking has been noted in 
Croatia. The United Kingdom, Italy and the 
Netherlands (in that order) account for most of the 
heroin seized in Europe. In February 2004, some 
113 kg of heroin were seized in Austria, the largest 
heroin seizure ever made in that country. Ferry 
connections between Albania and Italy are increasingly 
being used for smuggling heroin. Albania and the 
Kosovo area (in Serbia and Montenegro) are 
increasingly being used for storing and trans-shipping 
heroin destined for member States of the European 
Union. 
519. In addition to heroin, amphetamines, MDMA 
(Ecstasy) and LSD are becoming more popular as 
drugs of choice in some countries in Central and 
Eastern Europe. Synthetic drugs are increasingly being 
illicitly manufactured locally, as evidenced by the fact 
that the number of detected illicit drug laboratories has 
continued to grow. In the Czech Republic, 32 illicit 
drug manufacturing laboratories were dismantled in 
2003 and over 35,000 MDMA (Ecstasy) tablets and 
7,300 doses of methamphetamine were seized. Poland 
continues to be a major supplier of amphetamines and 
MDMA (Ecstasy), mostly due to increased domestic 
demand. Seizures indicate that synthetic drugs are 
being illicitly manufactured on a large scale in 
Bulgaria, and that that country is becoming a major 
source of amphetamines, MDMA (Ecstasy) and 
precursors in Europe, having seized 350 kg of 
amphetamines and 1.5 tons of precursors in 2003. 
There has been a similar increase in the illicit 
manufacture of synthetic drugs in the Baltic States, 
where many clandestine laboratories for large-scale 
illicit drug manufacture were dismantled and record 
quantities of illicit drugs were seized in 2003. There 
has also been a shift in the amounts of the various 
drugs seized: the total volume of seizures of locally 
manufactured amphetamines and MDMA (Ecstasy) is 
overtaking that of heroin and other opiates in Estonia 
and Lithuania. 
520. Russian border guards stationed on the 800-mile 
border between Afghanistan and Tajikistan have 
continued to be effective in fighting illicit drug 
trafficking, as they seized 5.3 tons of illicit drugs, 
including 2.7 tons of heroin, in 2003. Although that 
figure is only a fraction of the total amount being 
smuggled, it represents an increase of 33 per cent over 
the figure for 2002. According to the Russian Federal 
Drug Control Service, over 70 per cent of the opiates 
seized on the Russian border and inside the country 
originate in Afghanistan. 
521. According to the United Nations Office on Drugs 
and Crime, some 4 million people in Europe abuse 
opiates; two thirds of those people are in countries in 
Eastern Europe, primarily in the Russia Federation 
where the level of opiate abuse is very high. According 
to official estimates, there are over 1 million heroin 
abusers in the Russian Federation; thus, that country 
has become the largest heroin market in Europe. In 
Western Europe the country with the highest level of 
opiate abuse is Luxembourg, followed by Portugal, the 
United Kingdom, Italy and Switzerland. Whereas 
heroin abuse is stable or declining in Western Europe, 
it has been increasing in most countries in Eastern 
Europe. 
522. The ongoing illicit production of poppy straw in 
the Russian Federation, supplemented by illicit 
imports, the availability of heroin of lower purity and a 
fivefold drop in prices in recent years may be some of 
the causes of the sudden increase in the abuse of 
opiates in that country. 
523. The Board is concerned about a recently revealed 
fact: fentanyl, a synthetic opioid, has been illicitly 
manufactured in Ukraine. The fentanyl from Ukraine 
was reportedly illicitly supplied to the Baltic States and 
to Scandinavian countries. Given the potency of that 
substance and the immediate proximity of large 
consumer markets, the Board requests the Government 
of Ukraine to monitor the situation closely and to take 
the necessary measures to eliminate the illicit 
manufacture of fentanyl.  
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  Psychotropic substances 
 
524. The Netherlands continues to be the country most 
frequently reported by other countries as being the 
main source of MDMA (Ecstasy) and amphetamine; 
however, the frequency of those reports is declining 
and the manufacture of amphetamine-type stimulants is 
increasingly being reported in Central and Eastern 
Europe. Estonia and Poland have been identified as the 
main sources of amphetamines and MDMA (Ecstasy). 
The Polish law enforcement authorities report the 
dismantling of an average of 10 clandestine ampheta-
mine laboratories every year; however, 8 such 
laboratories were dismantled already in the first quarter 
of 2004. In Ukraine, several well-equipped clandestine 
laboratories, manufacturing amphetamine-type stimu-
lants and phencyclidine, a psychotropic hallucinogen, 
have been detected and dismantled in recent months. 
The fact that nine laboratories for the small-scale 
manufacture of GHB were discovered in Germany in 
2003 indicates the increasing importance of that 
substance for the illicit drug market in that country. 
525. Polish amphetamine is smuggled into Germany, 
Norway, Sweden and Ukraine, as well as the Baltic 
States, while an estimated 65 per cent of illicitly manu-
factured amphetamine is abused locally. Similarly, in 
most countries in Central and Eastern Europe and CIS 
member States, the abuse of stimulants has increased. 
Stimulants are becoming the most common drug of 
abuse among registered first-time drug abusers. 
526. The abuse of both MDMA (Ecstasy) and 
amphetamine appears to have stabilized in most 
European countries. The level of abuse of MDMA 
(Ecstasy) in European countries is among the highest 
in the world, second only to the level in Australia. In 
Europe, the level of abuse of MDMA (Ecstasy) is 
reportedly highest in Ireland, followed by the Czech 
Republic, the United Kingdom and Spain. The highest 
level of amphetamine abuse in Europe is reportedly in 
the following European Union member States (listed in 
decreasing order): United Kingdom, Ireland, Denmark, 
Spain, Czech Republic, Estonia and Poland. In 
Sweden, one of the first countries in Europe to be 
seriously affected by amphetamine abuse, a survey 
undertaken among military conscripts suggested that in 
2003, amphetamine abuse in that subpopulation had 
reached its lowest level since 1996. 
527. Psychotropic substances from the Balkan 
countries, as well as the Netherlands and Poland, 
continue to be smuggled into Belarus, the Russian 
Federation and Ukraine. Furthermore, flunitrazepam 
(Rohypnol) tablets have been diverted from licit trade 
in that area and have been appearing on the illicit 
markets of the Baltic States and the Nordic countries 
(Denmark, Finland, Iceland, Norway and Sweden). 
Flunitrazepam is smuggled into Sweden, usually using 
Lithuanian couriers, by ferry either via the other Baltic 
States or via Germany and Denmark. Some of the 
shipments are also destined for Norway. 
Buprenorphine (opioid analgesic) reportedly 
originating in France is frequently seized in Finland. 
The Board urges Governments to intensify their efforts 
to maintain effective control over international trade in 
psychotropic substances and to strengthen international 
cooperation aimed at preventing or reducing the illicit 
manufacture of and trafficking in those substances. The 
Board also encourages law enforcement agencies in 
Europe to keep statistics on the different types of 
psychotropic substances seized. 
528. Preparations containing psychotropic substances 
continue to be abused in several countries in Europe. 
The abuse of tranquillizers and sedatives has been 
reported in the Baltic States; as in Latvia, the lifetime 
prevalence rate for the abuse of such substances among 
persons aged 15-64 reached 22 per cent in 2003. 
529. Several countries in Western Europe have placed 
khat under national control and regularly seize signi-
ficant quantities of the substance. In Sweden, for 
example, the quantity of khat seized has steadily 
increased over the past few years, reaching almost 
7 tons in 2003. In Norway, dried khat is reportedly 
either smoked in a mixture with tobacco or drunk as 
tea. 
 
  Missions 
 
530. The Board sent a mission to Belgium in 
September 2004 to review the drug control situation 
and the progress made by the Government following its 
mission to that country in 1994. The Board notes with 
satisfaction that the Government of Belgium continues 
to be committed to addressing all aspects of the drug 
problem through an integrated and balanced approach. 
531. The Board notes that, under the new legislation 
adopted by the Government of Belgium in January 
2001, while the penalty for abuse of cannabis by an 
adult under specific circumstances has been reduced to 
administrative sanctions, the illicit manufacture of, 
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trafficking in and possession of drugs with the intent to 
resell or distribute remain prohibited. The Board 
encourages the Government to conduct a 
comprehensive evaluation of the effects of the 
implementation of the new legislation on the 
consumption and possession of or trafficking in 
cannabis, as well as on demand reduction, in order to 
ensure that the new legislation is achieving the desired 
results through the provision of treatment to, and 
assistance in the social reintegration of, the offender 
rather than through imprisonment. 
532. The Board notes with concern that a Belgian 
pharmaceutical company continues to use seized 
cocaine materials for the licit manufacture of 
pharmaceuticals for export, reportedly because of 
problems regarding the quality of cocaine materials 
licitly manufactured in and exported from Peru. The 
Board urges the Government of Belgium to explore 
alternatives to the use of seized cocaine materials for 
such purposes. The Board notes the intention of the 
Belgian authorities to assist in resolving the issue of 
the quality of imported cocaine materials. 
533. The Board notes with concern that the illicit 
manufacture of MDMA (Ecstasy) has apparently 
shifted from the Netherlands to Belgium. The 
Government of Belgium has placed a high priority on 
the suppression of illicit manufacture of and trafficking 
in synthetic drugs, including MDMA, in particular the 
detection and dismantling of clandestine drug 
laboratories and the interception of illicit drug 
consignments along the border. The Board notes with 
appreciation the efforts of the Belgian authorities in the 
prevention of illicit manufacture of and trafficking in 
synthetic drugs and, in view of the increasing illicit 
manufacture of MDMA in Belgium, encourages the 
authorities to continue to strengthen drug control 
efforts focusing on that substance. 
534. A mission of the Board visited Denmark in 
September 2004. The Board commends the 
Government of Denmark for the development of the 
action plan against drug abuse entitled “The Fight 
against Drugs”, which is based on the international 
drug control treaties and rejects any legalization of 
drugs. The Board also welcomes the considerable 
progress that has been made in the implementation of 
the initiatives of the action plan. The Board commends 
the Government of Denmark for the introduction of a 
“treatment guarantee”, which requires municipalities to 
provide a variety of options for the treatment of drug 
addicts within 14 days of each addict’s request for such 
treatment.  
535. The Board welcomes action taken by the 
Government of Denmark against the trafficking of 
cannabis in the district of Christiania in Copenhagen, 
which has reduced the availability of the drug in 
Copenhagen, as well as in the south of Sweden. The 
Board invites the Government to communicate to the 
general public the objectives and results achieved by 
bringing drug trafficking under control in that area. 
536. The high level of khat seizures in Denmark 
indicates that there may be a problem involving the 
abuse of that substance, and the Board requests the 
Government to investigate the matter. As khat is not 
controlled under the international drug control treaties, 
problems with trafficking in the substance, which are 
experienced in all Scandinavian countries and in many 
other countries in Europe, may exacerbate. The 
Government may also wish to notify the Secretary-
General of the khat problem with a view to initiating 
the procedure for bringing that substance under 
international control.  
537. It appears that, contrary to Economic and Social 
Council resolution 1999/32, in which States were 
called upon to import poppy seeds only from countries 
where opium poppy was grown licitly in accordance 
with the provisions of the 1961 Convention, poppy 
seeds originating in Afghanistan have been exported to 
Denmark. The Board urges the Government of 
Denmark to complete its investigation of the matter as 
soon as possible and to do its utmost to prevent such 
imports in future. 
538. A mission of the Board visited Portugal in April 
2004. The Board examined the legal framework that 
has been applicable to drug-related offences involving 
small quantities of drugs since July 2001 and noted 
that the acquisition, possession and abuse of drugs had 
remained prohibited. While the practice of exempting 
small quantities of drugs from criminal prosecution is 
consistent with the international drug control treaties, 
the Board emphasizes that the objective of the treaties 
is to prevent drug abuse and to limit the use of 
controlled substances to medical and scientific 
purposes. The Board calls on the Government of 
Portugal to examine ways in which the commissions 
for the dissuasion of drug abuse can contribute towards 
preventing drug abuse. 
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539. The Board notes that the rate of licit consumption 
of psychotropic substances in Portugal is higher than 
that of every other European country except Ireland 
and that the reasons for the high level in Portugal are 
not known. In Portugal, seizures of medicines 
containing diazepam, alprazolam or oxazepam indicate 
that, despite the strict control system in place, there is 
some diversion of those substances from the licit 
market to the illicit market. The Board therefore calls 
on the Government of Portugal to examine the current 
system of control of the distribution of pharmaceutical 
products, as well as current practice concerning 
prescription and use of benzodiazepines. The Board 
would also like to draw the attention of the 
Government to Commission on Narcotic Drugs 
resolution 44/13, entitled “Contribution to the 
appropriate use of benzodiazepines”. 
540. A mission of the Board visited Sweden in 
September 2004. The Board commends the 
Government of Sweden for its commitment and efforts 
in the fight against drug abuse and illicit trafficking, in 
line with the international drug control treaties.  
541. The Board welcomes the national drug action 
plan of Sweden covering the four-year period (2002-
2005) which envisages the achievement of a drug-free 
society by implementing initiatives that will both 
reduce the demand for and limit the supply of illicit 
drugs. The Board stresses that drug control efforts can 
only be effective if they are long-term and sustained. 
The Board underlines the importance of continuing the 
coordinating effort of the Office of National Drug 
Policy Coordination.  
542. On licit control, the Board welcomes action by 
the Government of Sweden that has been successful in 
curtailing larger-scale diversions of psychotropic 
substances, particularly flunitrazepam. The Board 
encourages the Government to strengthen its capacity 
to monitor prescriptions for internationally controlled 
drugs in order to detect non-medical use of those 
drugs.  
543. Noting that access to treatment is often difficult 
for drug abusers in Sweden, the Board strongly 
encourages the Government to accord higher priority to 
the treatment of drug abusers, which is one of the 
pillars of the national drug action plan, and to 
substantially increase the budgetary allocation to the 
provision of treatment.  
544. A total of almost 7 tons of khat were seized in 
Sweden in 2003. The Board stresses that those seizures 
may indicate that there is a problem involving khat 
abuse and requests the Government to investigate the 
matter and develop countermeasures. As khat is not 
controlled under the international drug control treaties, 
problems with trafficking in the substance, which are 
experienced in all Scandinavian countries and in many 
other countries in Europe, may exacerbate. The 
Government may also wish to notify the Secretary-
General of the khat problem, with a view to initiating 
the procedure for bringing khat under international 
control. 
545. The Board reviewed the drug control situation in 
Albania and the Government’s compliance with the 
international drug control treaties. Following a mission 
to Albania in September 2002, the Board had 
recommended that the Government take various 
measures to strengthen drug control, including 
administrative reforms to ensure adequate coordination 
between government agencies. 
546. Despite several communications to the 
Government of Albania, the Government has failed to 
provide the Board with any information regarding the 
implementation of its recommendations. The Board 
continues to be concerned over persistent reports about 
the serious drug control problems in the country, 
including the lack of attention to the widespread 
smuggling of drugs into other countries. The Board 
urges the Government to take immediate measures to 
implement fully the provisions of the international 
drug control treaties and to provide the Board with 
detailed information on the steps that have been taken. 
547. The Board, while examining the drug control 
situation in Serbia and Montenegro, reviewed the 
progress made by the Government in the 
implementation of the Board’s recommendations 
following its mission to that country in 2001. The 
Board notes with concern that the Government of 
Serbia and Montenegro has not established a drug 
coordinating body at the federal level or adopted a 
drug control master plan to address the situation with 
regard to drug abuse and trafficking, although such 
efforts are being made within the Republic of Serbia 
pursuant to the Board’s recommendations. 
548. Given the fact that Serbia and Montenegro is on 
the traditional Balkan route, the Board urges the 
Government to take the necessary steps to ensure that 
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drug control activities are well coordinated and 
effectively implemented, not only in the area of supply 
and demand reduction, but also in the control of licit 
activities related to narcotic drugs, psychotropic 
substances and precursors. 
549. The Board notes with appreciation that, despite 
the lack of human and financial resources, a number of 
well-coordinated law enforcement activities have taken 
place in Serbia and Montenegro, resulting in the 
detection of some illicit laboratories with a large 
capacity for manufacturing amphetamine-type 
stimulants. The Board encourages the Government to 
continue its efforts in that area, with a view to 
addressing the increasing activities of organized crime, 
especially those activities related to drug trafficking. 
550. The Board reviewed progress made by the 
Government of Ukraine in the implementation of the 
Board’s recommendations following its mission to that 
country in July 2001. The Board notes with 
appreciation that the Government has acted on its 
recommendations and has made considerable progress 
in some areas of drug control. In particular, the Board 
notes that the position of the National Narcotics 
Control Committee has been improved within the 
administrative structure, with a view to strengthening 
its role as coordinator of the relevant drug control 
agencies within the country. Ukraine has acceded to the 
1972 Protocol amending the 1961 Convention, adopted 
legislation against money-laundering and introduced 
additional controls over substances such as codeine and 
phenobarbital. 
551. The Board shares the concern of the Government 
of Ukraine over the worsening drug abuse situation in 
that country, particularly with regard to the significant 
increase in the number of heroin addicts, as well as the 
fact that the majority of registered addicts are 
adolescents. The Board urges the Government to 
strengthen its efforts in the area of prevention and 
demand reduction in order to halt and even reverse that 
alarming trend. 
 
 
 E. Oceania 
 
 
  Major developments 
 
552. Australia and New Zealand account for the 
majority of the drug and precursor seizures made in 
Oceania. There has been a considerable increase in the 
illicit manufacture and abuse of amphetamine-type 
stimulants in those two countries. The total number of 
clandestine laboratories detected in Australia reached 
314 in 2003. 
553. In Australia, heroin abuse has declined to a level 
below the levels recorded prior to the heroin shortage 
of early 2001. Most (90 per cent) of the heroin abused 
in Australia originated in South-East Asia; Sydney is 
the main port of entry for heroin shipments arriving in 
the country. The reduction in the availability of heroin 
in Australia has resulted in heroin abusers turning to 
other drugs. 
554. Party drugs such as GHB, as well as ketamine 
trafficking and abuse, are a cause for serious concern 
in Australia, as is the abuse of several benzodiazepines 
diverted from licit distribution channels.  
555. Trafficking organizations based outside of New 
Zealand are shipping into the country large quantities 
of amphetamine-type stimulants, including MDMA 
(Ecstasy) tablets (266,000 tablets were seized in 2003). 
The trafficking organizations include Chinese 
syndicates that bring in medicines containing 
ephedrine and pseudoephedrine, which are used for the 
illicit manufacture of methamphetamine. Seizures of 
ephedrine and pseudoephedrine are also increasing. 
556. Most of the Pacific island countries continue to 
be vulnerable to drug transit trafficking and the abuse 
of amphetamine-type stimulants.  
 
  Treaty adherence 
 
557. The Board continues to be concerned that, of the 
15 States in Oceania, only Australia, Fiji, New Zealand 
and Tonga are parties to all three international drug 
control treaties. Kiribati, Nauru, Niue, Samoa, Tuvalu 
and Vanuatu are not parties to any of the three treaties. 
Of the remaining five States, one (Solomon Islands) is 
a party only to the 1961 Convention and the others are 
parties to the 1961 Convention and the 1971 
Convention. The Board urges those States to accede to 
all the international drug control treaties without delay. 
The Board calls on regional organizations such as the 
Pacific Islands Forum to support those States in that 
respect. 
 
  Regional cooperation 
 
558. In June 2004, a joint operation involving Interpol 
and the law enforcement agencies of Australia, the 
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Hong Kong Special Administrative Region of China, 
Fiji, Malaysia and New Zealand led to the dismantling 
in Fiji of the biggest clandestine methamphetamine 
laboratory in Oceania, capable of manufacturing 1 ton 
of methamphetamine hydrochloride (commonly called 
“ice”) within a two-week period to supply illicit 
markets in Australia, New Zealand, the United States 
and countries in Europe. 
559. The leaders attending the thirty-fifth session of 
the Pacific Islands Forum, held in Apia from 5 to 
7 August 2004, noted with concern that countries in the 
region were facing major security problems and urged 
members of the Forum that had not yet done so to 
enact and implement existing provisions of model 
legislation, including those addressing terrorism and 
transnational organized crime, illicit drugs, weapons 
control and transport security. The Board welcomes the 
launching in the Cook Islands of a Combined Law 
Agency Group, which will facilitate the sharing by all 
government ministries and departments of information 
and other available resources to combat the various 
forms of crime, especially transnational crime. The 
Board also welcomes the establishment in Suva in June 
2004 of the Pacific Transnational Crime Coordination 
Centre, which is to collect and disseminate law 
enforcement intelligence throughout the region. 
560. Cooperation between law enforcement agencies 
in Australia and police authorities from several 
countries, including Cambodia, Peru and the 
Philippines, has resulted in major drug seizures. In 
March 2004, 1.5 tons of pseudoephedrine destined for 
Australia were seized in the Philippines and 750 kg of 
pseudoephedrine imported from Cambodia were seized 
at Australian borders. More than 44 kg of cocaine 
destined for Australia were seized in Peru. The Board 
encourages the Government of Australia to intensify its 
cooperation with the Governments of countries in 
South America with a view to fighting cocaine 
trafficking and abuse.  
561. The Board welcomes the assistance given by the 
Government of Australia to strengthen the capacities of 
law enforcement agencies, especially in the Pacific 
island countries.  
 
  National legislation, policy and action 
 
562. As mentioned in its previous reports,43, 44 the 
Board continues to be concerned about the 
establishment of a drug injection room in the 
Australian state of New South Wales and about the 
four-year extension of the trial period. The Board is 
pleased to note that no other state of Australia plans to 
establish such an injection room.  
563. The Board notes that the Government of Australia 
has adopted a national drug strategy for the period 
2004-2009 that is to guide local governments and 
non-governmental organizations in the development 
and implementation of drug strategies, programmes 
and initiatives aimed at the prevention and reduction of 
harmful drug use.  
564. The Board continues to be concerned that 
harmonized control over precursors in Australia is 
proving to be difficult. The Board welcomes the 
establishment of a working group on precursors that is 
addressing the matter with a view to finding solutions 
that would enhance cooperation between law 
enforcement agencies. 
565. The Board notes that the government of the 
Australian Capital Territory has adopted a new law for 
stricter control over possession of cannabis plants for 
personal use (reducing the maximum number of plants 
tolerated to 2 instead of 10) and, at the same time, is 
opening a cannabis treatment clinic, specialized in the 
prevention and treatment of drug addiction. 
566. The Board commends the Government of Fiji for 
establishing a transnational crime unit to fight drug 
trafficking, money-laundering and trafficking in human 
beings. 
567. Although new legislation has been passed in the 
Cook Islands and Nauru to address deficiencies in 
national legislation against money-laundering, the 
Board continues to be concerned that the Cook Islands 
and Nauru are still on the list of countries and 
territories considered by FATF to be “non-cooperative” 
in efforts to counter money-laundering. The Board 
invites those two States to continue their efforts to 
comply with the FATF recommendations. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
568. In Australia, hydroponic cultivation continues to 
be the most common method used to cultivate cannabis 
for the domestic market, as it offers cannabis growers a 
higher yield from fewer plants and growers perceive 
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the risk of detection to be reduced. In addition, 
hydroponically grown cannabis is preferred by 
cannabis abusers. Thousands of cannabis plants and 
hydroponic systems and equipment are seized in 
Australia every year. As a result of the strategy “Tough 
on Drugs”, introduced by the Government in 1997, 
large quantities of cannabis have been seized at 
Australian borders (640 kg were seized in 2004). 
569. In Australia, the purity of seized heroin increased 
slightly in 2003 compared with previous years. 
Furthermore, there was an increase in the detection of 
heroin at borders while there was a decrease in the 
total amount of heroin seized, suggesting that the 
methods used by heroin traffickers in Australia might 
be shifting from well-organized importation of large 
quantities of the drug to smaller-scale, opportunistic 
smuggling. A similar trend was observed in the illicit 
cocaine market; however, the purity of seized cocaine 
decreased slightly.  
570. In New Zealand, cannabis growers are also 
involved in the illicit manufacture of metham-
phetamine in clandestine laboratories. 
 
  Psychotropic substances 
 
571. Demand for amphetamine-type stimulants, 
including MDMA (Ecstasy), remains high in Australia 
and New Zealand, as confirmed in both countries by 
seizures and the number of clandestine laboratories 
used to manufacture amphetamine-type stimulants that 
have been dismantled recently. 
572. Precursors of amphetamine-type stimulants, such 
as ephedrine and pseudoephedrine, are also 
increasingly being seized at the borders of New 
Zealand; there are indications that medicines 
containing those substances are smuggled into the 
country by mail and using air passengers from China 
and countries in South-East Asia, to be used for the 
illicit manufacture of methamphetamine. An increased 
number of methamphetamine abusers have been 
brought to the attention of police and drug treatment 
centres, as serious violence and property crime have 
been associated with methamphetamine abuse. 
573. Seizures of MDMA (Ecstasy) in Australia have 
been increasing since the mid-1990s. MDMA (Ecstasy), 
mainly of Western European origin, is smuggled into 
Australia by couriers using the “body carry” method. 
574. The Board notes with concern that in New 
Zealand a foreign exchange company was used by a 
criminal syndicate to launder money believed to be 
profits derived from the importation of MDMA 
(Ecstasy) on a large scale. In New Zealand, some LSD 
in crystal and liquid form was intercepted in mail sent 
from Canada. 
575. According to the Party Drugs Initiative, a 
national study to investigate and monitor trends 
involving MDMA (Ecstasy) and other recreational 
drugs in Australia, GHB, ketamine (a hallucinogenic 
sedative) and various anti-depressants are increasingly 
being abused in that country as dance party drugs. 
Control of GHB is becoming a matter of concern, as 
large quantities of its precursor gamma-butyrolactone 
(GBL) are imported for legitimate use. The Board 
urges the Government of Australia to develop strate-
gies aimed at preventing the abuse of those substances. 
 
     (Signed)           (Signed) 
Hamid Ghodse             Alfredo Pemjean 
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Annex I 
 
 
  Regional groupings used in the report of the International 
Narcotics Control Board for 2004 
 
 
 The regional groupings used in the report of the International Narcotics 
Control Board for 2004, together with the States in each of those groupings, are 
listed below. 
Africa 
Algeria 
Angola 
Benin 
Botswana 
Burkina Faso 
Burundi 
Cameroon 
Cape Verde 
Central African Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic Republic of the Congo 
Djibouti 
Egypt 
Equatorial Guinea 
Eritrea 
Ethiopia 
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Lesotho 
Liberia 
Libyan Arab Jamahiriya 
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius 
Morocco 
Mozambique 
Namibia 
Niger 
Nigeria 
Rwanda 
Sao Tome and Principe 
Senegal 
Seychelles 
Sierra Leone 
Somalia 
South Africa 
Sudan 
Swaziland 
Togo 
Tunisia 
Uganda 
United Republic of Tanzania 
Zambia 
Zimbabwe 
Central America and the Caribbean 
Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
El Salvador 
Grenada 
Guatemala 
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
Saint Kitts and Nevis 
Saint Lucia 
Saint Vincent and the Grenadines 
Trinidad and Tobago 
E/INCB/2004/1  
 
88  
 
 
North America 
Canada 
Mexico 
 
 United States of America 
South America 
Argentina 
Bolivia 
Brazil 
Chile 
Colombia 
Ecuador 
 
Guyana 
Paraguay 
Peru 
Suriname 
Uruguay 
Venezuela 
 
East and South-East Asia 
Brunei Darussalam 
Cambodia 
China 
Democratic People’s Republic 
   of Korea 
Indonesia 
Japan 
Lao People’s Democratic  
   Republic 
 
Malaysia 
Mongolia 
Myanmar 
Philippines 
Republic of Korea 
Singapore 
Thailand 
Timor-Leste 
Viet Nam 
 
South Asia 
Bangladesh 
Bhutan 
India 
 
Maldives 
Nepal 
Sri Lanka 
 
West Asia 
 
Afghanistan 
Armenia 
Azerbaijan 
Bahrain 
Georgia 
Iran (Islamic Republic of) 
Iraq 
Israel 
Jordan 
Kazakhstan 
Kuwait 
Kyrgyzstan 
 
Lebanon 
Oman 
Pakistan 
Qatar 
Saudi Arabia 
Syrian Arab Republic 
Tajikistan 
Turkey 
Turkmenistan 
United Arab Emirates 
Uzbekistan 
Yemen 
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Europe 
Albania 
Andorra 
Austria 
Belarus 
Belgium 
Bosnia and Herzegovina 
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Germany 
Greece 
Holy See 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Liechtenstein 
 
 
Lithuania 
Luxembourg 
Malta 
Monaco 
Netherlands 
Norway 
Poland 
Portugal 
Republic of Moldova 
Romania 
Russian Federation 
San Marino 
Serbia and Montenegro 
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
The former Yugoslav Republic of 
   Macedonia 
Ukraine 
United Kingdom of Great Britain 
   and Northern Ireland 
 
Oceania 
Australia 
Fiji 
Kiribati 
Marshall Islands 
Micronesia (Federated States of) 
Nauru 
New Zealand 
Niue 
Palau 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Tuvalu 
Vanuatu 
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Annex II 
 
 
  Current membership of the International Narcotics Control 
Board 
 
  Edouard Armenakovich Babayan 
 
 
 Born in 1920. National of the Russian Federation. 
Professor, Doctor of Medical Science, Academician. 
Principal Scientific Researcher, Scientific Research 
Institute of Social and Forensic Psychiatry. Honorary 
Vice-President, International Council on Alcohol and 
Addictions. Graduate of the Second Moscow Medical 
Institute (1941). Author of over 200 scientific papers, 
inter alia, monographs and courses on drug control, 
published in many countries throughout the world. 
Winner of the E. Brauning International Award for 
valuable contribution to narcotic drug control; winner of 
the Skryabin Award for contribution to the development 
of biology and medical science; and winner of the 
Semashko Award for the best publication on public health 
management. Honorary member of the Purkine Society. 
Recipient of six orders of distinction and medals “For 
Service on the Battlefield”, awarded by the Government 
of the former Union of Soviet Socialist Republics and the 
Government of the Russian Federation; recipient of a 
number of medals of other countries, including Bulgaria, 
the former German Democratic Republic and Poland; 
recipient of honorary plaques awarded by the Ministry of 
Foreign Affairs, the Ministry of the Interior, the Ministry 
of Health and the Customs Administration of the Russian 
Federation. 
 Honoured Physician of the Russian Federation. 
Head of the Russian delegation to the Commission on 
Narcotic Drugs (1964-1993). Chairman of the 
Commission (1977 and 1990). President of the Standing 
Committee Narcotics Control Board of the Russian 
Federation (1999). 
 Member of the International Narcotics Control 
Board (since 1995). Second Vice-President of the Board 
and Chairman of the Standing Committee on Estimates 
(1997 and 2000). Member of the Standing Committee on 
Estimates (1995-2001 and 2004). First Vice-President of 
the Board (2003). 
 
 
  Madan Mohan Bhatnagar  
 
 
 Born in 1934. National of India. Various senior 
positions in narcotics control and administration in the 
Government of India (since 1972). Member of the Delhi 
High Court Bar Association (since 1993). 
 Bachelor of Law (1956) and Master of Arts in 
Political Science (1955), Patna University, India. Deputy 
Narcotics Commissioner (1972-1974). Officer on Special 
Duty (Narcotics) (1976-1979). Narcotics Commissioner 
of India (1979-1985). Director-General, Narcotics 
Control Bureau, Government of India (1988-1990). 
Member (Anti-Smuggling and Narcotics) of the Central 
Board of Excise and Customs and Additional Secretary to 
the Government of India (1990-1992). Author of 
numerous publications, including: “Current national laws 
and policies on narcotics control in India”, Current 
Research on Drug Abuse in India, All India Institute of 
Medical Sciences Research Book; “Drug trafficking: 
Indian perspective”, Narcontrol, Journal of Narcotics 
Control Board of India. Drafter of the provisions of the 
Narcotic Drugs and Psychotropic Substances Act of India 
(1985). Drafter of the licit opium production and export 
policy for India and the national strategy for combating 
the illicit traffic in drugs for India. Member of the expert 
group to study the modification of the Single Convention 
on Narcotic Drugs of 1961, Vienna (1982). Chairman of 
several international conferences on drug control, inter 
alia, the Tenth Meeting of Heads of National Drug Law 
Enforcement Agencies (HONLEA), Asia and the Pacific 
(1983), the Indo-Pakistan Committee meeting against 
drug trafficking (1989) and the South Asian Association 
for Regional Cooperation meeting on harmonization of 
drug laws (1989). First Vice-Chairman, Second 
Interregional Meeting of Heads of National Drug Law 
Enforcement Agencies, Vienna (1989). Participant in the 
Indo-United States bilateral talks on narcotics, 
Washington, D.C. (1989). Participant in the seventeenth 
special session of the General Assembly (1990). Member 
of the intergovernmental expert group on the economic 
and social consequences of drug abuse and illicit 
trafficking, Vienna (1990). Expert and Vice-Chairman, 
Economic and Social Commission for Asia and the 
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Pacific (ESCAP) regional seminar on drug abuse, Manila 
(1990). Head of the Indian delegation to the Commission 
on Narcotic Drugs (1990 and 1992), several meetings of 
HONLEA and the Subcommission on Illicit Drug Traffic 
and Related Matters in the Near and Middle East. Vice-
Chairman, Commission on Narcotic Drugs (1992).  
 Member of the International Narcotics Control 
Board (since 2002). Chairman of the Committee on 
Finance and Administration (2002). Member of the 
Standing Committee on Estimates (since 2002). 
Rapporteur of the Board (2003). First Vice-President of 
the Board (2004). Member of the Committee on Finance 
and Administration (2004). 
 
 
  Elisaldo Luiz de Araújo Carlini 
 
 Born in 1930. National of Brazil. Full Professor of 
Psychopharmacology, Federal University of São Paolo 
(since 1978); Director, Brazilian Centre for Information 
on Psychotropic Drugs (since 1988). 
 Master of Science, Yale University, United States of 
America (1962). Founder and President of the Latin 
American Society of Psychobiology (1971-1973). 
Member and Founder of the Academy of Sciences of the 
State of São Paulo (1976). President, Brazilian Society of 
Medication Vigilance (1991-1993). National Secretary, 
Sanitary Surveillance, Ministry of Health of Brazil (1995-
1997). Member of the World Health Organization (WHO) 
Expert Advisory Panel on Drug Dependence and Alcohol 
Problems, Geneva (1997-1998 and since 2002). Member 
of the Brazilian Academy of Sciences (2003). Recipient 
of numerous honours and awards, including: Councillor 
Emeritus, Federal Council of Narcotics of Brazil (1987); 
Honorary President, XI Symposium on Brazilian 
Medicinal Plants, João Pessoa, Brazil (1990); Member 
emeritus, Department of Biological Psychiatry, Brazilian 
Association of Psychiatry (1993). “Doctor of the Year”, 
Brazilian Chapter of the Medical Society of Israel (1993). 
“Personality of the Year”, Brazilian Association of 
Pharmachemical Industries (1996); Medal of “Grand 
Officer” of the Order of Rio Branco, Presidency of the 
Republic of Brazil (1996); Grand Cross Class of the 
Order of Scientific Merit, Presidency of the Republic of 
Brazil (2000); Doctor honoris causa, Federal University 
of Rio Grande do Norte, Brazil (2002). Author of more 
than 300 publications, including: “Use of anorectic 
amphetamine-like drugs by Brazilian women”, Eating 
Behaviors (2002); “Plants and the central nervous 
system” (2003).  
 Member of the International Narcotics Control 
Board (since 2002).  
 
 
  Philip Onagwele Emafo 
 
 
 Born in 1936. National of Nigeria. Consultant to the 
Organization of African Unity, Addis Ababa (1998-1999). 
 Lecturer, Biochemistry, University of Ibadan (1969-
1971). Lecturer and Senior Lecturer, Pharmaceutical 
Microbiology and Biochemistry, University of Benin, 
Nigeria (1971-1977). Chief Pharmacist and Director, 
Pharmaceutical Services, Federal Ministry of Health of 
Nigeria (1977-1988). Chairman, Pharmacists Board of 
Nigeria (1977-1988). Member of the WHO Expert 
Advisory Panel on the International Pharmacopoeia and 
Pharmaceutical Preparations (1979-2003). Rapporteur-
General, International Conference on Drug Abuse and 
Illicit Trafficking, Vienna (1987). Chairman, Commission 
on Narcotic Drugs at its tenth special session (1988). 
Member of the Secretary-General’s Group of Experts on 
the United Nations Structure for Drug Abuse Control 
(1990). Member of the WHO Expert Committee on Drug 
Dependence (1992, 1994 and 1998). Consultant to the 
United Nations International Drug Control Programme 
(1993-1995). Member of the ad hoc intergovernmental 
advisory group established by the Commission on 
Narcotic Drugs to assess strengths and weaknesses of 
global drug control efforts (1994). Member of the expert 
group convened by the Secretary-General pursuant to 
Economic and Social Council resolution 1997/37 to 
review the United Nations machinery for drug control 
(1997-1998). Member of the Advisory Group of the 
International Narcotics Control Board to review 
substances for control under article 12 of the United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 (1998-1999). 
 Member of the International Narcotics Control 
Board (since 2000). Member of the Standing Committee 
on Estimates (since 2000). Rapporteur of the Board 
(2001). President of the Board (2002-2003). 
 
 
  Gilberto Gerra 
 
 
 Born in 1956. National of Italy. Coordinator of the 
Centre for Studies on Drug Addiction, Drug Addiction 
Service, Health Department of Parma, Italy. University 
lecturer (master’s degree in neurology) on psycho-
pharmacology, University of Parma. Recipient of a 
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university degree in medicine (1981), a master’s degree in 
internal medicine (1986) and a master’s degree in 
endocrinology (1989). 
 Medical doctor at outpatient Drug Addiction 
Service, Health Department, Parma (1987-1994); head of 
Drug Addiction Service, Health Department, Parma 
(1995-2001). University lecturer (master’s degree in 
internal medicine and physical therapy), University of 
Parma (1990-1996). Researcher of drug-related issues at 
the University of Parma and other universities in Italy and 
the United States (New York State Psychiatric Institute, 
Columbia University) (1994, 1996 and 2001); participant 
in a research project supported by the National Institute 
on Drug Abuse Invest Programme (1996); coordinator of 
the Regional Committee for Addiction Research of the 
Emilia Romagna region (1995-2001); research collabora-
tion with the Istituto Superiore di Sanità, Rome (1998-
2000); consultant to the Ministry of the Interior for 
research on substance abuse (1996-1997); consultant to 
the United Nations International Drug Control 
Programme on amphetamine derivatives (1996-1999); 
consultant to the Department of Social Affairs on 
pharmacological and clinical aspects of substance abuse 
(1998-2000); expert for the National Plan of Information 
for Drug Prevention (Presidency of Ministries Consilium) 
(1999); lecturer at several universities in Italy on 
neurobiology of substance abuse (1998-2002). Consultant 
to the National Department of Anti-drug Policies in the 
field of neurobiology of addiction, pharmacology and 
prevention (2003-2004). Member of the National 
Scientific Committee for Health Education and 
Prevention of Substance Abuse of the Ministry of 
Education of Italy (1997-2001); member of the expert 
group of the Ministry of the Interior (European Informa-
tion Network on Drugs and Drug Addiction) (Reitox) 
focal point) to prepare the national report on substance 
abuse for the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) (1998); member of the 
International Society of Psychoneuroendocrinology; 
member of the College on Problems of Drug Dependence 
(2002-2004); member of the Scientific Committee of the 
Italian Society on Drug Addiction (2000-2004); member 
of the Scientific Board of the international journal Heroin 
Addiction and Related Clinical Problems; member of the 
Scientific Board of the Bollettino per le 
Farmacodipendenze e l’Alcoolismo (Italian Journal on 
drug addiction and alcoholism), published by the Ministry 
of Health of Italy, in collaboration with the 
United Nations Interregional Crime and Justice Research 
Institute. Co-author of the Italian Ministry of Interior of 
the national report on drug abuse for EMCDDA; referee 
of five international journals on substance abuse and 
psychiatry; contributed to over 34 publications in 
scientific medical journals (1994-2004), including 
“Aggressive responding in abstinent heroin addicts: 
neuroendocrine and personality correlates,” Progress in 
Psycho-Neuropharmacology and Biology (2004); 
“Substance use among high-school students: relationship 
with temperament, personality traits and parental care 
perception”, Substance Use and Misuse (2004); “Long-
term methadone maintenance effectiveness: psychosocial 
and pharmacological variables”, Journal of Substance 
Abuse Treatment (2003); “Effects of ecstacy on dopamine 
system function in humans”, Behavioural Brain Research 
(2002); “Intravenous flumazemil versus oxazepam 
tapering in the treatment of benzodiazepine withdrawal: a 
randomized placebo-controlled study”, Addiction Biology 
(2002). Speaker at the United Nations International Drug 
Control Programme expert meeting on amphetamine-type 
stimulants, Vienna (1996); speaker at the North Atlantic 
Treaty Organization Advanced Study Institute conference 
on the biosocial bases of violence, Rhodes, Greece 
(1996); participant at the National Institute on Drug 
Abuse consensus conference concerning detoxification 
with alpha-2-agonists, clonidine and iofexidine, Bethesda, 
Maryland, United States (1998); participant at the annual 
meeting of the International Society of 
Psychoneuroendocrinology, Pisa, Italy (2003); speaker at 
the United Nations Office on Drugs and Crime meeting 
on young people and drug abuse: prevention and 
treatment, Stockholm (2003); expert at the EMCDDA 
meeting on targeted prevention, family prevention and 
community prevention, Lisbon (2003); speaker at an 
Andean Parliament meeting on anti-drug policies, 
Guayaquil, Ecuador (2003); speaker at a meeting 
organized by EMCDDA and the European Parliament on 
drug use among young people, Malaga, Spain (2003).  
 Member of the International Narcotics Control 
Board (2004). Member of the Standing Committee on 
Estimates (2004). Member of the Committee on Finance 
and Administration (2004). 
 
 
  Hamid Ghodse 
 
 
 Born in 1938. National of the Islamic Republic of 
Iran. Professor of Psychiatry and of International Drug 
Policy, University of London (since 1987). Director, 
International Centre for Drug Policy, St. George’s 
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Hospital Medical School, London (since 2003); President, 
European Collaborating Centres for Addiction Studies 
(since 1992); Member of the Executive Committee of the 
Federation of Clinical Professors, United Kingdom (since 
1994); Member of the Scientific Committee on Tobacco 
and Health, United Kingdom (since 2000); Director of the 
Board of International Affairs and Member of the 
Council, Royal College of Psychiatrists (since 2000); 
Non-Executive Director, National Clinical Assessment 
Authority of England (since 2001); Chairman, Higher 
Degrees in Psychiatry, University of London (since 
2003); Member of the Medical Studies Committee, 
University of London (since 2003). 
 Recipient of the following degrees: Doctor of 
Medicine (M.D.), Islamic Republic of Iran (1965); 
Diploma Psychological Medicine, United Kingdom 
(1974); Doctor of Philosophy (Ph.D.) University of 
London (1976); and Doctor of Science, University of 
London (2002). Fellow of the Royal College of 
Psychiatrists, United Kingdom (1985); Fellow of the 
Royal College of Physicians, London (1992); Fellow of 
the Royal College of Physicians of Edinburgh, Edinburgh 
(1997); Fellow of the Faculty of Public Health Medicine, 
United Kingdom (1997). Member of the WHO Expert 
Advisory Panel on Alcohol and Drug Dependence (since 
1979); Adviser, Joint Formulary Committee, British 
National Formulary (since 1984); Honorary Consultant 
Psychiatrist, St. George’s and Springfield University 
Hospitals, London (since 1978); Honorary Consultant 
Public Health, Wandsworth Primary Care Trust (since 
1997); Director, Regional Drug Dependence Treatment 
Training and Research Unit, London (1987-1993); 
Director of the Education and Training Unit and of the 
Research, Evaluation and Monitoring Unit and Chairman 
of the Department of Addictive Behaviour and 
Psychological Medicine, St. George’s Hospital Medical 
School, University of London, and Joint Faculty of 
Health Sciences, Kingston University (1987-2003). 
Consultant Psychiatrist, St. Thomas’s Teaching Hospital, 
London (1978-1987); member, rapporteur, chairman and 
convener of various WHO and European Community 
expert committees, review groups and other working 
groups on drug and alcohol dependence. M. S. McLeod 
Visiting Professor, Southern Australia (1990); Honorary 
Professor, Peking University (since 1997). Visiting 
Professor, Keele University, United Kingdom (since 
2002). Author or editor of over 300 scientific books and 
papers on drug-related issues and addictions, including 
the following books: The Misuse of Psychotropic Drugs, 
London (1981); Psychoactive Drugs and Health 
Problems, Helsinki (1987); Psychoactive Drugs: 
Improving Prescribing Practices, Geneva (1988); 
Substance Abuse and Dependence, Guildford (1990); 
Drug Misuse and Dependence: the British and Dutch 
Response, Lancashire, United Kingdom (1990); Misuse of 
Drugs, London (1997); Drugs and Addictive Behaviour: a 
Guide to Treatment, Cambridge (2002); Young People 
and Substance Misuse, London (2004). Editor-in-Chief, 
International Psychiatry (since 2002); Editor, Substance 
Misuse Bulletin; Member of the Editorial Board, 
International Journal of Social Psychiatry. Convener of 
WHO expert groups on medical education (1986), 
pharmacy education (1987), nurse education (1989) and 
rational prescribing of psychoactive drugs. Member of the 
British Medical Association (since 1995); Member of the 
Executive Board, Medical Council on Alcoholism (since 
1997); Honorary Secretary/Chairman, Association of 
Professors of Psychiatry of the British Isles (since 1991); 
Chairman, Association of European Professors of 
Psychiatry; Director, National Programme on Substance 
Abuse Deaths (since 1997); Member of the International 
Association of Epidemiology (since 1998); Member of 
the Institute for Learning and Training in Higher 
Education (since 2001). 
 Member of the International Narcotics Control 
Board (since 1992). Member of the Standing Committee 
on Estimates (1992). President of the Board (1993, 1994, 
1997, 1998, 2000, 2001 and 2004). 
 
 
  Nüzhet Kandemir  
 
 
 Born in 1934. National of Turkey. Ambassador of 
Turkey to the United States, Washington, D.C. (1989-
1998).  
 Master of Arts, Political Science, University of 
Ankara (1957). Third Secretary, Department of Economic 
and Commercial Affairs, Ministry of Foreign Affairs of 
Turkey, Ankara (1960-1961); Second Secretary, Turkish 
Embassy, Madrid (1960-1963); First Secretary, Turkish 
Embassy, Oslo (1963-1966); Director, Personnel 
Department, Ministry of Foreign Affairs, Ankara (1967-
1968); Deputy Permanent Representative, Permanent 
Mission of Turkey to the United Nations (Geneva) (1968-
1972); Deputy Director, Department of International 
Organizations, Ministry of Foreign Affairs (1972-1973); 
Deputy Director, Division of Narcotic Drugs, United 
Nations Office at Geneva (1973-1979); Director-General, 
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International Security Affairs, Ministry of Foreign Affairs 
(1979-1982); Ambassador of Turkey to Iraq, Baghdad 
(1982-1986); Deputy Minister of Foreign Affairs (1986-
1989). Author of more than 200 articles on drugs and 
various international issues. Frequently appearing 
television commentator on international issues. Member 
of the Institute of Strategic Studies (since 1985). Co-
Founder, Institute of Balkan and Middle Eastern Studies 
(1986). Board Member, Eurasian Strategic Studies (since 
2002). 
 Member of the International Narcotics Control 
Board (since 2000). Chairman of the Committee on 
Finance and Administration (2003). 
 
 
  Melvyn Levitsky 
 
 
 Born in 1938. National of the United States of 
America. Retired Ambassador in the United States 
Foreign Service; Professor of International Relations 
and Public Administration, Maxwell School of 
Citizenship and Public Affairs, Syracuse University; 
Distinguished Fellow, Daniel Patrick Moynihan 
Institute of Global Affairs, Maxwell School of 
Citizenship and Public Affairs, Syracuse University. 
 United States diplomat for 35 years, serving as, 
inter alia, Deputy Assistant Secretary of State for 
Human Rights and Humanitarian Affairs, United States 
Department of State (1982-1983); Deputy Director, 
Voice of America (1983-1984); Ambassador of the 
United States to Bulgaria (1984-1987); Executive 
Secretary and Special Assistant to the Secretary of the 
United States Department of State (1987-1989); 
Assistant Secretary of State for International Narcotics 
Matters (1989-1993); and Ambassador of the United 
States to Brazil (1994-1998). Consul, United States 
consulates in Frankfurt, Germany (1963-1965) and 
Belem, Brazil (1965-1967). Political officer, United 
States Embassy in Moscow (1973-1975). Officer-in-
charge for bilateral relations, Office of Soviet Union 
Affairs (1975-1978), and Director, Office of United 
Nations Political Affairs (1980-1982), United States 
Department of State. Recipient of several United States 
Department of State Meritorious and Superior Honor 
Awards, Presidential Meritorious Service Awards and 
the United States Secretary of State’s Distinguished 
Service Award. Member of the Washington Institute of 
Foreign Affairs, the American Academy of Diplomacy, 
the American Foreign Service Association. Member of 
the Advisory Board, Drug Free America Foundation. 
Member of the Institute on Global Drug Policy. 
Member of the Board, Global Panel of the Prague 
Society.  
 Member of the International Narcotics Control 
Board (since 2003). Chairman of the Committee on 
Finance and Administration (2004). 
 
 
  Robert Jean Joseph Chrétien Lousberg 
 
 
 Born in 1941. National of the Netherlands. Former 
Head of the Netherlands regulatory office for narcotic 
drugs and psychotropic substances. Former associate and 
senior scientist, National Institute of Health, Bethesda, 
Maryland, United States. Senior scientist and lecturer, 
University of Utrecht, Netherlands. 
 Recipient of a doctoral degree, University of 
Utrecht (1969). Author of numerous articles published in 
international journals on pharmacologically active 
principles of opiate and cannabinoid origin. Co-
coordinator for the regulation of methadone programmes 
for the treatment of heroin addicts. National coordinator 
of the investigation of leuco-encephalopathy among 
heroin addicts. Member of the delegation of the 
Netherlands at numerous sessions of the Commission on 
Narcotic Drugs. Member of International Narcotics 
Control Board expert groups on the preparation of 
article 12 of the 1988 Convention. Member of the 
delegation of the Netherlands at the United Nations 
Conference for the Adoption of a Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances (1988). Representative for European Union 
directives and regulations on article 12 of the 1988 
Convention. Appointments by the Minister of Health of 
the Netherlands: member of the supervisory board of the 
national drug information and monitoring system and the 
board investigating the medical prescription of heroin for 
the treatment of heroin addicts; member of the 
supervisory board for the assessment and monitoring of 
drugs in the Netherlands; and member of the supervisory 
board of the national agency for national hemp 
production for scientific and medicinal purposes. Expert, 
assessment missions to Albania and the former 
Yugoslav Republic of Macedonia carried out within the 
scope of the European Union-Phare licit drug control 
project. Representative at meetings for the assessment of 
new synthetic drugs by the Extended Scientific 
Committee of the European Monitoring Centre for Drugs 
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and Drug Addiction, Lisbon. Chairman, Pompidou 
Group/International Narcotics Control Board Conference 
on the Control of Psychotropic Substances in Europe. 
Chairman, WHO Working Group on Revised Guidelines 
for the WHO Review of Dependence-Producing 
Psychoactive Substances for International Control.  
 Member of the International Narcotics Control 
Board (since 2002). Vice-Chairman of the Committee on 
Finance and Administration (2003). Second Vice-
President of the Board (2004). Vice-Chairman (2003) and 
Chairman (2004) of the Standing Committee on 
Estimates. 
 
 
  Maria-Elena Medina-Mora 
 
 
 Born in 1953. National of Mexico. Director, 
Epidemiology and Psychosocial Research, National 
Institute of Psychiatry, Mexico City (since 1999). Full-
time researcher, National Institute of Health. Researcher 
in Medical Sciences (1986).  
 Recipient of a Bachelor of Arts degree in 
Psychology, Universidad Iberoamericana, Mexico (1976), 
and a Master of Arts degree in Clinical Psychology 
(1979), Universidad Iberoamericana, Mexico; recipient of 
a doctorate in Social Psychology, Universidad Nacional 
Autonoma de México (1992). Researcher, Centro 
Mexicano de Estudios en Farmacodependencia (Mexican 
centre for studies on drug dependence) (CEMEF) (1973-
1978). Head of the Department on Social Research, 
Centro Mexicano de Estudios en Salud Mental (Mexican 
centre for studies on mental health) (CEMESAM) (1978-
1980). Head of the Division of Epidemiology and Social 
Research, Mexican Institute of Psychiatry (1984-1999). 
Member of the National System of Researchers (since 
1984). Author of numerous articles, including: “What 
happened to street kids? An analysis of the Mexican 
experience”, Substance Use and Misuse, vol. 32, No. 3 
(1997); “The measurement of drinking patterns and 
consequences in Mexico”, Journal of Substance Abuse, 
vol. 12, Nos. 1-2 (2000); and “Adolescent drug use in 
Mexico and among Mexican American adolescents in the 
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characteristics”, Cultural Diversity and Ethnic Minority 
Psychology, vol. 7, No. 1 (2001). Temporary adviser to 
WHO and to the Pan-American Health Organization 
(since 1976). Member of the WHO Expert Committee on 
Addictions (since 1986). Member of the National School 
of Psychologists (since 1991). Member of the National 
Academy of Sciences (since 1992). Member of the 
National Academy of Medicine (since 1994). Member of 
the Board of Directors, National Institute of Public Health 
(since 1997). Member of evaluation committees on 
research, graduate studies and university curricula, 
Consejo Nacional de Ciencia y Tecnología (CONACYT) 
(1994-2003). Member of the Board of Directors, National 
Autonomous University of Mexico (since 2003). 
 Member of the International Narcotics Control 
Board (since 2000). Rapporteur (2002) and Second Vice-
President (2003) of the Board. Member (since 2000) and 
Chairman (2003) of the Standing Committee on 
Estimates.  
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 Born in 1945. National of Chile. Professor of 
Psychiatry, School of Psychology, Universidad Católica 
de Chile (since 1983). 
 Medical Doctor (1968). Psychiatrist (1972). Head 
of the Psychiatry Clinical Service, Hospital Barros Luco-
Trudeau (1975-1981). Head of the Department of Mental 
Health and Psychiatry, Faculty of Medicine, Campus 
South, University of Chile (1976-1979 and 1985-1988). 
Professor of Psychiatry, University of Chile (1978-2000). 
President of Sociedad Iberoamericana para el Estudio del 
Alcohol y las Drogas (1986-1990). Head of the Mental 
Health Unit, Ministry of Health of Chile (1990-1996). 
Professor in the Magister Program entitled “Public 
Health, Mention in Mental Health”, School of Public 
Health, University of Chile (1993-1996).  
 Member of the International Narcotics Control 
Board (since 1995). Second Vice-President (1998 and 
2002) and First Vice-President (1999) of the Board. Vice-
Chairman (1997 and 2001) and Chairman (1998 and 
2002) of the Standing Committee on Estimates. 
Rapporteur of the Board (2004). Member of the Standing 
Committee on Estimates (2004). 
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Professor, Department of Medical and Chemical 
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Medical University of Vienna. Head of the Section on 
Biomedical and Toxicological Analysis. 
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 Recipient of a doctoral degree in Chemistry, 
University of Vienna (1977). Postgraduate training in 
neurochemistry and neuropharmacology, Laboratory of 
Preclinical Pharmacology, National Institute of Mental 
Health, Washington, D.C. (1978-1980). Recipient of a 
Master’s degree in Toxicology, University of Vienna 
(1998). Author of 85 articles published in the fields of 
drug addiction, neuropharmacology, clinical 
pharmacology and analytical chemistry. Co-Chairman, 
4th International Congress of Therapeutic Drug 
Monitoring and Clinical Toxicology, Vienna (1995). 
Member of the expert panel on designer drugs of the 
Ministry of Health of Austria and of the Drug Expert 
Forum of the City of Vienna (since 1997). Project leader 
of several scientific projects of the city of Vienna: 
monitoring designer drugs at large youth events (since 
1997). Member of the scientific committee of 
international scientific congresses on drug addiction, 
clinical toxicology and toxicological analysis. Member of 
numerous national and international scientific 
toxicological associations. Participant at drug-related 
meetings of the European Union (Pompidou Group and 
European Union-Parliament). Member of the Austrian 
delegation to the Commission on Narcotic Drugs (1999-
2001). 
 Member of the International Narcotics Control 
Board (since 2002). Member of the Standing Committee 
on Estimates (since 2002). Vice-Chairman of the Standing 
Committee on Estimates and member of the Committee 
on Finance and Administration (2004). 
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 Born in 1943. National of China. Professor of 
Pharmacology, Peking University, Beijing (since 1991); 
Professor of Pharmacology and Chief of the Department 
of Neuropharmacology, NIDD, Beijing Medical 
University (since 1993), Director, National Institute on 
Drug Dependence (NIDD), Peking University (1999-
2003). 
 Doctor of Medicine, Beijing Medical College 
(1969). Assistant and Associate Researcher, Department 
of Neuropharmacology, Beijing Chemical and 
Pharmacological Institute (1969-1987); Chief of the 
Department of Neuropharmacology, NIDD (1987-1990); 
Visiting Scientist, Addiction Research Center, National 
Institute on Drug Abuse, United States (1990-1991). 
Author of numerous articles, including: “Involvement of 
µ-opioid receptors and α-adrenoceptors in the 
immunomodulatory effects of dihydrotropine”, European 
Journal of Pharmacology (1998); “Immunosuppressive 
effects of dihydrotropine, a potent narcotic analgesic, in 
dihydroetorphine-dependent mice”, European Journal of 
Pharmacology (1999); “Effect of dizocilpine maleate on 
discrimination properties of methamphetamine in rats”, 
Acta Pharmacologica Sinica (2000); “GABAB receptor 
agonist baclofen attenuates the development and 
expression of d-methamphetamine-induced place 
preference in rats”, Life Science (2001); “The effect of 
7-nitroindazike on the acquistion and expression of 
d-methamphetamine-induced place preference in rats”, 
European Journal of Pharmacology (2002); “The 
situation of drug dependence for the last 10 years in 
China”, Chinese Journal of Drug Dependence (2002). 
Member of the Chinese Pharmacological Society (since 
1993). Editor-in-Chief, Chinese Journal of Drug 
Dependence (since 1999). Director, Section of Drug 
Dependence Toxicology, Chinese Society of Toxicology 
(since 2000). Vice-Director, Chinese Society of 
Toxicology (since 2000). 
 Member of the International Narcotics Control 
Board (since 2000). Member of the Standing Committee 
on Estimates (2000 and 2001). Vice-Chairman of the 
Standing Committee on Estimates (2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
The role of the International Narcotics Control Board 
 
 The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the international drug control treaties. It had predecessors under the 
former drug control treaties as far back as the time of the League of Nations. 
 
Composition 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their 
personal capacity, not as government representatives (see annex II of the present publication for the current 
membership). Three members with medical, pharmacological or pharmaceutical experience are elected from a list of 
persons nominated by the World Health Organization (WHO) and 10 members are elected from a list of persons 
nominated by Governments. Members of the Board are persons who, by their competence, impartiality and 
disinterestedness, command general confidence. The Council, in consultation with INCB, makes all arrangements 
necessary to ensure the full technical independence of the Board in carrying out its functions. INCB has a secretariat 
that assists it in the exercise of its treaty-related functions. The INCB secretariat is an administrative entity of the 
United Nations Office on Drugs and Crime, but it reports solely to the Board on matters of substance. INCB closely 
collaborates with the Office in the framework of arrangements approved by the Council in its resolution 1991/48. 
INCB also cooperates with other international bodies concerned with drug control, including not only the Council and 
its Commission on Narcotic Drugs, but also the relevant specialized agencies of the United Nations, particularly WHO. 
It also cooperates with bodies outside the United Nations system, especially the International Criminal Police 
Organization (Interpol) and the Customs Co-operation Council (also called the World Customs Organization). 
 
Functions 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following: 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control over 
chemicals used in the illicit manufacture of drugs and assists them in preventing the diversion of those chemicals into 
the illicit traffic; 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contributes to correcting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of drugs, in order to determine whether they should be placed under 
international control. 
 In the discharge of its responsibilities, INCB: 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs through a statistical returns system, with a view to assisting 
Governments in achieving, inter alia, a balance between supply and demand; 
 (b)  Monitors and promotes measures taken by Governments to prevent the diversion of substances frequently 
used in the illicit manufacture of narcotic drugs and psychotropic substances and assesses such substances to determine 
whether there is a need for changes in the scope of control of Tables I and II of the 1988 Convention; 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other 
competent international organizations, with a view to ensuring that the provisions of the international drug control 
treaties are adequately carried out by Governments, and recommends remedial measures; 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations under 
the international drug control treaties and, to that end, recommends, where appropriate, technical or financial assistance 
to be provided. 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose 
appropriate remedial measures to Governments that are not fully applying the provisions of the treaties or are 
   
 
 
encountering difficulties in applying them and, where necessary, to assist Governments in overcoming such difficulties. 
If, however, INCB notes that the measures necessary to remedy a serious situation have not been taken, it may call the 
matter to the attention of the parties concerned, the Commission on Narcotic Drugs and the Economic and Social 
Council. As a last resort, the treaties empower INCB to recommend to parties that they stop importing drugs from a 
defaulting country, exporting drugs to it or both. In all cases, INCB acts in close cooperation with Governments. 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it proposes 
and participates in regional training seminars and programmes for drug control administrators. 
 
Reports 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation worldwide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at both the national and international levels. The annual report is 
based on information provided by Governments to INCB, United Nations entities and other organizations. It also uses 
information provided through other international organizations, such as Interpol and the World Customs Organization, 
as well as regional organizations. 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit 
movement of narcotic drugs and psychotropic substances required for medical and scientific purposes, together with an 
analysis of those data by INCB. Those data are required for the proper functioning of the system of control over the 
licit movement of narcotic drugs and psychotropic substances, including preventing their diversion to illicit channels. 
Moreover, under the provisions of article 12 of the 1988 Convention, INCB reports annually to the Commission on 
Narcotic Drugs on the implementation of that article. That report, which gives an account of the results of the 
monitoring of precursors and of the chemicals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, is also published as a supplement to the annual report. 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which 
INCB presents its conclusions and recommendations in order to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The following topics were covered in past annual reports: 
 1992: Legalization of the non-medical use of drugs 
 1993: The importance of demand reduction 
 1994: Evaluation of the effectiveness of the international drug control treaties 
 1995: Giving more priority to combating money-laundering 
 1996: Drug abuse and the criminal justice system 
 1997: Preventing drug abuse in an environment of illicit drug promotion 
 1998: International control of drugs: past, present and future 
 1999: Freedom from pain and suffering 
 2000: Overconsumption of internationally controlled drugs 
 2001: Globalization and new technologies: challenges to drug law enforcement in the twenty-first century 
 2002: Illicit drugs and economic development 
 2003: Drugs, crime and violence: the microlevel impact 
 Chapter I of the report of the International Narcotics Control Board for 2004 is entitled “Integration of supply 
and demand reduction strategies: moving beyond a balanced approach”.  
 Chapter II presents an analysis of the operation of the international drug control system based primarily on 
information that Governments are required to submit directly to INCB in accordance with the international drug 
control treaties. Its focus is on the worldwide control of all licit activities related to narcotic drugs and psychotropic 
substances, as well as chemicals used in the illicit manufacture of such drugs. 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by 
Governments to implement the international drug control treaties by addressing those problems. Specific comments are 
made on the drug control situation in each of the countries in which an INCB mission or technical visit took place. 
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